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Introduction and outline of the thesis
Introduction
Colorectal cancer
Almost 1.4 million Europeans died of cancer in 2015; 766,200 men and 592,900 
women (1). The cancer with the second largest impact after lung cancer was intes-
tinal cancer (colon and rectum) with 172,600 projected deaths or 13% of the total 
number of cancers. This makes colorectal cancer one of the most common cancers 
in the Western world.
Approximately 50% of the patients with colorectal cancer develop metastases which 
are found at presentation (2) or during follow-up (3). The liver is the predominant 
location for metastases (4). Treatment with curative intent consist of resection of 
the liver metastases (5). Non-resectable metastatic disease is usually treated with 
cytotoxic agents such as 5-fluorouracil, capecitabine, oxaliplatin and/or irinotecan 
which may be combined with targeted agents such as the anti-angiogenic drug 
bevacizumab (6) or EGFR-targeting agents such panitumumab and cetuximab 
(7-14). This palliative systemic therapy prolongs the median overall survival, but 
only a subset of patients responds to this potentially toxic and expensive treatment. 
Currently, in standard clinical practice, approximately 8-9 weeks after starting a 
systemic treatment, computed tomography (CT) is performed and the response to 
treatment is monitored by size response evaluation according to the RECIST criteria 
(15). However, size response evaluation may be a suboptimal method to assess effi-
cacy of targeted therapies, since necrosis or fibrosis without reduction in tumor size 
may occur (16,17). Furthermore, also after conventional chemotherapy, changes in 
size are inherently slow. Therefore, a reliable tool that predicts response early after 
start of therapy is desirable, as this would prevent unnecessary toxicity and costs. 
Tissue sample analysis by histopathology would be possible but taking biopsies 
for histopathological analysis has some disadvantages. Besides patient discomfort, 
there is a change that the needle misses the cancer foci. In addition, a biopsy sample 
only captures a part of the tumor and, thus, provides limited information on tumor 
heterogeneity. Moreover, due to this heterogeneity the biopsy may not be repre-
sentative of the whole tumor (18,19). Also, the needle might loosen cancerous cells 
which could result in tumor dissemination along the needle track (20). Thus, to 
monitor treatment non-invasive advanced imaging techniques are preferred.
rationale
Factors that affect treatment are, for example, the delivery of the drug via the 
vascular system of the tumor, cellular uptake, its retention and metabolism, and 
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the intrinsic sensitivity of the tumor to a drug. Systemic treatment could change 
tumor physiology before anatomical changes are evident (21). The vascularity, 
metabolism and cellular density of tumor tissue may, for example, change early 
after start of therapy. Among the available in vivo functional and molecular imag-
ing methods to assess the physiology of tumors for clinical and research purposes 
magnetic resonance (MR) and positron emission tomography (PET) are two of the 
most important modalities (22). With these methods it is also possible to assess 
drug pharmacokinetics and dynamics. Both MR and PET have shown potential for 
prediction of response as well as early response monitoring. In recent years it has 
become possible to combine MR and PET, which may provide information for a more 
complete and reliable diagnosis (23).
The first aim of the work described in this thesis was to investigate and validate 
several of these molecular and functional imaging techniques assessing potential 
predictive biomarkers. The second aim was to implement and apply a selection of 
these techniques to obtain data on the biology of colorectal cancer. The third aim 
was to correlate the pre-treatment characteristics of liver metastases of colorectal 
cancer and early changes (one week after start of treatment) in these characteristics 
with treatment outcome. 
Introduction to magnetic resonance
A major modality to obtain anatomical information is magnetic resonance (MR). 
The MR technique is very versatile and it also offers many possibilities to acquire 
more functional information. Before elaborating on specific MR techniques, first the 
basic concepts of MR are presented using a classical mechanics and a short quantum 
mechanics description. This should provide the reader with sufficient background to 
understand the biological and clinical applications of MR. More information can be 
found in, among others: de Graaf (24), Levitt (25), Nave (26).
Classical mechanics description
Spin is an intrinsic property of a particle, just like mass. Elementary particles with 
spin are, for example, photons (spin 1), electrons (spin ½) and Higgs bosons (spin 
0). In the classical mechanics description nuclear spin is named intrinsic angular 
momentum and it is often depicted as a particle spinning around its axis, although in 
reality it is unrelated to motion in space.
Momentum is the tendency for an object to continue its motion. For an object with 
mass m and velocity v the momentum p is defined as:
13
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p=mv (1)
If the object is rotating with a constant velocity around a fixed point at distance 
r, the angular momentum L can be defined as the momentum p multiplied by the 
distance r perpendicular to p:
L=r×p (2)
Figure 1, for example, shows an electron orbiting a proton nucleus, while at the same 
time the electron spins around its own axis. Substituting equation (1) in (2) gives for 
the electron with mass m, and a constant 900 angle between the momentum and r:
L=mvr (3)
A charged particle (e.g. the electron) rotating around a point (e.g. the proton 
nucleus) can also be considered as a current loop and will generate a magnetic 
moment µ according to:
µ=AI (4)
where A is the surface area enclosed by the loop and I the current in the loop. The 
electric current is the rate at which charge q flows through a given surface point:
I=-dq/dt (5)
In the given electron example the charge is equal to the elementary charge e and the 
rotation time T of the electron is equal to 2πr/v with r the radius and v the velocity. 
The current I is then given by:
I=-ev/2πr (6)
The surface area is:
A=πr2 (7)
Substituting (6) and (7) in (4) gives:
µ=(-ev/2πr)(πr2 )=(-ev/2)(r) (8)
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Combining (3) and (8) results in: 
μL=-(e/2m)L=γL L (9)
where γ is the gyromagnetic ratio. It has a specific value for each particle and angular 
momentum. Thus, along with an angular momentum, charged particles come with 
a magnetic moment. For electrons these vectors point in the opposite direction, as 
indicated by the minus sign. Besides orbiting the nucleus, electrons rotate around 
their own axis (in the classical mechanics description) and therefore have a spin 
angular momentum (S). It can be deduced in a similar way:
μS=gs (e/2m)S=γS S (10)
where gS is the electron spin g-factor. The combined angular momentum (J) is then 
defined by:
μ=gJ (e/2m)J=γJ J  (11)
where J is the vector sum of L and S, and gJ is the Landé g-factor, a combination of gS 
and gL, where gL is the orbital g-factor, which equals 1.
Nuclear spin
In contrast to electrons, having orbital and spin angular momentum, atomic nuclei 
often act as a single entity with intrinsic angular momentum (I) (26). Determin-
ing the value of the nuclear angular momentum is complicated as atomic nuclei 
consists of protons and neutrons. Although not being elementary particles, protons 
and neutrons have spin 1/2, like the electron. According to the nuclear shell model, 
protons and neutrons occupy specific ‘shells’, thereby defining the energy state of 
the nucleus and its spin. Protons tend to form pairs of opposite angular momenta 
and cancel each other’s spin. Neutrons behave in the same way and, therefore, nuclei 
with even numbers of protons and even numbers of neutrons have spin zero. Only 
atomic nuclei with unpaired neutrons and/or unpaired protons have spin and are 
detectable by MRI. Atomic nuclei with an odd mass number have a half-integer spin 
(1/2, 3/2, 5/2, …) and those with even mass number and odd charge number have 
integer spin (1, 2, 3, …).
precession or Larmor frequency
When an atom (figure 1) is placed in an external static magnetic field B0, the nuclear 
magnetic moment will try to align with this field. However, due to the angular 
15
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the so called Larmor frequency v0 (=ω0/(2π)), as shown in figure 2. This can be 
explained by the generated torque τ, which is defined as:
τ=r×F=r×(dp/dt)=dL/dt (12)
where F is the force perpendicular to the distance r. The generated torque experi-
enced by the previously described current loop is given by:
τ=μ×B0 (13)
where B0 is the external static magnetic field. The torque can also be described by 
(using equation (12) and figure 2):
τ=dL/dt=dφ/dt Lsinθ=ω0 Lsinθ=ω0×L (14)
where dφ is the small change in angle around B0 due to a small time step dt. Combin-
ing (13) and (14) gives:
τ=μ×B0=L×ω0 (15)
Figure 1: Classical mechanics representation of an electron with mass me, charge e
-, and velocity v 
orbiting a proton nucleus at a distance r. The angular momentum is defined by: L=mevr. The electron 
rotating around the proton can be considered a current loop and will generate a magnetic moment 
µ. Due to the negative charge of the electron, the angular momentum and the magnetic moment are 
pointing in opposite directions. Adapted from Nave (86).
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Combining (11) and (15) gives:
τ=γL×B0=L×ω0 (16)
Which leads to the Larmor or precession frequency ν0:
ω0=γB0  (17)
v0=ω0/2π (18)
The gyromagnetic ratio γ has a specific value for each particle or nucleus. This 
implies that every type of nucleus has a different precession frequency, proportional 
to the B0 field strength. At a field strength of 3T, which is commonly used for human 
Figure 2: The same electron-proton system as shown in figure 1, but now placed in an external magnetic 
field B0. Due to the angular momentum L the magnetic moment µ is not aligned with the external 
magnetic field, instead it is rotating (presessing) around it with the Larmor frequency ω0. Adapted from 
Nave (86).
17
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applications, these frequencies for 1H, 31P and 13C are: 127.7MHz, 51.8MHz, and 
32.1MHz respectively, which is in the radiofrequency (RF) range.
The magnetic energy associated with a magnetic moment µ in an external magnetic 
field B0 is defined as:
E=-μ∙B0=-μB0  cosθ (19)
where θ is the angle between B0 and µ.
Quantum mechanics description
With the classical mechanics description the angular momentum L can have any 
magnitude and orientation. This is not in agreement with real observations and 
requires a quantum mechanical description. Quantum mechanics was initially devel-
oped to describe the atom and to explain the behavior of the subatomic particles. 
This requires quantization of certain physical properties to discrete values. One of 
these quantized properties is the angular momentum L. In quantum mechanics its 
amplitude is given by:
L2=ħ2  I (I+1) (20)
|L|=ħ√(I (I+1)) (21)
with 
ħ=h/2π (22)
where I is the spin quantum number, which can only be an integer (1, 2,…) or half-
integer (1/2, 3/2, …), ħ the reduced Planck’s constant, and h the Planck’s constant 
(6.626 x 10-34 J.s). The orientation of L is characterized by its projection Lz along 
the direction of the external magnetic field B0. The projection Lz is quantized by a 
second quantum number m:
Lz=ħm  (23)
where m can only have values in the range -I, -I+1, -I+2, …, I. Thus, if the spin quan-
tum number I of the nucleus is 1/2 (e.g. for 1H, 31P and 13C nuclei) m can only be 
-1/2 and 1/2, meaning there are only two possible orientations (figure 3).
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The z-component of the magnetic moment µ is then according to equation (9):
μz=γLz (24)
With (23) this becomes:
μz=γħm (25)
The angle θ is then defined by:
cos 𝜃𝜃𝜃𝜃 =
𝑚𝑚𝑚𝑚
√𝐼𝐼𝐼𝐼 (𝐼𝐼𝐼𝐼+1)
𝐸𝐸𝐸𝐸 = −𝜇𝜇𝜇𝜇 ∙ 𝐵𝐵𝐵𝐵0 = −𝜇𝜇𝜇𝜇𝐵𝐵𝐵𝐵0 cos 𝜃𝜃𝜃𝜃 = −𝛾𝛾𝛾𝛾ħm𝐵𝐵𝐵𝐵0
γħ
γħ
α β
∆𝐸𝐸𝐸𝐸 = 𝛾𝛾𝛾𝛾ħ𝐵𝐵𝐵𝐵0
𝐸𝐸𝐸𝐸 = ℎ𝑣𝑣𝑣𝑣0
𝑣𝑣𝑣𝑣0 =
𝛾𝛾𝛾𝛾𝐵𝐵𝐵𝐵0
2𝜋𝜋𝜋𝜋
α
β
𝑛𝑛𝑛𝑛𝛼𝛼𝛼𝛼
𝑛𝑛𝑛𝑛𝛽𝛽𝛽𝛽
= 𝑒𝑒𝑒𝑒∆𝐸𝐸𝐸𝐸/𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘 ≅ 1 +
∆𝐸𝐸𝐸𝐸
𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘
 (26)
For the spin 1/2 nucleus the angle is 54.74 degree. Combining (19) and (25) gives 
the magnetic energy:
E=-μ∙B0=-μB0  cos θ=-γħmB0 (27)
Since m is a quantized number, the magnetic moment µz and the energy levels 
are also quantized, which is in agreement with observations. For nuclei with spin 
quantum number 1/2 the ‘parallel’ and ‘anti-parallel’ orientations relative to B0 are 
associated with a low (-1/2γħB0) and a high (+1/2γħB0) energy state, respectively 
Figure 3: The quantized angular momentum L of a nucleus with spin quantum number I of 1/2. The 
amplitude of L is quantized by: |L|=ħ√(1 (1+1)) and its projection Lz is quantized by Lz=ħm where m is 
-1/2 or 1/2 and ħ the reduced Planck’s constant.
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(figure 4). The lower energy level is often referred to as the α spin state and the 
higher energy level to the β spin state. The energy difference between the two spin 
states equals:
∆E=γħB0 (28)
Figure 4: The magnetic energy E as a function of the external magnetic field B0. The low energy level 
or α spin state has magnetic moments parallel to B0 while the high energy level or β spin state has 
magnetic moments antiparallel to B0. Adapted from de Graaf et al. (24).
By adding energy that equals this energy difference, spins can flip between the low 
and high energy levels. Energy can be applied with an electromagnetic wave with an 
oscillating magnetic field perpendicular to µz, which is given by:
E=hv0 (29)
where v0 is the frequency of the wave. Combining (28) and (29) gives the required 
frequency v0 which is equal to the Larmor frequency defined in (18):
v0=(γB0)/2π (30)
Macroscopic magnetization
In MRI we are looking at macroscopic samples containing many individual nuclear 
spins. In a simplified representation they are randomly distributed over the two 
energy levels (figure 5A). At room temperature, there are slightly more spins in the 
lower energy level, nα, than in the upper level, nβ. The distribution over these energy 
levels is given by Boltzmann statistics:
cos 𝜃𝜃𝜃𝜃 =
𝑚𝑚𝑚𝑚
√𝐼𝐼𝐼𝐼 (𝐼𝐼𝐼𝐼+1)
𝐸𝐸𝐸𝐸 = −𝜇𝜇𝜇𝜇 ∙ 𝐵𝐵𝐵𝐵0 = −𝜇𝜇𝜇𝜇𝐵𝐵𝐵𝐵0 cos 𝜃𝜃𝜃𝜃 = −𝛾𝛾𝛾𝛾ħm𝐵𝐵𝐵𝐵0
γħ
γħ
α β
∆𝐸𝐸𝐸𝐸 = 𝛾𝛾𝛾𝛾ħ𝐵𝐵𝐵𝐵0
𝐸𝐸𝐸𝐸 = ℎ𝑣𝑣𝑣𝑣0
𝑣𝑣𝑣𝑣0 =
𝛾𝛾𝛾𝛾𝐵𝐵𝐵𝐵0
2𝜋𝜋𝜋𝜋
α
β
𝑛𝑛𝑛𝑛𝛼𝛼𝛼𝛼
𝑛𝑛𝑛𝑛𝛽𝛽𝛽𝛽
= 𝑒𝑒𝑒𝑒∆𝐸𝐸𝐸𝐸/𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘 ≅ 1 +
∆𝐸𝐸𝐸𝐸
𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘
 (31)
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where k is Boltzmann’s constant (1.3805x10-23 J/K) and T is the temperature (K). 
At 3.0T and 37 oC (310 K), the population difference represents only a small fraction 
of the total spin population (approximately 20 in a sample with 2.000.000 nuclear 
spins). This population difference results in a net macroscopic magnetization M0. 
Only this net magnetization is detectable. At thermal equilibrium, the macroscopic 
magnetization M0 equals:
𝑀𝑀𝑀𝑀0 = ∑ 𝜇𝜇𝜇𝜇𝑖𝑖𝑖𝑖 =
𝑛𝑛𝑛𝑛
𝑖𝑖𝑖𝑖=1 (
𝛾𝛾𝛾𝛾ℎ
2𝜋𝜋𝜋𝜋
)
2
(
𝑛𝑛𝑛𝑛𝐵𝐵𝐵𝐵0
4𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘
)
α β
γ
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 2𝜋𝜋𝜋𝜋𝜋𝜋𝜋𝜋𝐵𝐵𝐵𝐵1𝑡𝑡𝑡𝑡
 (32)
where n is the sum of nα and nβ. From this equation it follows that a larger net 
macroscopic magnetization M0 can be achieved when nuclei with high gyromagnetic 
ratio γ, like protons (1H), are used, due to the quadratic dependence. A larger static 
magnetic field B0 also increases the energy difference, resulting in a larger spin polar-
ization and thus a larger M0. A lower temperature also increases the spin polarization 
and thus M0.
Spin system excitation, flip angle, t1, and t2
The net macroscopic magnetization M0 can be considered as a static vector aligned 
with the external magnetic field B0. The net magnetization vector can be broken 
down into a longitudinal component (Mz, along the Z axis, aligned with B0), and 
Figure 5: Simplified scheme of the distribution of individual nuclear spins over two energy levels in a 
macroscopic sample. (A) At thermal equilibrium more spins are in the low energy level or α spin state, 
aligned with the external magnetic field (in the direction of the +z axis). As there is no phase coherence, 
the net magnetization vector M0 equals Mz. (B) An RF excitation pulse with a magnetic field (B1) 
applied along the –x axis rotates the net magnetization towards the +y axis. On the microscopic level 
a higher degree of phase coherence is generated and some spins flip to the higher energy level. (C) 
After a 900 RF pulse, the spins have attained complete phase coherence and the spins states are equally 
populated. As a result the net magnetization vector M0 is pointing in the direction of the +y axes and 
equals My. Adapted from de Graaf et al. (24).
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a transverse component, Mxy, lying on the XY plane perpendicular to the Z axis. In 
equilibrium Mz equals M0 and Mxy is zero (figure 5A).
To detect the net macroscopic magnetization M0, a RF excitation pulse with a 
magnetic field (B1) perpendicular to the main external magnetic field B0 and with 
a frequency equal to the precession frequency is sent with a so called RF transmit 
coil. As a consequence of the applied RF pulse, the net macroscopic magnetization 
vector M0 will spiral down (figure 6) toward the transverse plane (x-y plane); or in 
the rotating frame of reference, it will rotate away from the z-axis (figure 5B). The 
angle to which the net magnetization is rotated relative to B0 is called the flip angle 
(FA). The flip angle depends on the duration t and power of the RF pulse:
FA=2πγB1t (33)
Figure 6: In the nonrotating frame of reference the net macroscopic magnetization vector M0 will spiral 
down toward the transverse plane (x-y plane) when applying a 90 degree RF pulse. Adapted from de 
Graaf et al. (24).
A so-called 90o RF excitation pulse will therefore rotate M0 into the transverse plane. 
On the microscopic level the added energy causes more spins to flip from the low 
energy state to the high energy state and more spins will precess more coherently in 
phase (figure 5). Similarly, an 180o RF excitation pulse will rotate the magnetization 
vector away from the z-axis via the transverse plane towards the -z-axis.
The transverse component Mxy of the M0 magnetization precesses with the Larmor 
frequency at resonance and will induce a current in the RF coil when switched to 
receive mode. The measured current is converted to a digital signal and can be 
mathematically converted by a Fourier transform from the time to the frequency 
domain, which results in a so called MR spectrum that may contain one or more 
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resonances, signals or peaks at particular frequencies. This MR spectrum is explored 
in MR spectroscopy.
Immediately after the RF pulse the spin system starts to return towards the original 
energy level distribution and towards incoherent precession (dephasing). After a 
while the system will be in equilibrium again. The measured signal, decaying over 
time, is called the free induction decay (FID) response signal (Figure 7). The time 
constant, describing the recovery of the z component of the magnetization to its 
original longitudinal magnitude is called the spin lattice relaxation time T1, which is 
given by: 
𝑀𝑀𝑀𝑀𝑧𝑧𝑧𝑧(𝑡𝑡𝑡𝑡) = 𝑀𝑀𝑀𝑀0(1− 𝑒𝑒𝑒𝑒
−
𝑡𝑡𝑡𝑡
𝑇𝑇𝑇𝑇1)
𝑀𝑀𝑀𝑀𝑥𝑥𝑥𝑥𝑥𝑥𝑥𝑥(𝑡𝑡𝑡𝑡) = 𝑀𝑀𝑀𝑀𝑥𝑥𝑥𝑥𝑥𝑥𝑥𝑥(0)𝑒𝑒𝑒𝑒
−
𝑡𝑡𝑡𝑡
𝑇𝑇𝑇𝑇2
 (34)
where t is the time. The phase coherence decreases due to fluctuations in micro-
scopic magnetic fields, caused by surrounding dipoles (spins, molecular structures). 
The time constant which describes the return to incoherent precession is called the 
spin-spin relaxation time T2: 
𝑀𝑀𝑀𝑀𝑧𝑧𝑧𝑧(𝑡𝑡𝑡𝑡) = 𝑀𝑀𝑀𝑀0(1− 𝑒𝑒𝑒𝑒
−
𝑡𝑡𝑡𝑡
𝑇𝑇𝑇𝑇1)
𝑀𝑀𝑀𝑀𝑥𝑥𝑥𝑥𝑥𝑥𝑥𝑥(𝑡𝑡𝑡𝑡) = 𝑀𝑀𝑀𝑀𝑥𝑥𝑥𝑥𝑥𝑥𝑥𝑥(0)𝑒𝑒𝑒𝑒
−
𝑡𝑡𝑡𝑡
𝑇𝑇𝑇𝑇2  (35)
where Mxy(0) is the transverse magnetisation at time t=0, immediately after the 90 
degree excitation pulse. Macroscopic field inhomogeneities increase the dephasing 
even more and the combined effect is called the T2* relaxation. While the effect of 
Figure 7: A free induction decay (FID) response signal, as measured in the xy plane. The two projections 
on the (Mx, time) and (My, time) planes are the so-called real and imaginary components of the FID. 
Adapted from de Graaf et al. (24)
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T2 relaxation is irreversible, the effect caused by macroscopic field inhomogeneities 
can (partially) be recovered. In most situations T1 is longer than T2 which itself is 
again longer than T2*. The T1 and T2 (and T2*) relaxation times are tissue dependent 
and are the basic cause of contrast in MR images.
Imaging
For MR imaging the spatial origin of the measured signals needs to be determined. 
This can be achieved in several ways, but the application of linear magnetic field 
gradients (introduced in 1973 (27)) turned out to be most efficient for this purpose. 
These magnetic field gradients are momentarily added to the main static magnetic 
field B0, pointing in the direction of B0, and spatially increasing or decreasing the 
main magnetic field. In this way they create spatially depended Larmor frequencies. 
End 1970s, early 1980s spatial encoding with gradients was improved and combined 
with Fourier based imaging methods (28-30). These techniques are currently still 
the basic ingredients for MR imaging. After the next paragraph that introduces pulse 
sequences, two examples of the spatial encoding are presented.
pulse sequences
The MR signal is spatially encoded by switching on and off specific magnetic field 
gradients that are superimposed on the main external magnetic field B0. These 
magnetic field gradients are generated by gradient coils that can easily be switched 
on and off in a specific order. A so-called ‘pulse sequence’ describes a series of RF 
and gradient pulses. Of the many different pulse sequences developed, the gradient 
echo and the spin echo sequence and their variants are most often used (figure 8). 
2D gradient echo sequence
When reading the diagram in figure 8A from left to right we see that first a slice 
selection gradient (Gslice) is switched on. As a result, the resonance frequency of the 
spins becomes dependent on the position in the direction of the gradient. (See equa-
tions 17/18 and figure 9) At the same time an RF excitation pulse with a specific 
frequency and bandwidth is applied. As a consequence only those spins are excited 
that have a resonance frequency that is similar to a frequency in the bandwidth of 
the excitation pulse. Thus only a slice of spins in the object or patient is selected by 
excitation. At the end of the RF pulse the gradient is switched off. 
During slice selection some spins rotate faster than others, depending on their posi-
tion in the gradient field. After switching off the gradient all spins resonate again 
with the original frequency, but have gained a spatial dependent phase shift given 
by:
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φ1=γ∫rGr dt (36)
φ1=γrGr δ (37)
where r is the position of the point of interest, Gr is the magnetic field gradient 
strength in the direction of r and δ the duration. Equation (37) applies to a square 
gradient pulse. An inverted gradient after slice selection is applied to rephase the 
spins that were dephased during this excitation. 
Figure 8: A 2D gradient echo (A) and a 2D spin echo (B) pulse sequence diagram.
Figure 9: The principle of slice selection. A magnetic field gradient dBz/dz is superimposed on the main 
magnetic field B0. The resonance frequencies of the spins now become linearly dependent on the spatial 
position z. A RF pulse with a specific bandwidth Δω now only excites spins having a resonance frequency 
within this bandwidth, and thus only a selective range of spatial positions Δz is selected. Adapted from 
de Graaf et al. (24).
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In the next step, a phase encoding gradient perpendicular to the slice selection direc-
tion is switched on. Just like before, the resonance frequency of the spins becomes 
again dependent on the position in the direction of the gradient. Some spins are thus 
rotating faster than others, depending on their position. After switching off the gra-
dient all spins resonate again with the original frequency, but have gained a spatial 
dependent phase shift. The amplitude and duration of the gradient determines the 
acquired phase.
Together with the phase encoding gradient, a negative dephasing frequency encod-
ing gradient is applied to ensure that the spins are in phase at the center of the 
acquisition window. Just before signal acquisition the frequency encoding gradient 
is switched on and rephases the signal to generate a (gradient recalled) echo. The 
direction of this gradient is orthogonal to the slice selection and phase encoding 
gradients. Due to this gradient, the acquired signal consists of a range of frequencies 
that can be related to their spatial position. 
The recorded signal is sampled and stored as one line in a 2D complex data space, 
the so called k-space (figure 10). The same pulse sequence is repeated with dif-
ferent phase amplitudes, resulting in new lines in k-space. The required number of 
phase encoding steps depends on the desired resolution. Finally, the MR image is 
reconstructed by Fourier transformation of the complete k-space (figure 10).
The time period between the RF excitation pulse and the maximum in the echo 
signal is called the echo time (TE). The repetition time (TR) is the time after which 
the sequence is repeated. After the RF excitation pulse the signal is decaying due 
to T2* relaxation and macroscopic magnetization is recovering along B0 due to T1 
relaxation. The relative amount of T1 and T2* weighting for contrast in the image 
can be adjusted by varying the TE and TR times and the flip angle.
2D spin-echo sequence
Another commonly applied MR sequence is the spin-echo sequence. This sequence 
enables T2 weighting for image contrast due to the inclusion of an 180
0 rephasing 
pulse. The pulse sequence diagram is to some extent similar to the gradient echo 
pulse sequence. The slice selection and the phase encoding are performed in the 
same way. After half the echo time, a 1800 inversion pulse is applied (together with 
the slice selective gradient) along the y axis that mirrors the magnetization vectors 
with respect to this axis (figure 11). The spins will sense the same field inhomoge-
neities as before the inversion pulse and thus rephase. At time TE the magnetization 
vectors will be completely rephased, resulting in a spin echo. The FID, which occurs 
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directly after the 900 pulse, is not sampled. The frequency encoding compensat-
ing gradient is now positive as it is applied before the inversion pulse. The relative 
amount of T1 and T2 weighting for image contrast can be adjusted by changing the 
TE and TR times.
Figure 10: The k-space and the Fourier transform. (A) The filling of k-space by a 2D gradient echo pulse 
sequence (see figure 8A). The negative gradient pulse labeled with ‘b’ in the pulse sequence diagram 
moves the start of the acquisition from (0,0) to (-kf,max, 0). The positive gradient pulse labeled with ‘a’ 
in the pulse sequence diagram moves the start of the acquisition from (-kf,max, 0) to (-kf,max, +kp,max). 
During acquisition the positive gradient pulse labeled with ‘c’ causes the line ‘acquisition 1’ to be filled 
with data. The filling process is repeated with a less positive gradient pulse ‘a’ until the required number 
of lines are stored. (B) The filling of k-space by a 2D spin echo pulse sequence (see figure 8B). This time 
pulse ‘b’ is positive and pulse ‘a’ starts negative, so that the start of the acquisition moves from (0, 0) to 
(+kf,max, -kp,max). The 180 degree inversion pulse flips the start of the acquisition to (-kf,max, +kp,max). (C) 
A completed k-space is then Fourier transformed and results in the final image (D). Adapted from de 
Graaf et al. (24).
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Diffusion weighted MrI
Diffusion weighted MR imaging (DWI) is a very successful and widely used func-
tional imaging protocol providing information about the mobility of (mainly) water 
molecules. When the water molecules can move freely in all directions and are 
not hindered by any boundaries we can measure the diffusion coefficient D. The 
diffusion coefficient is a measure of the mean square displacement of the water 
molecules, as a result of their kinetic energy of random motion in a certain time. The 
water molecules in tissue, however, usually cannot move freely in all directions; they 
are hindered by many obstacles, such as macromolecules, fibers, and membranes. 
Therefore this diffusion coefficient is called apparent diffusion coefficients (ADC). 
The higher the ADC value the more freely the water molecules can move.
Cellular processes, like apoptosis and proliferation may influence cell membrane den-
sity and thus the ADC value. Therefore DWI is a promising functional imaging tool 
for tissue characterization, response prediction and evaluation in cancer (31,32).
DWI is frequently implemented as a spin echo sequence with two identical gradient 
pulses around the 1800 inversion pulse (figure 12). The first gradient pulse adds a 
Figure 11: The rephasing during a spin-echo experiment. (A) The pulse sequence diagram. (B) After 
the 90 degrees excitation pulse there is complete phase coherence of the spins. The generated FID is 
not recorded. (C) Due to field inhomogeneities and spin-spin interactions (T2* relaxation) the spins lose 
their phase coherence. (D) After the 180 degree inversion pulse all magnetization vectors are mirrored. 
The spins sense the same field inhomogeneities and start to rephase. (E) At time TE the spins have 
completed the rephrasing and an echo is generated. The fast decay due to the field inhomogeneities is 
(partially) recovered and only the slow decay due to spin-spin interactions (T2 relaxation) and some T1 
relaxation remain. Adapted from de Graaf et al. (24).
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position depended phase to the spins. The second gradient pulse adds the exact 
opposite position depended phase to the spins. If the spins did not move in between 
these two pulses the phases cancel and the echo will be at its maximum value com-
pared to a spin-echo without these extra gradients. However, when spins move in 
the direction of the gradient the added phases no longer cancel and the final echo 
will be lower due to increased dephasing. The larger the displacement of the spins, 
the lower the signal. This means that the magnitude of the signal loss reflects the 
mobility of the spins or water molecules. By using different gradient durations and 
amplitudes the rate of diffusion can be measured. The duration and amplitudes are 
often expressed in a so-called b-value, the diffusion-sensitizing factor. The signal 
S measured in the presence of a diffusion gradient S(b), and without a diffusion 
gradient S(0) relate to the diffusion coefficient D by:
𝑆𝑆𝑆𝑆(𝑏𝑏𝑏𝑏)
𝑆𝑆𝑆𝑆(0)
= 𝑒𝑒𝑒𝑒−𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
𝑏𝑏𝑏𝑏 = 𝛾𝛾𝛾𝛾2𝐺𝐺𝐺𝐺2𝛿𝛿𝛿𝛿2 (∆ −
𝛿𝛿𝛿𝛿
3
)
γ δ
Δ
 (38)
where b is given by (also see figure 12):
𝑆𝑆𝑆𝑆(𝑏𝑏𝑏𝑏)
𝑆𝑆𝑆𝑆(0)
= 𝑒𝑒𝑒𝑒−𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
𝑏𝑏𝑏𝑏 = 𝛾𝛾𝛾𝛾2𝐺𝐺𝐺𝐺2𝛿𝛿𝛿𝛿2 (∆ −
𝛿𝛿𝛿𝛿
3
)
γ δ
Δ
 (39)
where γ is the gyromagnetic ratio, G is the magnetic field gradient strength, δ the 
gradient duration, Δ the time between the start of the gradient pulses. When ADC 
values of multiple restricted diffusion experiments are compared, the diffusion time 
should be kept the same between measurements as this relates to the distance trav-
eled by the spins of water molecules. A shorter diffusion time reduces the traveled 
distance by these molecules, meaning fewer molecules are affected by surrounding 
barriers.
Figure 12: Diffusion gradients applied in a spin echo pulse sequence diagram.
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t2
* MrI
There is an increasing interest in T2
* or R2
* (=1/ T2
*) MRI, also known as intrinsic 
susceptibility-weighted or blood oxygenation level dependent (BOLD) MRI as a mea-
sure for tumor vascularity and hypoxia (1,16,33-36). The transverse magnetization 
relaxation T2
* represents both spin-spin relaxation and magnetic field inhomogene-
ities (37). Deoxygenated hemoglobin in blood is paramagnetic (38,39) and affects 
the local magnetic field and thus decreases the T2
* relaxation time. As vessels near 
hypoxic tissue may have higher levels of deoxyhemoglobin the T2
* relaxation time in 
and near these vessels is expected to decrease. Knowledge of hypoxic regions is of 
clinical importance, since hypoxic tumors are likely to have an increased resistance 
to radiation therapy and chemotherapy (40,41).
A T2* map can easily be generated by obtaining many images with varying echo 
times TE and fitting the data voxel by voxel to the mono-exponential curve:
𝑀𝑀𝑀𝑀𝑥𝑥𝑥𝑥𝑥𝑥𝑥𝑥(𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇) = 𝑀𝑀𝑀𝑀𝑥𝑥𝑥𝑥𝑥𝑥𝑥𝑥(0)𝑒𝑒𝑒𝑒
−
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇2
∗
 (40)
As the decay due to T2* is usually much faster (in the human liver) than the decay 
due to T1, the latter has only limited influence. The total acquisition time can be long 
as many scans with different TE values need to be performed for a reliable fit. To 
reduce the total acquisition time a so-called fast low angle shot (FLASH) sequence 
is often applied. This sequence is basically a gradient echo but with a flip angle lower 
than 900. With a typical 150 flip angle the amplitude of the FID is still 26% (sin(15o)) 
of the amplitude when it was excited by a 900 pulse. However, 96.6% (cos(15o)) of 
the longitudinal magnetization Mz remains unaffected and is available for the next 
excitation (42). Immediately after the readout gradient the sequence is repeated, 
thereby considerably shortening the TR and thus the total acquisition time. After 
several excitations the spin system reaches a steady state where the loss of longitu-
dinal magnetization due to excitation is compensated by the T1 relaxation.
Dynamic contrast-enhanced MrI
Dynamic contrast-enhanced MRI (DCE-MRI) is a functional imaging method where 
fast T1-weighted MRI scans are acquired dynamically in time after injection of an MRI 
contrast agent. The contrast agents most often used are based on gadolinium (Gd) 
complexes , e.g. Gadoteric acid (Gd-DOTA), and are administered intravenously. 
Depending on the permeability of the vessels, it can leak into the extracellular extra-
vascular space and re-enter the vessels again. The contrast agent lowers the T1 (and 
to some extend the T2) relaxation time of the surrounding tissue water protons. 
Vascular and (tumor) tissue concentrations of the contrast agent can be calculated 
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by comparing the T1 relaxation times before and after the injection of contrast agent. 
Pharmaco-kinetic modeling can be applied to obtain quantitative kinetic parameters 
like the rate constant of contrast exchange between extracellular extravascular 
space and blood plasma (kep), the corresponding volume transfer constant (K
trans) 
which depends on local blood flow and/or vessel permeability, and the fractional 
extracellular space (ve) (43-46). The predictive value of DCE-MRI parameters for 
treatment outcome has been shown for rectum carcinoma and other tumor types 
(47). These parameters are especially promising to assess tumor angiogenesis and 
effects of antiangiogenic therapy (48-51).
As DCE-MRI requires a high temporal resolution to capture the first contrast agent 
bolus passage, the same 2D FLASH sequence as discussed above is often applied. 
Mr spectroscopy
MR spectroscopy (MRS) is of particular interest in examinations of tumors as it can 
provide specific information on metabolism related to their pathophysiology. This 
may include metabolic data associated with the type, grade, and stage of the tumor, 
which thus can assist in further management of the disease.
In vivo MRS allows for the noninvasive measurement of the levels of some com-
pounds in body tissues by exploiting the magnetic properties of certain atomic 
nuclei in these molecules. The nuclei that are best accessible for in vivo MRS experi-
ments are those of proton (1H), phosphorus (31P), and carbon-13 (13C) atoms. The 
principles of MR spectroscopy with these nuclei and its application to liver tumors 
and metastasis is presented in more detail in chapter 2 of this thesis. In this section 
only a few general remarks are made per nucleus.
1h-Mr spectroscopy
A major signal of importance in the 1H MR spectrum of tumors is that of the methyl-
protons of choline. It has emerged as a key biomarker to identify malignant tumors 
(52-54). The signal is also known as the total choline (tCho) peak as it may originate 
from several different choline compounds. The relative increase in the tCho signal 
commonly seen in human tumors is due to an abnormal choline uptake and/or 
metabolism related to cell membrane turnover. tCho levels also have been correlated 
with tumor aggressiveness (55).
Another interesting signal in 1H spectra of tumors is that of lactate. In contrast to 
normal cells, tumor cells often have an increased glucose uptake and glycolytic rate, a 
decreased oxidative phosphorylation and thus an increased lactate production, even 
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in the presence of abundant oxygen; the so-called Warburg effect (56-59). Thus, in 
liver tumor studies the lactate signal may represent its typical energy metabolism.
31p-Mr spectroscopy
Compared to 1H the intrinsic sensitivity of 31P is about 6.6% and therefore larger 
sampling voxels are required for an appropriate signal-to-noise. 
With 31P MRS phosphorylated choline and ethanolamine containing compounds can 
be resolved. From several studies it is known that the increase of phophomonoesters 
(PME, mainly phosphocholine and phosphoethanolamine) is associated with tumor 
progression and that successful treatment is associated with a decrease of PME 
levels (60-63). Therefore 31P MRS could very well be used for treatment response 
monitoring. Besides the signals from phospholipid metabolism, 31P MR spectra 
of liver also show signals of adenosine triphosphate (ATP), being the main direct 
energy supply within cells, and of inorganic phosphate (Pi), which together can be 
used to investigate tumor energy metabolism.
13C-Mr spectroscopy
As nearly all metabolites in the body contain carbon it seems attractive to apply 
in vivo 13C MRS. However, about 98.9% of the carbons are 12C, which has no net 
nuclear spin and therefore are not detectable by MRS. With a natural abundance 
for 13C of 1.1% the signal-to-noise of in vivo 13C MRS only allows to detect very 
concentrated compounds such as lipids. Therefore substrates of interest are usually 
enriched with 13C which increases the SNR of these substrates and their products 
and offers the unique possibility to monitor metabolic conversions by following the 
labeling of these products. A well-known substrate in these studies is 13C-1-glucose 
(64).
The 13C-glucose is transported into the cell similar to 18F-FDG used in PET (see 
next paragraph) (65). Where the derivative of 18F-FDG is trapped inside the cell, 
revealing areas of high glucose uptake and thus indirectly glycolytic activity, the 
13C-of glucose enters metabolic pathways like glycolysis and the citric acid cycle. 
This allows direct studies of glucose uptake and conversions (rate, flux) through 
metabolic pathways by following metabolite labeling: e.g. relative contributions of 
glycolysis and oxidative phosphorylation, as well as oxygen consumption (33,66).
A new 13C application concerns the hyperpolarization of 13C spins of labeled sub-
strates to temporarily enhance their MR signals by orders of magnitude (67,68). A 
commonly employed substrate in this approach is 13C-pyruvate, but others may be 
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used as well (34,69). Infusion of these hyperpolarized substrates allows imaging by 
13C MRS to provide spatial specific information on metabolites and metabolic rates 
involved in energy metabolism. 
Introduction to positron emission tomography
Another major imaging modality to obtain molecular information is positron emis-
sion tomography (PET). For PET, molecular probes labeled with positron emitting 
radionuclides are administered to a patient. When a positron is emitted after radio-
active decay by such a radioactive isotope, it will typically travel a few millimeters 
before colliding with one of the electrons in the surrounding tissue (figure 13). The 
two particles will then annihilate, and typically emit two 511 keV photons in (almost) 
opposite directions. These photons can then be detected by two ‘opposite’ detec-
tors located in a ring consisting of many detectors and surrounding the patient (70).
Figure 13: Schematic representation (transaxial view) of the PET detector ring, the positron-electron 
annihilation process and the detection of the two gamma photons. Adapted from Delso et al. (70).
When two ‘opposite’ detectors register a photon within a certain time window, the 
event is called a coincident and the photons are assumed to originate from the same 
annihilation event located somewhere on the line between the two detectors. After 
detecting many coincident events a reliable biodistribution of the molecular probes 
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in the body can be deduced by using standard image reconstruction techniques 
like filtered back-projection (FBP), maximumlikelihood-expectation maximization 
(MLEM) and ordered subsets-expectation maximization (OSEM) (71-73).
Typically, PET scanners have a high molecular sensitivity which is orders of magni-
tude away from what other modalities can achieve. The molecular sensitivity for PET 
is 10-11 – 10-12 mole/liter, whereas e.g. the sensitivity in conventional MRI is 10-3 
– 10-5 mole/liter (74). However, the spatial resolution of PET is limited, and typi-
cally between 3 and 10 mm, compared to the typical 1 mm for MRI and computed 
tomography (CT).
The introduction of modern integrated PET/CT scanners not only resulted in easier 
coregistration of the PET and CT images (75,76), but the anatomical CT images can 
also be used for accurate localization of lesions detected with PET.
Furthermore, the CT data can be used for PET attenuation correction: Tissues 
deeper inside the body or near dense material like e.g. bones may appear to have less 
PET activity as the annihilate photons originating from it have a higher probability to 
be absorbed or scattered and may never be detected. Body surface tissue and lung 
tissue on the other hand may appear to have more activity as these photons have 
a lower probability to be absorbed or scattered. Attenuation correction corrects 
for these artifacts by using attenuation maps based on measured tissue densities. 
This means that, after rescaling for the higher energy PET photons, the CT tissue 
density data can easily be used for PET attenuation correction, thereby replacing the 
conventional transmission scan with the external radionuclide (e.g. 68Ge) sources. 
This has improved attenuation correction since CT has much lower noise and is more 
patient friendly, since it can be performed in a shorter scan time (75,77).
18F-FDG pet
By far the most commonly used PET tracer is 2-deoxy-2-[18F]fluoro-D-glucose (18F-
FDG). It is a glucose analog where the oxygen in the C-2 position is replaced by 
fluorine-18.
Glucose metabolism
Almost all cells in the human body are able to metabolize glucose. Glucose trans-
porters located in the cell membrane actively transport glucose into the cell when 
needed. Once in the cell, glucose is phosphorylated by hexokinase as the first step 
toward glycolysis. 
34
• 
C
ha
pt
er
 1
Normal cells metabolize glucose to pyruvate via glycolysis yielding for every molecule 
of glucose, two molecules of adenosine triphosphate (ATP); a cell’s energy transport-
ing molecule. When oxygen is present, pyruvate is further oxidized to CO2 and H2O in 
the mitochondria in processes called citric acid cycle and oxidative phosphorylation; 
yielding up to 36 molecules of ATP. When the available oxygen is limited, pyruvate 
is converted to lactic acid while regenerating NAD+ from NADH+H+. The lactic acid 
is, together with H+, transported out of the cell by monocarboxylate transporters 
(MCTs) and released into the bloodstream, thereby reducing the excess of H+ in the 
cell, and allowing glycolysis to continue (78).
18F-FDG and tumor metabolism
In contrast to normal cells, tumor cells often show increased glucose uptake and gly-
colysis with decreased oxidative phosphorylation, even in the presence of abundant 
oxygen; the so-called Warburg effect (56-59). 
For cancer imaging this higher uptake of glucose by many tumors is exploited. After 
the injection of 18F-FDG in the bloodstream it is, like glucose, transported into the 
cells and once inside it is phosphorylated to 18F-FDG-6-phosphate. However, unlike 
glucose-6-phosphate, 18F-FDG-6-phosphate cannot be metabolized any further, as 
this would require an oxygen atom at the C-2 position. Due to the low concentration 
of glucose-6-phosphatase in tumor cells, the reverse reaction to 18F-FDG does not 
take place or only very limited. The 18F-FDG-6-phosphate is thus trapped inside the 
cell where it accumulates (79). Hence, a location with high PET activity reflects the 
location of cells with high glucose uptake and metabolism, like in a tumor cell.
However, high glucose uptake and metabolism is not specific for tumor tissue. Other 
tissues like e.g. the nervous system (brain), the heart and active skeletal muscles 
have a high glucose metabolism. In inflammatory processes (infection, sarcoid, 
arthritis, etc.), granulation tissue, activated white blood cells and macrophages have 
high glucose uptake and metabolism. In addition, the urinary tract shows higher 
activity concentrations as FDG is excreted via the kidneys.
18F-FDG pet in treatment response
A review study evaluated the role of 18F-FDG PET in treatment response prediction 
and monitoring in advanced stage colorectal cancer (80). It indicated that 18F-FDG 
PET imaging can be used to predict the clinical outcome of chemotherapy in patients 
with advanced colorectal cancer (36,81-84). Already after one cycle of chemother-
apy, 18F-FDG PET was able to identify tumors unlikely to respond to treatment (85).
35
Introduction and outline of the thesis
Outline of the thesis
To address the aims of this thesis, described in the section Rationale (see above), 
several MR and PET imaging techniques have been validated experimentally and 
assessed for their value to predict response to systemic treatment of liver tumors.
Chapter 2 reviews the status of magnetic resonance spectroscopy (MRS) applied to 
liver tumor research starting with the basic concepts of MRS, followed by a descrip-
tion of the metabolites of interest visible in the 1H-, 31P-, and 13C-MR spectra of liver 
tumors and metastases. In addition, the available literature on MRS of primary liver 
tumors and metastases is summarized and discussed, for both in vivo MRS and in 
vitro high field MRS.
A high total choline (tCho) signal is commonly detected in 1H-MR spectra of malig-
nant tumors. This signal is associated with a poor outcome and decreases upon suc-
cessful treatment. In chapter 3 the diagnostic potential of the tCho signal in in vivo 
1H-MRS in human liver metastases of colorectal cancers was assessed. In addition, 
for interpretation purposes, a few ex vivo normal and tumor tissue specimens were 
subjected to high-resolution magic angle spinning (HRMAS) NMR spectroscopy.
To predict treatment outcome or monitor therapy by MRI, differences in imaging 
parameters (e.g. ADC and T2
*) should reflect true differences in tumor biology and 
not variations in the MR system or artefacts such as motion. Knowledge of repeat-
ability is of special relevance in early response monitoring as the expected differ-
ences in these parameters are small. If changes within a tumor are larger than can 
be attributed to normal variation, it can be assumed that this is due to a treatment 
effect. Chapter 4 and 5 describe the repeatability and biological validation of DWI 
and T2
* MRI, respectively. 
Tumor vascularization can be assessed by DCE-MRI. The analysis of the DCE-MRI 
data, yielding e.g. the quantitative parameters Ktrans, kep and ve, may however be 
hampered due to respiratory and cardiac motion. In chapter 6 we present a suc-
cessful implementation of a procedure that removes motion displaced or distorted 
images as identified by a structural similarity method to reduce the effect of motion 
in fast multi-slice 2D DCE-MRI of the liver.
CT examinations of the liver require the application of a contrast agent, as without 
contrast these tissues have similar Hounsfield units. CT contrast agents are opaque 
for the x-rays used in CT but less opaque to the PET photons. Therefore, using 
contrast enhanced CT data for attenuation maps in PET may result in artifacts and 
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overestimation of radionuclide activity in PET. Chapter 7 investigates and discusses 
the use of a contrast enhanced CT for PET attenuation correction. 
Chapter 8 investigates the potential of 18F-FDG PET, DWI, and T2
* MRI to predict 
response to systemic treatment in patients with colorectal liver metastases. Pre-
treatment measurements and early changes one week after start of therapy were 
evaluated for their predictive value.
Chapter 9 summarizes and discusses all findings of the previous chapters and pro-
vides future perspectives.
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Chapter 2
In vivo Mr Spectroscopy of liver tumors 
and metastases
This chapter is based on: 
ter Voert EG, Heijmen L, van Laarhoven HW, Heerschap A. In vivo magnetic 
resonance spectroscopy of liver tumors and metastases. World J Gastroenterol. 
2011;17:5133-49.
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abstract
Primary liver cancer is the fifth most common malignancy in men and the eighth 
in women worldwide. The liver is also the second most common site for metastatic 
spread of cancer. To assist in the diagnosis of these liver lesions non-invasive 
advanced imaging techniques are desirable. Magnetic resonance (MR) is commonly 
used to identify anatomical lesions, but it is a very versatile technique and also can 
provide specific information on tumor pathophysiology and metabolism, in particular 
with the application of MR spectroscopy (MRS). This may include data on the type, 
grade, and stage of tumors, and thus assist in further management of the disease. 
The purpose of this review is to summarize and discuss the available literature on 1H, 
31P and 13C-MRS as performed on primary liver tumors and metastases, with human 
applications as the main perspective. Upcoming MRS approaches with potential 
applications to liver tumors are also included. Since knowledge of some technical 
background is indispensable to understand the results, a basic introduction of MRS 
and some technical issues of MRS as applied to tumors and metastases in the liver 
are described as well. In vivo MR spectroscopy of tumors in a metabolic active organ 
as the liver has been demonstrated to provide important information on tumor 
metabolism, but it also is challenging as compared to applications on some other 
tissues, in particular in humans, mostly because of its abdominal location where 
movement may be a disturbing factor.
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Introduction
Primary liver cancer is the fifth most common malignancy in men and the eighth in 
women worldwide. In 2000, it was estimated that there were about 564,000 new 
cases of liver cancer worldwide, and a similar number of patients died as a result 
of this disease (1). Also, the liver is the second most common site for metastatic 
spread of cancer (2). In fact, liver lesions are more likely to represent a metastatic 
tumor than a primary liver tumor (3,4). For further clinical management a proper 
diagnosis is crucial. Currently tissue sample analysis by histopathology is the golden 
standard for the diagnosis of suspected cancer in the liver. However, taking biopsies 
for histopathological analysis has some disadvantages. Besides patient discomfort, 
there is a change that the needle misses the cancer foci. Also, the needle might 
loosen cancerous cells which could result in tumor dissemination outside the liver 
along the needle track (5).
Thus, non-invasive advanced imaging techniques are desirable to assist in the diag-
nosis of liver lesions. A major modality to obtain anatomical information is magnetic 
resonance (MR). The MR technique is very versatile and it also offers many possibili-
ties to acquire more functional information. Among these, MR spectroscopy (MRS) 
is particular interesting as it can provide specific information on tumor pathophysiol-
ogy and metabolism. This may include data on the type, grade, and stage of the 
tumor, which thus can assist in further management of the disease.
In this review we will summarize and discuss the available literature on MRS of 
primary liver tumors and metastases. We will focus on the main nuclei employed in 
MRS, proton (1H), phosphorus-31 (31P), and carbon-13 (13C). Since knowledge of 
some technical background is indispensable to appreciate the impact of the results 
described in this paper we first give an introduction into the basics of MRS and some 
technical issues of MRS as applied to tumors and metastases in the liver.
Basic concepts of magnetic resonance spectroscopy
In vivo MR spectroscopy (MRS) allows for the noninvasive measurement of the 
levels of some compounds in body tissues. It exploits the magnetic properties of 
certain atomic nuclei that are present in these molecules. The nuclei that are best 
accessible for in vivo MRS experiments are those of proton (1H), phosphorus (31P), 
and carbon-13 (13C) atoms. 
The following sections present a short introduction of MR spectroscopy to provide 
the reader with sufficient background to understand the biological and clinical 
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applications of MR spectroscopy. For more in-depth information the reader is referred 
to other publications, see for example (6).
Mr spectra
The key feature of MR spectroscopy is that certain biochemical compounds, mostly 
metabolites, can be identified in an MR spectrum by their specific spectral pattern, 
which is composed of one or more distinct signals. The intensity of the signal is pro-
portional to the tissue amount of a certain nuclei and thus reflects the tissue levels of 
the compound in which it is present. An example of a typical in vivo 1H MR spectrum 
of a healthy liver is shown in figure 1. The horizontal axis of a spectrum represents 
the resonance frequency or chemical shift (both terms are explained below), the 
vertical axis represents the signal intensity. This spectrum is dominated by three 
main signals and in addition there are some smaller peaks, and broad underlying 
resonances.
Recall from chapter 1 that atomic nuclei placed in an external static magnetic field B0 
are precessing with the so called Larmor frequency ν0 = ω0/(2π) = γB0/(2π) where 
the gyromagnetic ratio γ has a specific value for each nucleus. This implies that every 
type of nucleus has a different precession frequency, proportional to the B0 field 
strength. After sending a RF pulse with the RF coil, the transverse component of 
the M0 magnetization also precesses with the Larmor frequency at resonance and 
will induce a current in the RF coil when switched to receive mode. The decaying 
signal of this component is called the free-induction decay (FID) response signal. 
The measured current is converted to a digital signal and can be mathematically 
converted by a Fourier transform from the time to the frequency domain, which 
results in a so called MR spectrum that may contain one or more resonances, signals 
or peaks at particular frequencies. This MR spectrum is explored in MR spectroscopy.
Shielding and chemical shift
An MR spectrum of the liver would not be very interesting if all nuclei of a certain 
type resonate at the same frequency. Fortunately, each nucleus in a given molecule 
is shielded from the main field by a weak opposing field from the surrounding 
electrons, induced by and also proportional to B0. The amount of shielding by these 
electrons highly depends on the chemical environment of the nucleus. This shield-
ing, which is generally unique for each chemically distinguishable site in a molecule, 
is expressed as the shielding constant σ, and the total effective field experienced by 
a given nucleus is: Beff = B0(1−σ). The resulting change in resonance frequency νeff 
= ωeff  / 2π = γB0 (1−σ)/2π relative to that of a chosen reference compound,  νref , is 
generally referred to as the chemical shift σ = ( νeff – νref )/νref expressed in units of 
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ppm (1 ppm = 100 Hz at ν0 = 100 MHz). Thus the chemical shift is the key property 
of MR spectroscopy which enables to detect a wide variety of chemical groups and 
metabolites containing these groups. Special RF pulses are used to excite a band of 
frequencies covering the chemical shift range of a particular nucleus in a biological 
sample. 
the 1h Mr spectrum of the liver explained
As shown in figure 1 the 1H spectrum of the liver is dominated by 3 peaks. The peak 
on the right originates from the 1H nuclei in methylene groups (-CH2-) in lipids, the 
peak in the middle originates from the 1H nuclei in the three methyl groups (CH3) 
of choline containing compounds ( (CH3)3N
+CH2CH2O-), and the peak on the left 
originates from the 1H nuclei in water (H2O). The electronegative oxygen atom in 
the water molecule shifts the electron density away from the 1H nuclei, leading to a 
reduced shielding and thus to a higher resonance frequency compared to 1H nuclei 
in the methylene groups of lipids. Thus 1H nuclei in water have a higher chemical 
shift value then the 1H nuclei in the methylene groups from lipids (compared to 1H 
nuclei in a reference compound at 0 ppm) and appear on the left side. Note that the 
chemical shift scale on the horizontal axis increases from right to left. 
The peak area rather than its amplitude is proportional to the amount of 1H nuclei in 
the same chemical environment and thus the tissue content of that chemical group 
or metabolite. Quantification of metabolite concentrations is performed by compar-
ing peak areas with those of known substances and concentrations.
The content of water in the liver is much higher than that of metabolites. Hence, 
the proton signals of the latter have a much lower SNR (figure 1). For this reason 
signal averaging is usually required and it is also needed to measure larger voxels 
than commonly done with MR imaging of water.
Water signal suppression
As the water resonance in 1H MR spectra is at least 200 times more intense than the 
resonances of hydrogen containing metabolites (figure 1) it may hamper the proper 
detection of metabolites signals, e.g. by artifacts such as side bands of this huge sig-
nal (7), the suppression of the water signal is commonly performed. There are many 
ways to do this : a well-known sequence is chemical shift selective (CHESS) water 
suppression (8). A frequency selective RF pulse excites the water spin magnetiza-
tion into the transverse plane after which all coherences are dephased by magnetic 
field gradients.  The spectrum shown in figure 1 was obtained with only partial water 
signal suppression.
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Magnetic field homogeneity
As the purpose of MR spectroscopy is to separate signals with different chemical 
shift it is crucial for its proper application that good magnetic field homogeneity is 
obtained over the object of interest. However, due to the many different tissue types 
and air containing compartments, the magnetic field in the human body is usually not 
very homogeneous, leading to broadened spectral lines, which may overlap. There-
fore optimizing field homogeneity (a process called shimming) is usually a required 
step in an MR spectroscopy experiment. Good homogeneity is most important in 1H 
MRS as it has a relatively small chemical shift range and needs a well separated and 
defined water signal for proper suppression and to avoid artifacts. By selecting small 
volumes of interest, a limited amount of different tissues are included which will 
result in a more homogeneous magnetic field. The requirements for homogeneity 
are much less strict for 31P and 13C MRS because resonances in their spectra are 
more separated (larger spectral dispersion).
Spin-spin coupling and decoupling
Nuclei which are close to one another exert an influence on each other’s effec-
tive magnetic field through electrons in chemical bonds (figure 2). If the distance 
between non-equivalent nuclei is less than or equal to three bond lengths, this effect 
,may be observable in the in vivo MR spectrum. Instead of one peak for a certain 
nucleus several smaller peaks are observed in the spectrum. This interaction of nuclei 
is often referred to as scalar coupling, J coupling or spin-spin coupling. Because of this 
splitting the signal to noise decreases and spectral interpretation may become more 
complicated. However, the specific pattern may also be helpful to identify specific 
molecular groups and with special pulse sequences the phenomenon of spin-spin 
coupling may be used to identify the resonances of these groups in the presence of 
other overlapping resonances (so-called editing).
Spin-spin couplings are expressed in Hertz (Hz). A typical value for a three bond 
proton-proton coupling in metabolites is 7Hz. For example this can be used to iden-
tify the methyl doublet resonance of lactate in 1H MR spectra. At magnetic fields 
above about 2T, line width broadening will obscure the direct visualization of this 
coupling. Two bond 31P – 31P couplings occur  at about 17Hz in ATP. Heteronuclear 
couplings commonly dealt with in in vivo MRS are between protons and 31P or 13C. 
To improve signal to noise and spectral resolution  the spin-spin splitting can be 
removed by a technique called decoupling.  Special RF pulses are used to irradiate 
selected resonance(s) of nuclear spins such that their field directionality is averaged 
out. As a result nearby spins in a molecule experience no field of these irradiated 
spins anymore and the resonance splitting disappears.
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Decoupling is important in MRS of 31P and 13C as these atoms often show splitted 
resonances due to nearby hydrogen atoms. Irradiation of these protons for decou-
pling increases the signal to noise ratio and improves spectral resolution. Irradiation 
also induces a through space effect called nuclear overhauser enhancement (NOE), 
which can increase signal intensity even more (9–11). Typical enhancement values 
reached in vivo by NOE are 1.3-2.9 and 1.4-1.8 for 13C-1H and 31P-1H interactions 
respectively (6). 
Dynamic nuclear polarization
Carbon-13 labeled (enriched) substrates combined with 13C MRS have traditionally 
been used to monitor metabolic conversions during steady-state conditions and 
even has been used to assess active metabolism in human tumors (12–14). The 
relative low sensitivity of 13C MRS prevented imaging of these processes. However, 
with polarization transfer techniques sensitivity can be enhanced (14–16).
Recently a new method has been introduced in biomedical MR, dynamic nuclear 
polarization (DNP), that mostly makes use of 13C MRS, to image metabolic conver-
sions at reduced acquisition times (in an order of minutes or less) . Inspection of 
Equation 2 (above) reveals that decreasing the temperature also will increase the 
population differences between energy levels. DNP is a hyperpolarization technique 
that increases the spin polarization obtained at room or body temperature in tradi-
tional MR, by orders of magnitude by cooling the sample to very low temperatures 
and using selective microwave irradiation for efficient transfer of spin polarization 
from electron spin to nuclear spin (6,17,18). The substrate is then rapidly transferred 
to body temperature for administration.  The major disadvantage of DNP is that the 
polarization decay is determined by the spin-lattice relaxation time T1 of the nucleus 
(20-40 seconds for a 13C nucleus in a carboxyl group). The consequence is that only 
conversions in which substrates are rapidly taken up by tissues and metabolized 
within minutes can be imaged successful. With efficient uptake usually one or two 
metabolic steps can be imaged, before the signal has decayed away.
Localization
To analyze different regions of interest (ROIs) in the liver with healthy tissue or 
tumor lesions by in vivo MRS it is needed that only signals that originate from these 
locations appear in the spectra. This can be achieved in different ways. The most 
rudimentary one is to use only a surface coil on the body adjacent to the liver with a 
simple pulse sequence globally selecting the area next to the coil. However, in most 
cases a better localization is desired. More advanced spatial localization is possible 
with single voxel or multi-voxel methods.
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Single voxel localization
The most common single voxel localization techniques are Image Selected In Vivo 
Spectroscopy (ISIS) (19), Stimulated Echo Acquisition Mode (STEAM) (20) and 
Point Resolved Spectroscopy (PRESS) (21).
ISIS uses three frequency-selective inversion pulses, in the presence of three orthog-
onal magnetic field gradients. By turning on and off the inversion pulses, according 
to an encoding scheme, eight different scans are recorded. Adding and subtracting 
the different scans will add signal from the desired location while canceling signal 
from other locations. A disadvantage of ISIS is its sensitivity to motion as eight scans 
need to be obtained for a full 3D localization. ISIS is rarely used for 1H MRS, because 
of potential artifacts such as those arising from incomplete water signal suppression. 
However, it is the favored method in 31P MRS localization as effects due to relatively 
rapid T2 decay and to J-coupling are avoided.
For 1H MRS the most common single voxel localization techniques are STEAM 
and PRESS, which both use three spatially slice selective RF pulses to produce an 
echo signal from a well-defined region. STEAM uses 90o-90o-90o pulses and PRESS 
90o-180o-180o pulses to define three orthogonal slices. Only signal from the volume 
of interest remains in the final echo. In STEAM 50% of the original signal is lost as the 
second 90o pulse only rotates half of the transverse magnetization to the longitudi-
nal axis, while the other half is dephased by crushers. The PRESS technique retains 
full signal intensity, but the minimal possible TE is commonly larger than for STEAM. 
Multi voxel localization
Multi voxel localization allows the detection of localized spectra from a multidi-
mensional array of locations. Disadvantages compared to single voxel localization 
concerns some more magnetic field inhomogeneities due to the many different tis-
sue types in the field of view, intervoxel contamination, and the minimally required 
number of scans that may end up in long acquisition times. Spectroscopic imaging 
techniques acquire the signal from multiple voxels by using phase encoding gradients 
(22), analogous to the phase encoding technique used in MR imaging. The nominal 
voxel size is the field of view divided by the number of phase encoding gradient steps. 
The actual voxel size can deviate substantially from the nominal value as the signal 
is sampled only over a finite time. This introduces intervoxel contamination due to 
the characteristics of the Fourier transform. This voxel bleeding can be decreased by 
apodization functions like those with Gaussian or Hamming shapes, however at the 
expense of decreased spatial resolution. 
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Conventional encoding of N1xN2xN3 volume elements (voxels) requires N1xN2xN3 
acquisitions. A typical 16x16x16 dataset obtained with a repetition time of 2000ms 
and 4 averages would require a measuring time of  (16x16x16x2000x4/3600 = 9 
hours). Therefore techniques are developed that increase the temporal resolution 
e.g. by special k-space trajectories. For example  ‘circular 2D or spherical 3D k-space 
sampling with k-space apodization during acquisition’. This also reduces the total 
acquisition time by spending less time acquiring the high k-space coordinates and 
more time acquiring the low k-space coordinates. Other methods are based on fast 
MRI sequences e.g. EPI, RARE, spiral and steady-state sequences (6).
Quantification
Although the tissue level of metabolites is proportional to the area under its signal 
curve in the spectrum, it commonly requires some corrections and calibration with a 
signal of known concentration to obtain an absolute number (e.g. in mM). 
Such a reference signal maybe that of water or of another metabolite in the liver 
assuming a stable and known value for its tissue level. In the liver, the unsuppressed 
water signal is often used as an internal reference after correction for T1 and T2 
relaxation. However, dietary regimes and liver pathologies may affect the amount of 
water. Li et al. reported a 1.8 fold difference in five normal liver studies between the 
largest and smallest water signal intensity obtained from localized liver tissues. In 
four hepatocellular carcinoma studies, they observed a 3.2-fold difference between 
the largest and smallest water signal intensities obtained from the localized liver 
tumors. Lipid peaks exhibited even larger variations than did the water peaks (23).
External phantoms with known concentrations sometimes are also used for calibra-
tion purposes, but this may be not so practical in a clinical environment. In addition 
differences in coil loading have to be taken into account in this approach. To avoid 
correction and calibration issues spectral quantities are sometimes also assessed as 
ratio’s between integrals of signals of different compounds.
Motion and other artifacts
Motion can lead to voxel misregistration and outervoxel contamination. Motion of 
tissue through inhomogeneous fields (e.g. air in the lungs) results in broadening of 
the spectral resonances. Broadening of the resonances increases the risk of signal 
overlap and also lowers the signal to noise ratio. Compared to other organs like brain 
and skeletal muscle, MR spectroscopy of  the liver is challenging as there are poten-
tial field inhomogeneities and artifacts caused by respiratory movement, cardiac and 
aortic pulsations (24–26). Although often applied breath-hold acquisitions may be 
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problematic. Long acquisition times are needed to increase the signal to noise ratio 
and, since a breath-hold period can only last for about 15s in patients, the acquisition 
will require multiple breath-hold periods. Even when the acquisition is performed at 
end-expiration, there is no guarantee that the tissue is at exactly the same position, 
leading to outervoxel contamination. Respiratory and cardiac gating can be applied 
to reduce motion artifacts at the cost of an increased scan time. Another options is 
to align individual spectra and/or exclude bad spectra before averaging during post 
processing. Some liver pathologies e.g. due to long-term total parenteral nutrition 
may induce iron accumulation in the liver, which will result in field inhomogeneities 
and broadening of the spectral resonances.
repeatability
In order to predict treatment outcome or monitor therapy, differences in in vivo MR 
spectroscopy outcome parameters should reflect true differences in tumor biology 
and not differences induced by variations in the MRS protocol or interfering body 
physiology. This issue is relevant, since the time of MR scanning during the day (e.g. 
before or after a meal) or differences in eat patterns might already influence the 
metabolic activity and thus the concentrations of metabolites in the liver. Large 
inter- and intrapatient variability of MRS outcome parameters have been described 
(23).
1h Mr spectroscopy
In MR, hydrogen (proton) is the most commonly studied nucleus. Compared to 
other  MR sensitive nuclei it has the highest sensitivity and occurs at 100 % isotopic 
abundance. Almost all metabolites in the human body contain protons. Therefore, 
in principle a large amount of metabolites can be investigated. However, in practice, 
sensitivity restrictions set the in vivo detection limit of metabolites to a minimum 
tissue concentration of about 0.1 mM. An advantage of 1H MRS is that it uses the 
same nucleus as MRI techniques. Therefore, it can be performed with the same 
hardware and there is no need for special equipment. The major drawback of 1H 
MRS is the relatively small chemical shift range (~10ppm) for the many resonances 
of in vivo detectable compounds, resulting in limited spectral resolution. Moreover, 
these have to be resolved from a dominating water peak, in certain cases a large lipid 
peak, and at short echo times a high baseline due to macro-molecules.
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Metabolites visible in 1h Mr spectra of liver tumors
Lipids
Outside the brain 1H MR spectra of tissues usually show large signals of mobile 
lipids, mostly triglycerides: in particular a methylene peak at 1.2 ppm with smaller 
methylene peaks between 2.1 and 2.4 ppm and a peak for methyl protons at 0.9 
ppm (figure 1). Triglycerides occur in fatty liver , but also may be a marker of 
membrane breakdown and can be seen in tumors, abscesses and other pathological 
processes(27).
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Figure 1: In vivo 1H MR spectra of human liver tissue obtained from a healthy volunteer on a 3.0T MR 
system. Left: Spectrum with unsuppressed water signal. Right: Spectrum with partial suppressed water 
signal, showing the overlapping resonances for N-(CH3)3 protons at about 3.2 ppm occurring in choline 
compounds (tCho) and resonances for specific protons in lipids .
Lactate
Due to the Warburg effect tumor cells obtain relative less energy than normal cells 
from oxidative phosphorylation and have a more glycolytic character (28,29). 
Pyruvate, the end product of glycolysis, is converted into lactate (Lac), which is fur-
ther promoted by hypoxic conditions. Therefore MR spectra of tumor tissue often 
show signals for lactate. The three equivalent methyl protons of lactate give rise to 
a resonance at 1.31 ppm, which is a doublet due to coupling with the methylene 
proton, while the single methylene proton resonates as a quartet at 4.10 ppm due 
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to coupling with the methyl protons. In liver and tumor tissue, the lactate signal at 
1.3 ppm will  overlap with large lipid resonances. However, with so-called spectral 
editing techniques it is possible to separate the lactate signal from the lipid signals.
Creatine
Creatine (Cr) and phosphorylated creatine (PCr) play an important role in energy 
metabolism of many tissues. PCr serves as a spatio-temporal  energy buffer, main-
taining a constant level of ATP, facilitated by the creatine kinase reaction. The methyl 
protons of Cr and PCr resonate at about 3.03 ppm and the methylene protons reso-
nate at approximately 3.9 ppm. Under normal conditions, the concentration of total 
creatine (tCr) is relatively constant in muscle and brain and therefore often used as 
an internal reference. However, decreased Cr levels have been observed in tumors 
and other pathologies. Furthermore, hepatocytes do not express creatine kinase 
under normal circumstances(30), and therefore no creatine peak will be visible in 
the spectrum of healthy liver tissue. In vitro experiments at 9.4T have shown 5-10 
times increased levels of Cr in liver metastasis compared to normal liver tissue(31).
Choline and ethanolamine containing compounds
The signals of choline containing compounds in MR spectra have been used as key 
biomarkers to identify malignant tumors.(32–34) In vivo 1H MR spectra of the 
liver show the N-trimethyl (+N(CH3)3) resonances of choline compounds at about 
3.2 ppm. This resonance is also known as the total choline (tCho) peak as it may 
originate from several different choline compounds. The relative increase in the tCho 
Figure 2: From A to D: Two bonded nuclei, carbon (C) and hydrogen (H) in decreasing energy levels 
associated with spin states: ββ, βα, αβ, and αα. The electron clouds around each nucleus is indicated in 
light green and red. Arrows indicate individual spin states.
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signal seen in human tumors is due to an abnormal choline uptake and/or metabo-
lism related to cell membrane turnover. However, metabolism of choline containing 
compounds in tissue cells is complex. Although far less prominent in 1H MR spectra 
than choline also ethanolamine signals may contribute to a characteristic spectral 
profile of tumor tissue. Therefore some important biochemical pathways involving 
choline metabolism and the closely related metabolism of ethanolamine in the liver 
are briefly described (figure 3).
Choline and ethanolamine metabolism
Choline is a key precursor molecule in several metabolic pathways. It can be acety-
lated, oxidized, phosphorylated or hydrolyzed. Choline oxidation plays a major role 
in the provision of methyl groups via its metabolite, trimethylglycine (betaine) that 
participates in the synthesis of S-adenosylmethionine (SAM). Methylation reactions 
are involved in the biosynthesis of lipids, the regulation of several metabolic path-
ways, and detoxification in the body. Choline phosphorylation results in compounds 
such as phosphatidylcholine (PtdCho), lysophosphatidylcholine, choline plasmalo-
gen, and sphingomyelin which are  essential for structural integrity and signaling in 
cell membranes (35–38).
Figure 3: Simplified schematic overview of choline and ethanolamine metabolism including parts of the 
Kennedy pathway, the Methionine and Folate cycle. Abbreviations: B12, vitamin B12; BHMT, betaine-
homocysteine methyltransferase; CDP-Cho, cytidine diphosphate-choline; CDP-Etn, cytidine diphosphate-
ethanolamine; DMG, dimethylglycine; Etn, ethanolamine; GPCho, glycerol-3-phosphorylcholine; 
GPEtn, glycerol-3-phosphorylethanolamine; MS, methionine synthase; PCho, phosphorylcholine; PEtn, 
phosphorylethanolamine; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; THF, 
tetrahydrofolate; 5mTHF, 5-methyltetrahydrofolate; TMG, trimethylglycine (betaine).
56
••
 C
ha
pt
er
 2
PtdCho, the major phospholipid component of cells is derived from the Kennedy 
pathway (39), which has two branches, one via CDP-choline and the other via CDP-
ethanolamine (see figure 3). In the CDP-choline branch choline is initially converted to 
phosphorylcholine (PCho) and after some steps to PtdCho which can be converted into 
choline or into PCho again (36). Alternatively, phosphatidylethanolamine (PtdEtn) is 
generated via the CDP-ethanolamine branch, employing similar biochemical reaction 
steps. The resulting PtdEtn can be methylated, using SAM as the methyl donor, to 
PtdCho (36–38,40). The methylation pathway is, however, only relevant in liver. In rat 
hepatocytes it accounts for 20-40% of PtdCho synthesis (41). Besides entering the 
CDP-Choline branch of the Kennedy pathway, choline can also enter another major 
pathway in the liver in which it is oxidized into betaine (42–44).
Contributions to the tCho peak
The contribution of the nine methyl protons of free choline, which resonate at 3.19 
ppm, to the tCho peak is limited as the concentration of free choline is usually low. 
Another potential contribution to the tCho peak may come from PtdCho, which 
makes up a very high proportion of the cell plasma membrane. However, it is a large 
molecule with a relatively short T2 relaxation time that becomes even shorter by 
being incorporated into a membrane. Therefore, it is almost invisible in the in vivo 1H 
MR spectrum. Nevertheless, some evidence suggests that PtdCho may contribute 
to the tCho signal (45). Precursors of PtdCho such as PCho and phosphoryletha-
nolamine (PEtn) are more likely to contribute to 1H MR spectra as these are small 
molecules with long T2 relaxation times. Experimental evidence suggests that the 
tissue levels of PCho and PEtn increase during cell proliferation and tCho levels also 
have been correlated with tumor aggressiveness (46). In addition to PCho and PEtn 
(together called phosphomonoesters (PME)) their glycerol derivatives GPCho and 
GPE (together called phosphodiesters (PDE)) also contribute to the tCho signal. 
Besides protons of choline and ethanolamine containing compounds, protons from 
other metabolites might also resonate around 3.2ppm, e.g.  glucose at 3.23 ppm, 
myo-inositol at 3.27 ppm, and taurine at 3.25 ppm. In liver and kidney the resonance 
at about 3.26 ppm is almost entirely composed of proton signals of betaine (tri-
methylglycine) (6).
Liver tumors and metastases
In vitro high field 1h Mr spectra of the liver
Soper et al. (47) performed a diagnostic correlation between MR spectra and 
histopathology. They analyzed liver tissue specimens from 54 patients undergoing 
partial or total hepatectomy. The samples included 31 normal, 59 cirrhotic and 32 
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hepatocellular carcinoma (HCC) histologically confirmed tissues and were analyzed 
by 1H MRS at 8.5 Tesla. They found reduced amounts of lipids and carbohydrate resi-
dues and increased tCho in HCC compared to all normal and all cirrhotic liver tissue. 
Cirrhotic liver tissue and HCC were distinguished with a sensitivity and specificity of 
95.8% and 88.9%, respectively. Lactate signals of variable intensity were found at 
1.3 ppm, probably resulting from anaerobic metabolism after excision.
In vivo liver 1h Mr spectrum
In vivo 1H MRS is characterized by a much poorer spectral resolution and SNR than 
in vitro 1H MRS (see above, technical issues). Kuo et al. (48) investigated the value 
of in vivo 1H MRS in the assessment of large focal hepatic lesions. They included 
43 consecutive patients and 8 normal volunteers in a prospective MRS study. MRS 
was performed at 3.0 T with shallow and regular breathing. Single voxel PRESS with 
TE=30 ms, TR=1500 ms, 256 averages,  was used to select a volume of 2x2x3 cm3. 
The voxel of interest was located in the largest solid portion of hepatic tumors in 
patients. Healthy liver data was collected from an area at the centre of the right 
hepatic lobe for normal volunteers, or in an uninvolved area of the right hepatic lobe 
in patients. Patients with diffuse-type HCC, with focal nodular hyperplasia and obvi-
ous fatty infiltration, and histological unconfirmed lesions were excluded. 33 lesions 
(21 HCC, 2 angiosarcomas, 1 lymphoma and 9 hemangiomas) were included. They 
found that malignant tumors had elevated tCho resonances compared to uninvolved 
liver or benign tumors, but the difference in mean tCho/lipid ratio between malig-
nant tumors or uninvolved liver did not reach statistical significance.  Several factors 
may have contributed to these results. First of all, the tumors in this study may have 
contained significant necrotic areas with less viable cells. This may have diluted more 
prominent changes observed in areas of rapid cell turnover, within viable tumor 
tissue and may have caused low signal to noise for metabolite signals leading to 
larger errors. Physiological motion due to breathing and cardiac movement will have 
contributed, especially if the tumor was located in the left lobe or at extreme end 
of the right hepatic lobe. Finally, three different tumor types were included in the 
malignant group, which may have resulted in a variation of different metabolites in 
phospholipid metabolism, and thus in a more variable tCho resonance. Thus, in vivo 
1H MRS is technically feasible at 3.0 T for the evaluation of focal hepatic lesions, but 
the clinical application of the measurement protocol used by Kuo et al. is limited as 
normal liver, benign and malignant tumors cannot be clearly differentiated.
In the second part of their study Kuo et al. attempted to measure metabolic changes 
in HCC after transcatheter arterial chemoembolization (TACE). Eight HCC were 
evaluated before and two to five days after TACE. The tCho peak at 3.2 ppm was 
58
••
 C
ha
pt
er
 2
significantly decreased while the lipid and water signals at 1.3 and  4.7 ppm respec-
tively, were increased. The mean tCho/lipid ratio significantly decreased from 0.23 
± 0.11 before to 0.01 ± 0.00 after TACE treatment. One of the post-TACE lesions 
showed recurrence three months later and MRS also revealed an elevated tCho/lipid 
ratio at that stage. Therefore,  1H MRS at 3.0T may be used for treatment monitor-
ing.
Fishbach et al. (49) improved the MRS acquisition and processing protocol compared 
to previous studies by introducing a control of respiratory motion using breath-hold 
acquisitions and an abdominal compression belt. They also applied dedicated pre and 
post-processing including automatic phase and frequency correction based on the 
residual and the unsuppressed water signal in order to remove potential distortions 
mainly introduced by motion. Apart from 39 volunteers, they included 55 patients 
with advanced cancer with lesions of more than 3cm in diameter in their study (22 
metastases of colorectal cancer, 11 hepatocellular carcinomas, 9 metastases of breast 
cancer, 3 metastases of pancreatic cancer and 1 metastasis of prostate cancer). Liver 
spectra were acquired at 3.0T using a body transmit/receive coil. Breath-hold at end-
expiration spectra were acquired with the single voxel (2x2x2 cm3) PRESS technique 
with TE=35 ms, TR=2000 ms, 128 averages and 16 additional unsuppressed water 
reference lines. The intra-individual repeatability of this 1H MRS acquisition in the liver 
was tested in 25 patients and volunteers and judged to be satisfactorily. In total 186 
spectra were acquired and 27 spectra had to be discarded because they did not meet 
the predefined quality specifications. The remaining 113 spectra were measured in 
normal-appearing parenchyma of 37 patients and 39 volunteers. 
Although, remarkably, tCho signals relative to those of water seemed to be lower in 
metastatic lesions compared to normal liver tissue, no significant differences were 
observed between malignant liver tumours and normal liver parenchyma for any of 
the parameters analyzed, in particular tCho signals relative to water and lipid signals. 
This was attributed to the large variability of normal values.
The divergent results observed in the above mentioned studies might also be due to 
the multiple contributions to the unresolved tCho signal. In normal liver tissue low 
concentrations of PMEs and high concentrations of PDEs have been shown while 
in tumor tissue elevated levels of PMEs and decreased levels of PDEs have been 
observed (50). This implies that in tumor tissue increased levels of PMEs, may be 
canceled out by decreased PDEs, resulting in an unchanged overall tCho level. Dif-
ferent tumor types might also have divergent contributions to the unresolved tCho 
signal. In addition, alterations of the metabolite concentrations might not be due 
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to malignancy, but due to proliferating healthy tissue such as a regenerating liver, 
benign tumors, and even some degenerative pathologies. With 31P MRS PME and 
PDE signals can be studied separately as discussed below.
31p Mr Spectroscopy
After 1H MRS, phosphorus-31 MR spectroscopy is the most commonly used MRS tech-
nique to study tumors in vivo. Phosphorus has an MR sensitivity of 6.6% compared to 
proton. However, the chemical shift dispersion of its signals observed in vivo is larger 
(~30ppm versus ~10ppm), resulting in a better spectral resolution. Also, 31P MRS is 
capable of detecting some key metabolites in tissue energy metabolism such as ATP, 
PCr, and inorganic phosphate (Pi). In addition some important metabolites involved in 
membrane metabolism such as PCho and PEtn (together called PME) and their glyc-
erol derivatives GPCho and GPE (together called PDE) may be resolved. In this respect 
31P spectra (figure 4) are more informative than 1H MR spectra in which signals of all 
choline compounds (tCho) usually are observed unresolved at about 3.2 ppm. Fur-
thermore, from 31P MR spectra physiological parameters like intracellular pH can be 
deduced from the chemical shift of the Pi resonance. The phosphoryl resonances from 
large and membrane bound compounds only may show up in a phosphorous-31 MR 
spectrum as broad underlying baseline signals due to their very short T2 values (51).
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Figure 4: In vivo 31P MR spectra of human liver tissue obtained from a healthy volunteer (top) and from 
a patient with hepatocellular carcinoma (bottom). (Reproduced with permission of John Wiley and Sons, 
www.interscience.wiley.com, from (64))
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Unfortunately, due to a lower sensitivity and less favorable spin relaxation the spatial 
resolution of 31P MR spectra is an order of magnitude less than that of 1H MRS. 
Higher magnetic fields provide improved experimental conditions for 31P MRS. 
Metabolites visible in 31p Mr spectra of liver tumors
phosphocreatine
The largest peak in 31P MR spectra of muscle, brain and other tissues  originates 
from phosphocreatine (PCr). Its spectral position  is used as an internal chemical 
shift reference and commonly has been assigned a chemical shift of 0.00 ppm. Phos-
phocreatine is, however, not detectable in spectra of healthy liver since hepatocytes 
do not express creatine kinase under normal circumstances(30). Tumors, however, 
might express creatine kinase and show some PCr.
adenosine triphosphate
Adenosine triphosphate (ATP) is the main direct energy supply within cells. ATP 
consists of adenosine and three phosphate groups. The phosphoryl groups, starting 
with those closest to the adenosine moiety, are referred to as alpha (α), beta (β), and 
gamma (γ) phosphates. ATP is produced by ATP synthase from inorganic phosphate 
and adenosine diphosphate (ADP) or adenosine monophosphate (AMP). Multiple 
processes in the cell can split ATP into ADP or AMP and inorganic phosphate, and 
use the energy that is released. At a pH of 7.2, with full magnesium complexation, 
the resonances of ATP appear at -7.52 ppm (α), -16.26 ppm (β), and -2.48 ppm (γ). 
The ATP resonances may overlap with the signals of other nucleotides: uridine tri-
phosphate (UTP), guanosine triphosphate (GTP) and cytidine triphosphate (CTP). 
Therefore these resonances are sometimes referred to as NTP, although the others 
usually occur at much lower concentrations.
Inorganic phosphate
Like the level of ATP that of inorganic phosphate (Pi) reflects the cellular phosphory-
lation potential. The chemical shift of Pi and some other phosphorus containing 
compounds is dependent on the intracellular pH (pHi) and magnesium concentra-
tions (52). The protonation or complexation with magnesium of phosphate affects 
the chemical environment of the 31P nucleus and hence its chemical shift. As proton 
exchange is fast on the NMR timescale, the resonance frequency is indicative of the 
relative amount of protonated and unprotonated molecules, and hence the pH can 
be deduced. The shift in resonance of Pi relative to PCr is most commonly used as it 
has a large dependence in the physiological pH range whereas the chemical shift of 
PCr is constant in this range. At a pH of 7.2 and normal magnesium level it occurs 
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at 5.02 ppm. The accuracy of pH determination from the Pi-PCr shift is typically 
0.05 pH units (6). However, as PCr is not detectable in the normal liver the α-ATP 
resonance is used instead as a reference.
tumor ph
Due to the Warburg effect and/or hypoxic conditions tumor cells preferentially con-
vert glucose to lactic acid. Lactic acid is largely dissociated in vivo to H+ and lactate-. 
Normal as well as tumor cells have multiple systems to continuously export H+ ions 
to maintain a constant pHi, as well as a system for exporting lactic acid (but not 
lactate-). This results in a neutral, or a slightly alkaline pHi of intact (tumor) cells. 
However, since tumors may be poorly vascularized the extracellular tumor pH (pHe) 
of tumors is more commonly acidic (53–59).
phosphodiesters
Signals of phosphodiesters (PDE) occur around 3 ppm in 31P MR spectra. Tumor 
tissue sometimes contains significantly lower concentrations of PDE than healthy 
liver tissue. Some in vitro studies show that the PDE levels increase with decreasing 
growth fraction of the tumor. This suggest that PDE signals may be dominated by 
breakdown products of phospholipids (60), and the concentration may be an indica-
tor of the necrotic fraction in tumors associated with phospholipid catabolism (61). 
The phospholipid derivatives, particularly glycerol-3-phosphorylcholine (GPCho) 
and glycerol-3-phosphorylethanolamine (GPEtn), where found to contribute to 
the PDE resonance (61). Their phosphor spins resonate at 2.76 ppm and 3.20 ppm 
respectively. 
phosphomonoesters
Resonances of phosphomonoesters (PME) occur at about 6 ppm in 31P MR spectra. 
Increased levels of PME have been hypothesized to be associated with intensified cell 
membrane synthesis, cellular growth, cell nutritional state and rate of cell replica-
tion. Several studies identified increased PME signals as a possible diagnostic marker 
for tumors. PME/PDE ratios were suggested to represent altered relative rates of 
membrane synthesis, catabolism and metabolic turnover (36,60,61). Phospholipid 
derivatives, particularly PCho and PEtn, contribute to the PME resonance (61). PCho 
and PEtn resonate at 5.88 ppm and 6.78 ppm respectively.
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Liver tumors and metastases
In vitro high field 31p Mr spectroscopy of liver
Many in vitro 31P MRS animal studies and several in vitro 31P MRS studies on human 
hepatic tumor tissues have been performed. Obtaining a fully representative human 
hepatic tissue sample for 31P MRS is difficult as the surgical removal and extraction 
usually results in a period of ischemia / hypoxia, which affects metabolic processes 
resulting in decreased ATP and increased Pi levels. Nevertheless, in vitro 31P MRS 
may be used to study signals in the PME and PDE peaks that are still unresolved in in 
vivo 31P MR spectra, as these are less affected by short periods of hypoxia.
Bell et al.(50) investigated the metabolic changes arising in hepatic tumors and the 
possible systemic effects of these tumors on the liver as a whole. Ten biopsy speci-
mens were obtained from hepatic tumors (one cystadenoma, four hepatocellular 
carcinomas, four metastatic colonic adenocarcinomas and one metastatic squamous 
cell carcinoma from the lungs). Five histologically proven normal tissue samples 
from the same tumor-bearing hepatic lobe were obtained immediately after the 
blood supply had been clamped and before partial hepatectomy. Six control samples 
were obtained from morphologically normal liver tissue from patients with histologi-
cally proven chronic pancreatitis and known to be free of any hepatic malignancy. 
Both 31P spectra with proton decoupling and 1H MR spectra with partially water 
suppression were acquired using high-resolution 11.7T systems. Betaine is the 
most prominent resonance in the in vitro rat liver 1H spectrum but no resonance 
for betaine was observed in any of the human biopsy samples, suggesting that its 
presence is species related. The in vitro 31P MRS spectrum showed that over 10 dif-
ferent compounds contributed to the PME resonance. The five principal resonances 
were: PCho, PEtn, glucose-6-phosphate, AMP, and glycerol-3-phosphate. The PDE 
region included at least 3 different compounds. The two main components were: 
GPCho and GPEtn. Compared to control tissue, tumor tissue showed significantly 
lower concentrations of GPCho (0.59±0.15 vs 2.46±0.37) and GPEtn (0.57±0.17 
vs 2.25±0.46), and elevated levels of PCho (1.36±0.50 vs 0.17±0.11) and PEtn 
(2.47±0.84 vs 0.16±0.10). It was suggested that the increase in PME/NTP observed 
in in vivo spectra of HCC and liver metastasis (see next section) is due to increased 
levels of PCho and PEtn. The decrease in concentration in GPC and GPE observed in 
this study might be responsible for the change in PDE/NTP seen in in vivo spectra. 
However, the underlying cause of these changes remains partially unknown and 
requires further study.
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Bell et al. also observed that spectra from histologically normal tissue from the liver 
tumor-bearing hepatic lobe contained more PCho (0.32±0.18 vs. 0.17±0.06) and 
PEtn (0.34±0.12 vs. 0.16±0.07) than spectra obtained from control tissue. The 
levels of GPC and GPE showed no significant change.
Previously, in 1993 Dagnelie et al. (62) studied liver metabolic changes in rats bear-
ing subcutaneous Dunning prostate tumors by in vivo and in vitro 31P MRS. Although 
absence of metastatic tumor cells in the liver of all tumor-bearing animals was con-
firmed by histological examination, hepatic phosphorylation status, phospholipid 
metabolism, and gluconeogenesis was significantly affected in the tumor-bearing 
animals. Dagnelie et al. (63) also investigated liver metabolism in humans with 
metastatic cancer without evidence of liver metastases by 31P in vivo MRS. They 
included 23 cancer patients and 12 healthy subjects and found markedly elevated 
PME and reduced PDE levels in the non-metastatic liver compared to controls. 
Thus this may complicate the use of increased PME (PCho and PEtn) levels as a 
sole diagnostic biomarker to detect (metastatic) liver cancer. In addition, as no 
significant differences between HCC and liver metastasis were observed in biopsy 
samples by in vitro 31P MRS (50,64). The use of in vivo 31P MRS seems limited in this 
differentiation.
In vivo 31p MrS of the liver
Already in 1985 Maris et al.(65) combined the results of in vivo and in vitro 31P MR 
spectroscopy studies to compare the spectral characteristics of the liver of 2 chil-
dren, one infant with neuroblastoma stage IV-S and the other with neuroblastoma 
stage IV disease. The 31P MR spectra from the primary tumor in the latter infant, and 
the spectra from the infiltrated liver regions in both the infants showed substantially 
elevated PME/β-NTP ratios compared with a spectrum from a normal control. The 
ratio increased during periods of rapid progression and persisted until treatment 
became effective. The PME/β-NTP ratio decreased to normal values, during either 
spontaneous or therapy-induced regression of the disease (66). It was suggested 
that the increased PME (corresponding to PEtn and PCho) was due to the need for 
increased phospholipid synthesis in these tissues. This study demonstrated that 31P 
MRS could be used to detect tumors and to monitor their response to treatment.
Dixon et al. (67,68) studied whether hepatic involvement in lymphoma produced 
biochemical changes that could be detected by in vivo 31P MRS of the liver. Twenty-
two patients were included. Lymph node biopsies showed that eight patients had 
Hodgkin’s disease and 14 non-Hodgkin’s lymphoma. Eleven patients of these 14 
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had high grade lymphoma and three low grade disease. Six patients, diagnosed with 
lymphomatous infiltration of the liver on the basis of liver function tests and either 
ultrasound or CT imaging, had a significantly higher PME/Pi ratio (1.43±0.37) or 
PME/ATP ratio (0.94±0.27) compared to 25 controls (ages 20-50) (0.58±0.11 and 
0.37±0.10 respectively) with normal livers. The PME/Pi ratio decreased following 
chemotherapy to an average of 66% of the initial value (range 40-82%). In two 
patients the ratio fell to the normal range and these patients showed clinical remis-
sion. Four patients whose liver spectra showed persistently high ratios after therapy 
died subsequently of progressive disease.  In vitro 31P MRS studies of extracts of 
lymphomatous lymph nodes suggested that PEtn was largely responsible for the 
increased PME signal. In this study, however, no difference was observed between 
Hodgkin’s and non-Hodgkin’s lymphoma and between histological grades.
Meyerhoff et al. (69) used 31P MRS to assess the metabolic state of hepatic can-
cers and their metabolic response to chemoembolization. Their preliminary report 
described studies on five patients (two with colon cancer metastasis, two with HCC, 
and one with adenocarcinoma of unknown primary) and thirteen healthy volun-
teers. Untreated hepatic tumors showed elevated PME/ATP ratios, reduced ATP and 
Pi content, and normal PDE levels compared to normal controls. ATP, PME, and/
or PDE levels diminished as an acute response to chemoembolization, whereas Pi 
content increased or stayed relatively constant. This could point to tumor regression 
and/or necrosis. Long-term follow-up after treatment showed decreased PME/ATP 
and increased ATP levels, even in the absence of changes on standard imaging. This 
could be the result of returning normal liver tissue and thus recovery.
Negendank (70) reviewed hundreds of cancer cases in 31P and/or 1H MRS studies 
that were published up to early 1992. In general he found that human cancers, other 
than brain, of different types in different locations had similar metabolic character-
istics: 173 of 194 cases had high PME and levels, 121 of 166 cases had high PDE 
levels, 59 of 125 cases had high Pi levels and 96 of 117 cases had low PCr. Table 1 
lists the cases with HCC, metastatic liver cancer and lymphoma in the liver. The most 
frequently used characteristic that differentiated healthy liver tissue from liver lym-
phoma was an increased PME level, and an increased PME/Pi and increased PME/
Pi for HCC, and increased PME/NTP and increased PDE/NTP ratios for metastasis 
in the liver. Also, an early decrease in PME (or in the PME/PDE ratio) was a good 
predictor of response to whatever treatment.
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Concluding remarks
From these studies it appears that the increase of PME levels is associated with 
tumor progression and that successful treatment is associated with its decrease. 
Therefore 31P MRS seems very suitable for treatment response monitoring. Since 
2003, however, only a limited number of in vivo 31P MRS studies on liver tumors and 
metastasis have been reported. The reason for this could be the low spatial and time 
resolution of in vivo 31P MRS on 1.5T MR systems. Currently, 3T MR systems have 
become widely available, dual tuned multi-channel 31P/1H coils have been developed 
and several techniques, e.g. 1H decoupling, Nuclear Overhauser Enhancement, 
polarization transfer, have been demonstrated (16) to improve 31P MRS sensitiv-
ity and spectral resolution. Finally, high field in vitro 31P MRS of cell-cultures might 
establish new markers to distinguish different tumor types and to separate benign 
from malignant tumors.
13C Mr Spectroscopy
As carbon-12 has no net nuclear spin it cannot be detected by MR spectroscopy. In 
contrast, carbon-13 can be detected by MRS but it has a natural abundance of only 
1.11%. Therefore carbon-13 has a relatively low MR sensitivity. In addition, the sig-
nal to noise ratio may be negatively affected by 1H coupling. To obtain spectra with 
acceptable signal to noise it is needed to apply averaging, polarization transfer, and 
1H decoupling. The chemical shift dispersion of 13C MRS in vivo is large (~200ppm) 
and is also characterized by narrow line widths, resulting in a very good spectral 
resolution (figure 5). Although carbon-13 MR spectroscopy is primarily known for 
MRS of 13C-labeled substrates (e.g. glucose), natural abundance 13C MRS can also 
be applied.
High PME High PDE High Pi Low PCr
HCC 91%
(of 11 cases)
75%
(of 4 cases)
0%
(of 4 cases)
100%
(of 11 cases)
Liver metastasis 100%
(of 7 cases)
33%
(of 6 cases)
17%
(of 6 cases)
100%
(of 4 cases)
Liver lymphoma 100%
(of 6 cases)
17%
(of 6 cases)
100%
(of 6 cases)
100%
(of 6 cases)
Table 1: Number of cases with high PME, high PDE, high Pi, and low PCr levels for HCC, metastasis 
and lymphoma in the liver. ‘High’ and ‘low’ levels are relative to the amount in normal or benign tissue. 
(From Negendank (70))
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Metabolites visible in natural abundance 13C Mr spectra
Almost all metabolites in the human body contain carbon and therefore in principle 
a large amount of metabolites can be investigated with 13C MRS, but because of 
the 1.11% natural abundance this is restricted to only a few highly concentrated 
compounds such as lipids. Chemical shifts above 150ppm are indicative of carbonyl 
groups; carbons adjacent to hydroxyl groups typically resonate in the 60-100ppm 
range; CH, CH2, CH3 groups resonate in the 45-60ppm, 25-45ppm and <25ppm 
ranges, respectively. The resonances of –CH=CH- groups are located around 
125ppm. Dominant lipid resonances are usually found in non-brain tissue. Two 
distinct resonances at 63 and 73 ppm originate from the glycerol backbone (6).
Carbon-13 labeled metabolites visible in 13C Mr spectra
Carbon-13 MRS with labeled substrates is the only way to study metabolic conver-
sions in the living intact body. Substrates enriched with 13C are usually administrated 
intravenously to reach a high and stable level in the blood. One of the most commonly 
used enriched substrate in humans is [1-13C]glucose. Others known substrates are 
[1,2-13C2]-choline, [1,2-
13C2]-ethanolamine, [3-
13C]pyruvate and lactate, [2-13C]
acetate, [2-13C]glucose and [1,6-13C2]glucose. The latter, often used in studies 
Figure 5: In vivo 13C MR spectra (1.5T) of human liver tissue obtained from a healthy volunteer before 
(bottom) and after exercise (top). Resonances of glycogen (101 ppm and around 75 ppm) are reduced 
after exercise. Other resonances are mainly lipids.
67
In vivo M
R
 Spectroscopy of liver tum
ors and m
etastases
involving rats and mice, results in two labeled [3-13C]-pyruvate molecules, and thus 
more signal. Pyruvate is an intermediate common to three major metabolic and 
catabolic pathways. After i.v. injection, pyruvate is rapidly distributed in the body and 
taken up by most cells, and then converted into alanine, lactate, or carbon dioxide, 
depending on the intracellular energy status.
Liver tumors and metastasis
Natural abundance 13C Mr liver spectrum
In 1983 Bottomley et al. (71) demonstrated the feasibility of natural abundance 
13C MRS at 1.5 T. The low sensitivity and the fact that most information could also 
be obtained from 1H and 31P MRS spectra has prevented widespread application of 
natural abundance 13C MRS. However, there are areas where it has some advantages 
such as in the detection of glycogen. Carbohydrate reserves are mainly stored as 
glycogen in animals and humans, in particular in muscle and liver.  Natural abundance 
13C MRS detection of glycogen is typically performed via the glycogen-C1 resonance 
at 100.5ppm (72). Some studies on rats have indicated that glycogen levels in hepatic 
tumors were markedly less than those observed in livers of control animals (73,74).
Carbon-13 labeled 13C Mr liver spectrum
13C-Labeled glucose
Infusion of enriched 13C-labeled glucose in combination with 13C MRS can provide 
highly specific information on metabolites and metabolic rates involved in energy 
metabolism. The 13C-labeled glucose is transported into the cell in the same way as 
18FDG used in PET (75). Where the derivative of 18FDG is trapped inside the cell, 
indicating areas of high glucose transport and thus indirectly indicating glycolytic 
activity, the 13C-labeled glucose will enter metabolic pathways like glycolysis and the 
TCA cycle. This allows the direct study of glucose uptake, the flux through labeled 
metabolites, relative contributions of glycolytic pathways and oxidative phosphory-
lation, as well as oxygen consumption (12,76).
Carbon-13 labeled glucose combined with 13C MRS in human liver tissue is, however, 
not without difficulties and the number of studies with this technique is still very 
limited. In 2008 Tomiyasu et al. (77) monitored liver glycogen synthesis in diabetic 
patients using 13C MRS on a 3.0T system. The MR signals of liver [1-13C]-glucose and 
glycogen were assessed and a correlation between the quantity of liver glycogen and 
the fasting plasma glucose levels was found. To investigate glucose metabolism of 
liver tumors would be of great interest, but such studies are still lacking.
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13C-labeled ethanolamine and choline in experimental tumors
Dixon et al. (67,78) administrated [13C2]-ethanolamine to mice with lymphomatous 
liver to study the kinetics of PtdEtn synthesis (79). The newly synthesized PEtn 
and PtdEtn could be distinguished from naturally-abundant compounds by their 13C 
label. The results showed that PtdEtn synthesis in the normal liver largely follows 
the Kennedy pathway. The data extracted from the 13C MR spectra were fitted to 
a kinetic model representing this pathway, which allowed them to determine the 
approximate rates of the various enzymes in the synthetic pathway in vivo. They 
also showed that the overall rate of PtdEtn synthesis from Etn was not increased in 
lymphomatous liver. 
Katz-Brull et al. (35) investigated the distribution of metabolites following infu-
sion of [1,2-13C]-choline by 13C MRS in mice. In their study MCF7 human breast 
cancer cells were inoculated s.c. in the right flank of CD-1 female athymic mice. In 
the tumors significantly more PCho (labeled and unlabeled) was observed than in 
normal liver and kidney tissue. Therefore, 13C MRS combined with modeling can be 
used to study choline and ethanolamine metabolism and enzymes rates in mice.
hyperpolarization and tumor metabolism 
Gallagher et al. (80) performed a 13C MRS in vitro study of glutaminase activity 
in human hepatocellular carcinoma cells using DNP hyperpolarized 13C-labeled 
glutamine. They showed that the conversion of hyperpolarized [5-13C]glutamine to 
glutamate senses intramitrochondrial glutaminase activity in hepatoma cells. These 
results represented the first step in the development of an imaging technique for 
the detection of glutamine metabolism in vivo. The rate of glutamine uptake and 
metabolism to glutamate in HCC cells was shown to be up to 30-fold higher than 
in normal hepatocytes. And thus this approach has clinical potential such as in the 
detection of small HCC in the presence of a cirrhotic liver. This study also suggests a 
new technique to detect changes in tumor cell proliferation in response to cytotoxic 
treatment since glutamine utilization has been correlated with cell proliferation.
Golman et al. (75) conducted a metabolic imaging study in P22 tumors implanted 
on the back of rats. The high signal, due to DNP hyperpolarization, allowed mapping 
of pyruvate, lactate and alanine in a 5 x 5 x 10 mm3 imaging voxel using a 1.5T scan-
ner. Tumor tissue showed a significantly higher lactate content than normal tissue, 
possibly explained by the Warburg effect. The results indicate that fast noninvasive 
quantification may be possible. To show that the DNP technique can be used both in 
small and larger animals Golman et al. (81) also conducted nearly similar real-time 
metabolic imaging studies in rats and pigs. The pig study would provide important 
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information as to whether [1-13C] enriched hyperpolarized dynamics also could be 
visualized in a more clinically relevant setting. They showed that in both species, 
where pharmacokinetic parameters widely differ, it is possible to map pyruvate and 
some of its metabolites in resting skeletal muscle within a clinical useful time frame 
of about 10 seconds. This indicates the technique may work in humans as well.
Concluding remarks
Hyperpolarization is a promising technique in MR cancer research. Similar images as 
those in 18FDG-PET can be obtained, but with the further advantages that ,without 
radiation, real (glucose) metabolism is observed. Although this new MR method is 
far more sensitive than conventional 13C MRS it only allows to measure single step 
metabolic conversions associated with rapid cellular uptake of the administered sub-
strate. Therefore, conventional 13C MRS studies will remain valuable to understand 
and complement results from hyperpolarized 13C MR imaging.
General conclusions
Hydrogen is the most commonly studied nucleus, as it has the highest sensitivity 
compared to 31P and 13C, and essentially can be performed with the same hardware 
as for standard MR imaging. In liver tumor studies the lactate resonance is related 
to energy metabolism (Warburg effect) of the tumor. Proton resonances of mobile 
lipids and the peak of total choline (tCho) have been explored as biomarkers to iden-
tify malignant tumors. However, the tCho peak is composed of several unresolved 
resonances of different choline containing compounds, which makes changes in this 
signal difficult to interpret.
With 31P MRS phosphorylated choline and ethanolamine containing compounds can 
be resolved. From several studies it is known that the increase of phophomonoesters 
(PME) is associated with tumor progression and that successful treatment is associ-
ated with a decrease of PME levels. Therefore 31P MRS could very well be used for 
treatment response monitoring. Besides the signals from phospholipid metabolism, 
31P MR spectra of liver also show signals of ATP and Pi which can be used to investi-
gate tumor energy metabolism.
MRS with 13C as label is a unique method to measure the dynamics of metabolic 
conversions in vivo, but it hardly has been used to examine human liver metabolism 
due to its technical complexity and relative low sensitivity. However, developments 
such as hyperpolarization may open new ways of liver assessment and imaging. 
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In vivo MR spectroscopy provides a number of adequate research tools to study 
metabolism in liver tumors and metastasis. However, they are not yet applied often 
in a clinical setting for diagnosis and treatment monitoring. This may be due to 
technical challenges associated with the body location of the liver,  relatively long 
scan times needed for a good signal to noise ratio, the need for additional hardware 
(except 1H MRS) and the need for expertise in spectral interpretation. With higher 
magnet fields becoming available, new multi-element detection probes, new acquisi-
tion techniques for improved spatial and time resolution, better postprocessing, and 
with new biomarkers it is expected that the research and clinical usefulness of MRS 
of liver and tumors therein will increase.
71
In vivo M
R
 Spectroscopy of liver tum
ors and m
etastases
references
 1.  Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastro-
enterology. 2004;127(5, Supplement 1):S5-S16.
 2.  Khan AN. Liver, Metastases: eMedicine Radiology. February 2009.
 3.  Gilbert H, Kagan A, Hintz B, Nussbaum H. Patterns of metastases. In: Weiss L, Gilbert H, eds. Liver 
Metastases. Boston, Mass: GK Hall Medical Publishers; 1982:19-39.
 4.  Pickren J, Tsukada Y, Lane W. Analysis of Autopsy Data. In: Weiss L, Gilbert H, eds. Liver Metastases. 
Boston, Mass: GK Hall Medical Publishers; 1982:2-18.
 5.  Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF. Needle track seeding following biopsy of 
liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 
2008;57(11):1592 -1596.
 6.  de Graaf RA. In Vivo NMR Spectroscopy. Chichester, UK: John Wiley & Sons, Ltd; 2007.
 7.  Clayton DB, Elliott MA, Lenkinski RE. In vivo proton spectroscopy without solvent suppression. 
Concepts Magn Reson. 2001;13(4):260-275.
 8.  Haase A, Frahm J, Hänicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys 
Med Biol. 1985;30(4):341-344.
 9.  Overhauser AW. Polarization of Nuclei in Metals. Phys Rev. 1953;92(2):411.
 10.  Freeman DM, Hurd R. Decoupling: theory and practice. II. State of the art: in vivo applications of 
decoupling. NMR Biomed. 1997;10(8):381-393.
 11.  Overhauser AW. Paramagnetic Relaxation in Metals. Phys Rev. 1953;89(4):689.
 12.  Gruetter R, Adriany G, Choi I-Y, Henry P-G, Lei H, Öz G. Localized in vivo 13C NMR spectroscopy of 
the brain. NMR Biomed. 2003;16(6-7):313-338.
 13.  Ross B, Lin A, Harris K, Bhattacharya P, Schweinsburg B. Clinical experience with 13C MRS in vivo. 
NMR Biomed. 2003;16(6-7):358-369.
 14.  Wijnen JP, Van der Graaf M, Scheenen TWJ, et al. In vivo 13C magnetic resonance spectroscopy 
of a human brain tumor after application of 13C-1-enriched glucose. Magn Reson Imaging. 
2010;28(5):690-697.
 15.  Klomp DWJ, Kentgens APM, Heerschap A. Polarization transfer for sensitivity-enhanced MRS using 
a single radio frequency transmit channel. NMR Biomed. 2008;21(5):444-452.
 16.  Klomp DWJ, Wijnen JP, Scheenen TWJ, Heerschap A. Efficient 1H to 31P polarization transfer on a 
clinical 3T MR system. Magn Reson Med. 2008;60(6):1298-1305.
 17.  Golman K, Ardenkjær-Larsen JH, Petersson JS, Månsson S, Leunbach I. Molecular imaging with 
endogenous substances. Proc Natl Acad Sci U S A. 2003;100(18):10435-10439.
 18.  Ardenkjær-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of > 10,000 times in 
liquid-state NMR. Proc Natl Acad Sci U S A. 2003;100(18):10158-10163.
 19.  Ordidge RJ, Connelly A, Lohman JAB. Image-selected in Vivo spectroscopy (ISIS). A new technique 
for spatially selective nmr spectroscopy. J Magn Reson 1969. 1986;66(2):283-294.
 20.  Frahm J, Merboldt K-D, Hänicke W. Localized proton spectroscopy using stimulated echoes. J Magn 
Reson 1969. 1987;72(3):502-508.
 21.  Bottomley PA. United States Patent: 4480228 - Selective volume method for performing localized 
NMR spectroscopy. October 1984.
 22.  Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad 
Sci U S A. 1982;79(11):3523-3526.
72
••
 C
ha
pt
er
 2
 23.  Li C-W, Kuo YC, Chen C-Y, et al. Quantification of choline compounds in human hepatic tumors by 
proton MR spectroscopy at 3 T. Magn Reson Med. 2005;53(4):770-776.
 24.  Hanley J, Debois MM, Mah D, et al. Deep inspiration breath-hold technique for lung tumors: the 
potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat 
Oncol. 1999;45(3):603-611.
 25.  Kitamura K, Shirato H, Seppenwoolde Y, et al. Tumor location, cirrhosis, and surgical history con-
tribute to tumor movement in the liver, as measured during stereotactic irradiation using a real-time 
tumor-tracking radiotherapy system. Int J Radiat Oncol. 2003;56(1):221-228.
 26.  Shirato H, Seppenwoolde Y, Kitamura K, Onimura R, Shimizu S. Intrafractional tumor motion: lung 
and liver. Semin Radiat Oncol. 2004;14(1):10-18.
 27.  Kuesel AC, Sutherland GR, Halliday W, Smith IC. 1H MRS of high grade astrocytomas: mobile lipid 
accumulation in necrotic tissue. NMR Biomed. 1994;7(3):149-155.
 28.  Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic 
Requirements of Cell Proliferation. Science. 2009;324(5930):1029-1033.
 29.  Warburg O, Posener E, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochem Z. 1924;152:319-
344.
 30.  Fischbach F, Bruhn H. Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a 
review. Liver Int. 2008;28(3):297-307.
 31.  Moreno A, López LA, Fabra A, Arús C. 1H MRS markers of tumour growth in intrasplenic tumours 
and liver metastasis induced by injection of HT-29 cells in nude mice spleen. NMR Biomed. 
1998;11(3):93-106.
 32.  Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline Phospholipid Metabolism in Can-
cer:  Consequences for Molecular Pharmaceutical Interventions. Mol Pharm. 2006;3(5):496-506.
 33.  Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid 
metabolism. Pharmacogenomics. 2006;7(7):1109-1123.
 34.  Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and 
therapy. Expert Rev Mol Diagn. 2006;6(6):821-829.
 35.  Katz-Brull R, Margalit R, Degani H. Differential routing of choline in implanted breast cancer and 
normal organs. Magn Reson Med. 2001;46(1):31-38.
 36.  Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12(7):413-439.
 37.  Zeisel SH. Choline: an essential nutrient for humans. Nutrition. 2000;16(7-8):669-671.
 38.  Zeisel SH, Costa K-A da. Choline: an essential nutrient for public health. Nutr Rev. 2009;67(11):615-
623.
 39.  Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. J 
Biol Chem. 1956;222(1):193-214.
 40.  Bremer J, Greenberg DM. Methyl transfering enzyme system of microsomes in the biosynthesis of 
lecithin (phosphatidylcholine). Biochim Biophys Acta. 1961;46(2):205-216.
 41.  Sundler R, Akesson B. Regulation of phospholipid biosynthesis in isolated rat hepatocytes. Effect of 
different substrates. J Biol Chem. 1975;250(9):3359-3367.
 42.  Barak AJ, Tuma DJ. Betaine, metabolic by-product or vital methylating agent? Life Sci. 
1983;32(7):771-774.
 43.  Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228-237.
 44.  Finkelstein JD. Methionine metabolism in liver diseases. Am J Clin Nutr. 2003;77(5):1094-1095.
 45.  Richards T. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring 
progression, and evaluating therapy. Am J Roentgenol. 1991;157(5):1073-1078.
73
In vivo M
R
 Spectroscopy of liver tum
ors and m
etastases
 46.  Herminghaus S, Pilatus U, Möller-Hartmann W, et al. Increased choline levels coincide with enhanced 
proliferative activity of human neuroepithelial brain tumors. NMR Biomed. 2002;15(6):385-392.
 47.  Soper R, Himmelreich U, Painter D, et al. Pathology of hepatocellular carcinoma and its precursors 
using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 
(Phila). 2002;34(5):417-422.
 48.  Kuo Y-T, Li C-W, Chen C-Y, Jao J, Wu D-K, Liu G-C. In vivo proton magnetic resonance spectros-
copy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and 
after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging. 
2004;19(5):598-604.
 49.  Fischbach F, Schirmer T, Thormann M, Freund T, Ricke J, Bruhn H. Quantitative proton magnetic 
resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 Tesla. Eur Radiol. 
2008;18(11):2549-2558.
 50.  Bell JD, Jane Cox I, Sargentoni J, et al. A 31P and 1H-NMR investigation in vitro of normal and abnor-
mal human liver. Biochim Biophys Acta BBA - Mol Basis Dis. 1993;1225(1):71-77.
 51.  Bates TE, Williams SR, Gadian DG. Phosphodiesters in the Liver: The Effect of Field Strength on the 
31P Signal. Magn Reson Med. 1989;12(1):145-150.
 52.  Moon RB, Richards JH. Determination of Intracellular pH by 31P Magnetic Resonance. J Biol Chem. 
1973;248(20):7276 -7278.
 53.  Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991;64(3):425-427.
 54.  Griffiths JR, Stevens AN, Iles RA, Gordon RE, Shaw D. 31P-NMR investigation of solid tumours in the 
living rat. Biosci Rep. 1981;1(4):319-325.
 55.  Griffiths JR, Cady E, Edwards RHT, Mccready VR, Wilkie DR, Wiltshaw E. 31P-NMR studies of a 
human tumour in situ. The Lancet. 1983;321(8339):1435-1436.
 56.  Iles RA, Stevens AN, Griffiths JR. NMR Studies of metabolites in living tissue. Prog Nucl Magn Reson 
Spectrosc. 1982;15(1-2):49-200.
 57.  Oberhaensli R, Bore P, Rampling R, Hilton-Jones D, Hands L, Radda G. Biochemical investigation 
of human tumours in vivo with phosphorus-31 magnetic resonance spectroscopy. The Lancet. 
1986;328(8497):8-11.
 58.  Vaupel P, Kallinowski F, Okunieff P. Blood Flow, Oxygen and Nutrient Supply, and Metabolic Micro-
environment of Human Tumors: A Review. Cancer Res. 1989;49(23):6449-6465.
 59.  Stubbs M, Veech RL, Griffiths JR. Tumor metabolism: The lessons of magnetic resonance spectros-
copy. Adv Enzyme Regul. 1995;35:101-115.
 60.  Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR 
Biomed. 1992;5(5):226-233.
 61.  Evanochko WT, Sakai TT, Ng TC, et al. NMR study of in vivo RIF-1 tumors: Analysis of perchloric 
acid extracts and identification of 1H, 31P and 13C resonances. Biochim Biophys Acta BBA - Mol Cell 
Res. 1984;805(1):104-116.
 62.  Dagnelie PC, Bell JD, Williams SC, Bates TE, Abel PD, Foster CS. Altered phosphorylation status, 
phospholipid metabolism and gluconeogenesis in the host liver of rats with prostate cancer: a 31P 
magnetic resonance spectroscopy study. Br J Cancer. 1993;67(6):1303-1309.
 63.  Dagnelie PC, Sijens PE, Kraus DJA, Planting AST, Dijk P van. Abnormal liver metabolism in cancer 
patients detected by 31P MR spectroscopy. NMR Biomed. 1999;12(8):535-544.
 64.  Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic 
tumours. NMR Biomed. 1998;11(7):354-359.
74
••
 C
ha
pt
er
 2
 65.  Maris JM, Evans AE, McLaughlin AC, et al. 31P nuclear magnetic resonance spectroscopic investiga-
tion of human neuroblastoma in situ. N Engl J Med. 1985;312(23):1500-1505.
 66.  Vaidya SJ, Payne GS, Leach MO, Pinkerton CR. Potential role of magnetic resonance spectroscopy in 
assessment of tumour response in childhood cancer. Eur J Cancer. 2003;39(6):728-735.
 67.  Dixon RM, Angus PW, Rajagopalan B, Radda GK. Abnormal phosphomonoester signals in 31P MR 
spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response 
to chemotherapy. Br J Cancer. 1991;63(6):953-958.
 68.  Dixon RM. NMR studies of phospholipid metabolism in hepatic lymphoma. NMR Biomed. 
1998;11(7):370-379.
 69.  Meyerhoff DJ, Karczmar GS, Valone F, Venook A, Matson GB, Weiner MW. Hepatic cancers and 
their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance 
spectroscopy. Invest Radiol. 1992;27(6):456-464.
 70.  Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5(5):303-324.
 71.  Bottomley PA, Hart HR, Edelstein WA, et al. NMR imaging/spectroscopy system to study both 
anatomy and metabolism. Lancet. 1983;2(8344):273-274.
 72.  Roser W, Beckmann N, Wiesmann U, Seelig J. Absolute quantification of the hepatic glycogen 
content in a patient with glycogen storage disease by 13C magnetic resonance spectroscopy. Magn 
Reson Imaging. 1996;14(10):1217-1220.
 73.  Lea MA, Murphy P, Morris HP. Glycogen Metabolism in Regenerating Liver and Liver Neoplasms. 
Cancer Res. 1972;32(1):61-66.
 74.  Sweeney MJ, Ashmore J, Morris HP, Weber G. Comparative Biochemistry of Hepatomas. Cancer Res. 
1963;23(7 Part 1):995-1002.
 75.  Golman K, Zandt R in’t, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic Imaging by 
Hyperpolarized 13C Magnetic Resonance Imaging for In vivo Tumor Diagnosis. Cancer Res. 
2006;66(22):10855-10860.
 76.  Nielsen FU, Daugaard P, Bentzen L, et al. Effect of Changing Tumor Oxygenation on Glycolytic 
Metabolism in a Murine C3H Mammary Carcinoma Assessed by in Vivo Nuclear Magnetic Reso-
nance Spectroscopy. Cancer Res. 2001;61(13):5318-5325.
 77.  Tomiyasu M, Obata T, Nishi Y, et al. Monitoring of liver glycogen synthesis in diabetic patients using 
carbon-13 MR spectroscopy. Eur J Radiol. 2010;73(2):300-304.
 78.  Dixon RM, Tian M. Phospholipid synthesis in the lymphomatous mouse liver studied by 31P nuclear 
magnetic resistance spectroscopy in vitro and by administration of 14C-radiolabelled compounds in 
vivo. Biochim Biophys Acta BBA - Mol Basis Dis. 1993;1181(2):111-121.
 79.  Dixon RM. Phosphatidylethanolamine synthesis in the normal and lymphomatous mouse liver; a 
13C NMR study. Anticancer Res. 1996;16(3B):1351-1356.
 80.  Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements 
of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled 
glutamine. Magn Reson Med. 2008;60(2):253-257.
 81.  Golman K, in ‘t Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci. 
2006;103(30):11270-11275.
75
C
holine levels recorded by 1H
 M
R
S
3
Chapter 3
Levels of choline-containing compounds in 
normal liver and liver metastases of colorectal 
cancer as recorded by 1h Mr spectroscopy
E.G.W. ter Voert, L. Heijmen, J.J.A. van Asten, A.J. Wright, I.D. Nagtegaal, C.J.A. Punt, 
J.H.W. de Wilt, H.W.M. van Laarhoven, A. Heerschap.
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abstract
Introduction: A relatively high signal for choline-containing compounds (tCho) is 
commonly found in 1H-MR spectra of malignant tumors, but it is unclear to what 
extent this occurs for tumors in the liver. Here we evaluate the potential of this sig-
nal in 1H-MR spectra of the human liver to assess metastases of colorectal cancers.
Material and methods: PRESS localized single voxel MR spectra (TE=30ms) were 
obtained at 3T of the liver of 12 healthy volunteers and 20 patients at two differ-
ent sessions. Sequentially recorded spectra were individually phased and frequency 
aligned before averaging, to correct for motion artefacts. Spectra were analyzed by 
LCModel and tissue levels were estimated by water referencing. HRMAS spectra of 
tumor and normal liver samples were obtained at 11.7T.
Results: The mean tCho content in tumorous voxels (4.2 mmol/kg wet weight; range 
1.3-9.3) was not significantly different from that in normal liver tissue (6.9 mmol/
kg wet weight; range 4.9-11.1). With increasing tumor volumes, tCho tissue levels 
decreased, possibly reflecting a larger necrotic voxel fraction. A Bland-Altman analy-
sis revealed average repeatability in normal livers and poor repeatability in tumors. 
HRMAS did not show substantial differences in choline-containing compounds for 
normal liver and metastasis.
Discussion: An increased tCho signal is not observed in 1H MR spectra of liver metas-
tasis of colorectal cancer. This may be due to the background of a high tCho signal 
for normal liver, due to the presence of tumor necrosis or due to an intrinsic lower 
tCho content of metastatic tissue.
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Introduction
In many cancer types, including colorectal cancer, increased expression of choline 
kinase is observed (1). This enzyme is responsible for synthesis of phosphorylcho-
line (PCho) from choline (Cho) and is essential for proliferation and transformation 
of cells (2,3).
With proton magnetic resonance spectroscopy (1H MRS) signals for protons of 
choline-containing compounds can be measured in tissues and extracts (4,5). The 
dominant signals of choline compounds are those of their N-trimethyl [+N(CH3)3] 
group, resonating at about 3.2 ppm. In 1H MR spectra of tissues in humans and 
animals, acquired on common MR systems, the different resonances of these methyl 
protons in individual choline-containing compounds are not resolved and therefore 
together often referred to as the total choline (tCho) peak. Phosphatidylcholine 
(PtdCho) makes up a high proportion of the cell plasma membrane, but as its 
protons have a short T2 relaxation time it is almost invisible in the in vivo 
1H MR 
spectrum. However, protons of its small molecular precursors, free choline (Cho) 
and PCho, and its glycerol derivative glycerol-3-phosphorylcholine (GPCho) have 
long T2 times and therefore contribute to the tCho signal in 
1H MR spectra of tissues 
(5). Protons from phosphorylethanolamine (PEtn), glucose, myo-inositol, taurine 
and betaine resonate near the tCho peak, but their signal contributions to this peak 
are generally considered to be low, for instance because of a complicated J-coupling 
pattern at the echo-times applied (6).
Several studies have shown that tCho levels in tumors, such as in brain, prostate and 
breast, are increased compared to healthy tissue and are linked to a poorer differ-
entiation grade and a worse outcome (7,8). In particular the levels of PCho appear 
to increase during cell proliferation (9,10). For these reasons the tCho signal was 
explored as biomarker to monitor response to therapy (10-17).
Also 1H MR spectra of normal liver and of primary tumors and metastases in the 
liver show a composite signal at about 3.2 ppm for the N-methyl protons of choline 
compounds. Despite the promising results in the diagnostics and treatment evalu-
ation of brain, prostate, breast and other body tumors, this tCho signal has been 
little explored in clinical studies of the liver (18), although it has been suggested as 
a biomarker in the response evaluation of liver tumor treatments (19,20). The liver 
is a metabolic active tissue which may impact the tCho signal (5,21). In addition, 
respiratory, cardiac and aortic motion aggravate outer voxel signal contamination 
and the magnetic field inhomogeneity of the liver, which may cause broadening of 
spectral peaks. To assess the potential of tCho measurements with 1H-MRS in the 
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treatment evaluation of liver metastases it is important to estimate the repeatability 
of the method. 
The aim of this study was to estimate the tCho levels in metastasis of colorectal 
cancers in the liver compared to normal liver tissue by a commonly used single voxel 
MR spectroscopy acquisition method and to assess its repeatability. For a better 
understanding of the in vivo results we also analyzed tumor samples obtained after 
metastasectomy by ex-vivo high-resolution magic angle spinning (HRMAS) NMR 
spectroscopy. 
patients and Methods
patients and healthy volunteers
Twenty patients with liver metastases of histologically proven colorectal cancer, 
scheduled for metastasectomy, participated in the study. In addition, 12 healthy 
volunteers were included. All participants were scheduled for two MR imaging 
(MRI) and MRS examinations to assess repeatability. All measurements were carried 
out after approval of the local institutional medical ethics committee and written 
informed consent was obtained from each patient and healthy volunteer.
In vivo MrI and MrS
MRI examinations were performed on a 3.0T whole body MR system (Magnetom 
Trio, Siemens Healthcare, Erlangen, Germany) using the body coil for excitation and 
a six channel body matrix coil combined with a twenty-four channel spine matrix 
coil for signal reception. After conventional T1- and T2-weighted imaging (echo 
time (TE): 80-92ms) for localization, 1H MRS spectra were acquired during free-
breathing.
Initially, the patients were scanned using the ‘1H universal body SVS version 2’ 
sequence, developed for the Syngo MR B15 platform (Siemens Healthcare, Erlan-
gen, Germany). It was a point resolved spectroscopy (PRESS) sequence with the 
added capability of online frequency correction. The sequence parameters were: 
repetition time (TR) 2000 ms, TE 30 ms, bandwidth 1000Hz, vector size 1024, 
voxel size 20x20x20 mm3, shim volume 30x30x30 mm3, weak water suppression 
(bandwidth 50Hz), 128 averages and a delta frequency of -1.5 ppm with respect 
to the water resonance, targeting that of choline at 3.2 ppm. In addition, spectra 
without water suppression were recorded with the same parameters except for the 
delta frequency of 0 ppm and 8 averages. After the inclusion of 16 patients, the 
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Syngo MR B17 platform (Siemens Healthcare, Erlangen, Germany) was installed 
on the scanner and the 1H universal body SVS version 2’ sequence was no longer 
available. The remaining patients and all the volunteers were scanned with a regular 
PRESS sequence with the same parameters except for the number of averages. To 
enable offline frequency correction, the number of averages was set to one, and the 
sequence was repeated 132 times for the water suppressed scans and 20 times for 
the unsuppressed scans, resulting in respectively 132 and 20 individual spectra.
In patients, the voxels were placed in the center of the metastasis guided by T1-and 
T2-weighted MR images. In smaller tumors the voxels could extend beyond the 
tumor. In healthy volunteers two or three single voxels were placed in normal appear-
ing liver tissue, approximately in segment 2/3, segment 5/6 and segment 7/8. 
Voxels were kept away from large vessels, ducts and the edge of the liver. Patients 
were scanned twice within eight days and at least 24 hours apart. Healthy volunteers 
were scanned twice on the same day and spent at least one hour between the scans 
outside the scanner. During the second scan session the voxels were placed on the 
same locations as during the first scan guided by the MR images.
hrMaS NMr spectroscopy
After the in vivo 1H MRS examinations, fresh material of the previously measured 
colorectal metastases was available from eight patients. The tissue samples were 
collected from the active rim of the tumor. The samples were cut in half and one 
side was used for microscopic evaluation by an experienced pathologist by staining 
4μm sections with hematoxylin and eosin. The other side of the samples were snap 
frozen for 1H HRMAS NMR analysis. All sections had vital tumor areas and some 
also contained normal appearing liver tissue. Non-tumor tissue was macroscopically 
resected by pathologist directions, leaving only the vital tumor areas for further 
analysis. In total ten tumor samples were available for 1H HRMAS NMR. In addition, 
three samples of fresh frozen normal appearing liver tissue were available for control.
1H HRMAS NMR was performed as described previously (22). In short: A 500MHz 
(11.7T) NMR spectrometer (Bruker Avance III, Bruker Biospin, Rheinstetten, Ger-
many) was equipped with a 1H optimized 1H/13C HRMAS probe head. The samples, 
weighing between 4-14 mg, were restricted by Teflon spacers to a 12 ml sphere with 
a diameter of 2.8 mm placed in a 4 mm ZrO2 MAS rotor that was sealed with a Kel-F 
cap. The remaining space was filled with D2O to prevent tissue damage. Samples 
were kept at a maximum of 40Cto slow down tissue degradation. Inside the NMR 
spectrometer the samples were spinning with a magic angle spinning rate (masr) of 
4 kHz and at the magic angle of 54.70, which suppresses the line broadening effects 
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of dipolar coupling and chemical shift anisotropy. The 1-D 1H NMR spectra were 
acquired with a Carr-Purcell-Meiboom-Gill (CPMG) sequence. The 900 pulse was 
optimized per sample (range 7.21 – 7.25 μs). An interval of one rotor period (1/
masr) between the 1800 pulses enabled suppression of J-modulation and minimiza-
tion of the diffusion component to relaxation processes. A T2 filter of 30 ms was 
used to limit contributions of macromolecular components and the water resonance 
was suppressed by presaturation. With an excitation bandwidth of 12 ppm or 6000 
Hz, collected in 8k complex points, the acquisition time was 2.7s, and with 256 
transients collected every 5s, the total measurement time of one sample was 27 
minutes.
Data analyses
The in vivo 1H MRS spectroscopic data was analyzed using LCModel software (23). 
A basis set, used by LCModel to fit the measured spectrum, was developed by 
simulating the spectral shapes of the six lipid resonances at 0.9, 1.3, 1.6, 2.1, 2.3, 
2.8 ppm, and the total choline resonance at 3.2 ppm with Topspin (Bruker Biospin, 
Rheinstetten, Germany) (3T, PRESS, TE: 30ms).
The water signal measured in the unsuppressed 1H MRS spectra was used as an 
internal reference for quantification of the tCho tissue levels. These tissue levels 
were first determined as a signal ratio with respect to the signal of water (tCho/
water) after which they were converted to absolute tissue concentrations in mmol/
kg wet weight following the procedure described by Ouwerkerk et al (24). In this 
procedure the tCho signal is considered to originate from the 9 protons in the 
N-trimethyl [+N(CH3)3] group and the water signal from 2 protons. This signal in 
the liver represents 40M water (72% of 55.5M). Signal saturation by T1 relaxation 
was ignored, but signal attenuation by T2 was taken into account with a T2 for water 
of 34 ms (25) and for tCho of 77.1 ms (24). For the calculations in this paper we 
assumed that different proton relaxation times and water tissue content in tumor 
tissue did not have a significant effect on the tCho levels in this tissue (see Discus-
sion).
All the spectra were visually inspected by three spectroscopists and only spectra 
with sufficient signal to noise ratio (SNR), an appropriate fit and an absence of severe 
baseline distortion were included. In LCModel the SNR is defined as the maximum 
in the spectrum (minus baseline) divided by two times the root-mean-square of the 
residuals (26). In case the fit failed the visual inspection due to baseline distortions 
the LCModel parameter ‘DKNTMN’ that controls node spacing of the spline function 
used for fitting the baseline was changed from the initial 0.25 ppm to 0.10 ppm and 
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a second attempt was made to fit the spectra. Besides the graph of the fit, LCModel 
outputs the quantified tissue concentrations of the metabolites, being the water 
corrected integral values of the resonances, together with the corresponding esti-
mated standard deviations (Cramér-Rao lower bounds) expressed in percent of the 
estimated concentrations (%SD). Only concentrations with a %SD smaller than or 
equal to 20% were accepted (26,27).
The multiple individual spectra, as obtained from individual patients and volunteers 
scanned after the system update to the Syngo MR B17 platform, were first prepro-
cessed, using in-house built software based on Matlab (MathWorks, Natick, MA), 
converting them to one spectrum, before they were analyzed using LCModel. In the 
first step a simple automatic zero order phasing was applied to ensure all individual 
spectra were phase aligned. It assumed the more positive the spectral region with 
the (suppressed) water peak, the better the phase. In the next step the spectra were 
aligned before the mean spectrum was calculated. Spectra for which the height of 
the (suppressed) water peak was higher than the average height plus one standard 
deviation were excluded.
All tumors were delineated using Inveon Research Workplace (IRW 3.0, Siemens 
Healthcare, Erlangen, Germany) which allowed T1- and T2-weigthed images to be 
viewed side-by-side as well as in fused mode. This allowed the 3D tumor volume to 
be extracted.
The 1H HRMAS spectroscopic data was analyzed using LCModel with a basis set 
developed for the applied measurement conditions (CPMG, T2=30ms, MASR=4kHz, 
11.7T) by simulating the spectral shapes of the lipid and choline resonances with 
Topspin. The basis set also included the resonances of GPCho, PCho, glycerolphos-
phorylethanolamine (GPEtn), phosphorylethanolamine (PEtn), and some others like 
creatine (Cr), phosphocreatine (PCr), glucose (Glc), myo-inositol (m-Ins), taurine 
(Tau), lactate (Lac).
Statistics
Statistical analyses were performed using Prism 7 (GraphPad Software Inc. San 
Diego, CA, USA). Differences between metabolite contents were evaluated using 
the Mann-Whitney and Wilcoxon tests for unpaired and paired nonparametric data-
sets, respectively. A difference was considered to be statistically significant when p 
< 0.05. 
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Repeatability of the tCho measurements were assessed by a Bland Altman analysis 
(28). The calculations were performed in Excel (Excel 2010, Microsoft, Redmond, 
WA, USA). The coefficient of repeatability (1.96x standard deviation of the differ-
ence) was calculated. The coefficient of repeatability describes -within the paired 
measurements- the difference that is smaller in 95% of the pairs.
results
Three of the 20 patients did not complete both MRI / MRS sessions due to technical 
difficulties or patient illness. In four patients the 1H-MR spectra were rejected, by 
visual inspection, either because of a disturbed baseline (1 case) or of peak broaden-
ing due to poor shimming or motion (3 cases). In the remaining 13 patients, two 
datasets obtained on day one and four datasets obtained on day two had a %SD 
larger than 20% and were discarded. In total 11 valid spectra measured on day one 
and 9 valid spectra measured on day two passed these quality criteria. Eight of these 
spectra measured on day one had corresponding spectra obtained on day two, and 
were therefor available for repeatability calculations.
One of the healthy volunteers was not able to return after the first scan. Eight of 
the eleven volunteers had three single voxels scans and three volunteers had only 
two single voxels scans giving a total of 30 spectra for each scan date. Four spectra 
obtained on day one had a %SD larger than 20% and were discarded. Twenty-six 
spectra, obtained in ten volunteers, had corresponding spectra measured on day 
two, and were therefore available for repeatability calculations.
Ten tumor samples and three normal appearing liver tissue samples obtained from 
eight patients, who underwent in vivo MRS, were analyzed by 1H HRMAS NMR. Six 
of the ten tumor spectra had a %SD larger than 20%, leaving a total of four valid 
spectra obtained in four patients. The three normal appearing liver tissue samples 
were also classified as valid spectra.
Typical in vivo 1H MR spectra of tumor and normal appearing liver tissue were 
dominated by signals for lipids and choline (Fig. 1). As referenced to the unsup-
pressed water peak, the area under the total choline peak at 3.2ppm is smaller in the 
spectrum obtained from a tumor in the patient (Fig. 1a) compared to the spectrum 
obtained in the normal appearing liver tissue of the volunteer (Fig. 1b). The indi-
vidual resonances of choline containing compounds in the total choline peak were, 
as expected, not resolved.
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1H HRMAS NMR spectra most individual resonances contributing 
to the tCho peak at about 3.2 ppm were resolved (Fig. 2). A comparison of a spectrum 
of an active tumor tissue sample (Fig. 2a) with a spectrum of normal appearing liver 
tissue (Fig. 2b) from a patient showed a relatively increased peak for PCho and GPCho.
Figure 2: Typical LCModel fit of ex vivo 1H HRMAS spectra obtained in the tumor rim (a) and in normal 
appearing liver tissue (b). Measured fractions for (a) and (b) are respectively: Cho/Weight: 5.04 and 
4.49, PCho/Weight: 4.06 and 1.77, GPCho/Weight: 11.73 and 2.88, PEtn/Weigth: 6.54 and 7.35, Tau/
Weight: 16.20 and 10.51, Lipid1.3a/Weight: 44.96 and 36.44, Lipid1.3b/Weight: 201.43 and 178.57. The 
horizontal axes show the chemical shift from 4.4 to 0.6 ppm. The vertical axes show the signal intensity in 
arbitrary units and are scaled differently in (a) and (b). See figure 1 for an explanation of the graphs.
Figure 1: Typical LCModel fit of in vivo 1H MR spectra obtained in tumor (a) and healthy appearing 
liver (b). The tCho/Water resonances are 0.21*10-3 (a) and 1.17*10-3 (b) and the lipid resonances 
at 1.3ppm / Water are 15.94*10-3 (a) and 10.32*10-3 (b). The insets show the axial slices with voxel 
locations. The gray curves represent the measured spectra and the red lines indicate the fit of the 
resonances. The smooth gray lines under the spectra represent the estimated baselines. The residues 
after the fit are shown on the top of the figure. The horizontal axes show the chemical shift from 3.6 to 
-1.0 ppm. The vertical axes show the signal intensity in arbitrary units and are scaled differently in (a) 
and (b).
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Using the unsuppressed water signal as an internal reference, the average tCho con-
centration in tumors in patients was 4.2 (1.3-9.3) mmol/kg wet weight (arithmetic 
mean and range) and in normal appearing liver in healthy volunteers 6.9 (4.9-11.1) 
mmol/kg wet weight. This difference in tCho between tumor and healthy liver is not 
significant (p = 0.20, Mann-Whitney unpaired nonparametric test).
The average tumor tissue concentration for tCho measured on day two was higher 
than on day one (see Table 1 and Fig. 3), but the difference was not statistically 
significant (p = 0.08, Wilcoxon paired nonparametric test). The average tCho con-
centration measured in normal appearing liver in healthy volunteers measured on 
day one and two were similar (Table 1). To investigate if it matters in which part of 
the liver the 1H MRS measurements are performed we obtained 1H MR spectra from 
different liver segments. This revealed that the average tCho tissue concentrations 
in the different liver segments 2/3, 5/6 and 7/8 are comparable (see Table 2 and 
Fig. 3, Fig. 4). Some individuals, however, showed large differences in tCho content 
between the measurements on day one and two, in tumor as well as in normal 
appearing liver (see Fig.3).
Tissue Time point 1 Time point 2 Total
tCho
(mmol/kg ww)
tCho
(mmol/kg ww)
tCho
(mmol/kg ww)
Normal liver
(n=10)
7.1 (4.9-11.2) 6.6 (4.2-11.0) 6.9 (4.9-11.1)
Tumor
(n=8)
3.4 (0.6-8.7) 5.1 (0.5-11.5) 4.2 (1.3-9.3)
Table 1: The tCho concentrations in normal appearing liver (in healthy volunteers) and in tumors in 
patients by in vivo 1H MRS. The number of participants is indicated by n. Data are presented as the 
arithmetic mean and the range. Mean values for each volunteer were calculated first, before averaging 
for time point 1 and 2 and the total. The difference between the tCho in tumor and healthy liver is not 
significant (p = 0.2, Mann-Whitney unpaired nonparametric test). ww = wet weight.
The analysis of the ex vivo 1H HRMAS NMR data revealed that the average levels of 
the choline compounds Cho, PCho, and GPCho were comparable between tumor 
and normal tissue, and no statistically significant difference (Table 3 and Fig. 4c) was 
found (Mann-Whitney unpaired nonparametric test). Taking the compounds that 
contribute to the tCho signal together there was no statistical difference between 
these two tissues. The levels of PEtn and Tau appeared higher in tumor tissue than in 
normal appearing tissue but the differences were not statistically significant (Table 
3).
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Figure 3: The tCho concentrations on day 1 and day 2 in normal appearing liver segments 2/3 (a), 5/6 
(b), 7/8 (c) of healthy volunteers and in tumors in patients (d). The measurements were performed in 
vivo by 1H MRS with a PRESS sequence. The lines connect the data points in the same patient. ww = wet 
weight.
Liver segment Time point 1 Time point 2 Total
tCho
(mmol/kg ww)
tCho
(mmol/kg ww)
tCho
(mmol/kg ww)
2/3 (n=8) 6.9 (4.7-14.3) 7.3 (4.7-12.0)) 7.1 (4.8-13.1)
5/6 (n=10) 6.7 (5.2-9.3) 6.2 (2.9-9.9) 6.5 (4.4-9.6)
7/8 (n=8) 7.9 (6.4-11.3) 7.2 (2.3-11.0) 7.6 (4.5-10.6)
Table 2: The tCho concentrations in different liver segments of normal appearing liver measured in 
healthy volunteers by in vivo 1H MRS. The number of volunteers is indicated by n. Data are presented 
as the arithmetic mean and the range. For the total, the first and second time points were averaged first 
for each subject. ww = wet weight.
A Bland-Altman analysis was performed to evaluate the results of the repeated 
in vivo 1H MRS measurements for both the patients and volunteers (Fig. 5). The 
coefficient of repeatability to measure the tCho concentration in tumor tissue in 
patients was 5.6, which corresponds to a fractional repeatability of 1.31. The mean 
difference was -1.7 and the limits of agreement were -7.3 and 3.9. The coefficient of 
repeatability of measuring the tCho tissue concentration in normal appearing liver in 
healthy volunteers was 2.8, which corresponds to a fractional repeatability of 0.40. 
The mean difference was 0.4 and the limits of agreement were -2.3 and 3.2.
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Cho / Weight
(a.u.)
PCho / Weight
(a.u.)
GPCho / Weight
(a.u.)
PEtn / Weight
(a.u.)
Tau / Weight
(a.u.)
Normal liver
(n=3)
3.31
(1.68-4.49)
2.72
(1.77-4.56)
7.48
(2.88-14.56)
3.05
(0.00-7.35)
13.71
(5.60-25.00)
Tumor
(n=4)
3.49
(1.19-5.04)
3.19
(1.68-5.04)
6.56
(0.82-11.73)
7.92
(4.12-10.65)
20.10
(9.05-29.82)
P (x<0.05) 0.86 0.86 >0.99 0.23 0.40
Table 3: The metabolite levels with sample weight correction of ex vivo normal liver and tumor tissue 
measured by 1H HRMAS NMR. The P values indicate, for the numbers in this study, that there is no 
significant difference between the metabolite levels in the liver and the tumor tissue (Mann-Whitney 
unpaired nonparametric test). The number of samples is indicated by n. Data are presented as the 
arithmetic mean and the range of measured values.
Finally, we observed that the tCho tissue concentration measured by in vivo 1H MRS 
depends on the tumor volume. The tCho concentration decreased from about 9.0 
mmol/kg wet weight in the smallest 2 cm3 volume to 1.5 mmol/kg wet weight in 
the largest 136 cm3 volume (Fig. 6).
Figure 4: (a) The arithmetic mean tCho concentrations in different liver segments of normal appearing 
liver measured in healthy volunteers by in vivo 1H MRS. The ratio of the first and second time points 
were averaged first for each subject. (b) The arithmetic mean tCho concentrations in normal appearing 
liver and tumors in healthy volunteers and patients, respectively, by in vivo 1H MRS. First the mean ratio 
for each volunteer was calculated by averaging the ratios measured in the liver segments. Then the 
ratio of the first and second time points were averaged for each subject. (c) The Cho/Weight in normal 
appearing tissue and in the tumor rim in patients, measured by ex vivo 1H HRMAS NMR spectroscopy. 
The red lines indicate the mean value. ww = wet weight.
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Figure 5: Bland Altman plots of the tCho concentrations for the healthy volunteers (a) and for the 
patients (b). The dashed black lines indicate the mean difference and the red dashed lines indicate the 
limits of agreement. There is one data point for every subject.
Figure 6: Scatter plot showing the relation between the arithmetic mean (day 1 and day 2) of tCho 
concentrations in tumor targeted 8cc voxels in the liver of patients and the estimated tumor volume. 
There is one data point for every patient. The left inset is showing an axial image of the liver with the 
smallest tumor, the right one is showing the largest tumor, as is indicated by the red arrow. ww = wet 
weight.
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Discussion 
In this study we assessed tCho content in normal liver tissue and in tumor tissue 
from colorectal metastasis in the liver using localized single voxel in vivo 1H MRS 
with corrections of spectral motion artefacts in post processing. The results show 
that the tCho levels in the tumor are not significantly different from normal liver 
tissue, although there is a tendency for lower levels in the tumor. The inter-session 
repeatability of the localized MRS measurement was better for the liver of the vol-
unteers than for the tumors in the liver of the patients.
Previous in vivo single voxel 1H MRS studies seem to report conflicting results on 
the difference in tCho content between tumor and normal liver tissue. In studies 
on groups with mostly hepatocellular carcinoma (relative) tCho levels appeared to 
be increased in malignant tissue, although not all parameters analysed for the tCho 
signal were significantly different (19,20,29,30). These studies did not include a 
particular motion correction procedure in the examination or analysis. Phospholipid 
profiling of biopsies showed a significantly increased PCho level in hepatocellular 
carcinoma compared to normal liver (31). However, a 1H MRS study on mostly 
metastatic tumors in the liver that included motion correction by acquisition during 
breath holding and frequency and phase correction of individual sequential spectra, 
did not detect a difference with normal liver tissue, with only a trend to a lower 
tCho to water ratio (18,32). Our 1H MRS exams of metastatic tumors in the liver, 
including individual spectral phase correction and frequency alignment for motion 
rectification, gave results that are in line with this study, i.e. we also observed no 
significant difference with only a weak trend for a lower tCho tissue concentration in 
the tumor voxels. There are several potential reasons for these findings. 
First, a redistribution of the tissue content of different choline containing compounds 
has occurred in such a way that no net change is observed for the tCho signal. 
Studies with perchloric acid extractions from a mixed set of liver tumor samples do 
indicate that PCho increases and GPCho decreases in tumors (33). In our HRMAS 
data of tissue samples from colorectal metastasis these changes are not significant, 
but taking all potential contributions to the tCho peak together including the methyl 
groups of free Cho, PCho, GPCho and possibly some intensity of Tau and PEtn, we 
would anticipate a similar tCho peak in 1H MR spectra of the tumor region. 
Second, due to a partial volume effect the selected voxel may contain necrotic areas, 
which is common in colorectal metastasis, that dilute the effect of area’s with rapid 
cell turnover having increased choline compound levels (18,32). The latter explana-
tion seems to be supported by a strong relation of a decreasing tCho concentration 
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with increasing tumor volume suggesting increased inclusion of tumor areas with 
low metabolite content such as necrosis.
A third reason for the absence of a difference could be the natural high tissue level of 
choline compounds in the liver. In an early 31P MR spectroscopy study the content of 
GPCho in the normal liver was estimated to be about 3.5 mmol/l of liver (34). Tak-
ing into account the relative contributions of PCho and Cho (Table 3) a total choline 
compound content of about 6.3 mmol/l of liver is derived. A dedicated localized 
1H MRS study on absolute metabolite levels of the liver in 44 middle-aged subjects 
report a tCho value of 8.6 ± 3.1 mmol/kg of wet weight (range, 3.8 – 17.6) (24). 
A recent similar study arrived at a mean tissue content of tCho in the adult healthy 
liver of 7.4 mM/ kg wet weight (range, 4.9 – 10.4) (35). In the present study we 
determined comparable absolute tissue levels and variations thereof for tCho in the 
normal liver (6.9 mmol/kg wet weight; range 4.9-11.1). Thus it appears that the 
tCho levels in the liver are higher and more variable than, for instance, the tCho 
content in the normal brain, which is about 1 – 2 mM (36) and in normal prostate, 
which is about 3 – 7 mmol/kg (37). Hence, even with a tCho increase of a few 
mmol/kg wet weight due to tumor growth it may be not very apparent in 1H MR 
spectra of voxels centered on tumor lesions surrounded by normal liver tissue.
Finally, the proton relaxation times of water or metabolites in tumor tissue may be 
different from normal liver. It is well known that T2 and T1 relaxation times increase 
in primary and metastatic tumors in the liver compared to normal liver tissue (38-
40), however, there are only few reports on proton relaxation times of tumors in the 
liver at 3T. In hepatic cancers an average T2 for the methyl protons in tCho of 133 
ms was reported (19), which is about twice that of tCho protons in normal healthy 
liver (24,35). As the T2 of water protons also appears to increase by a factor of 2 
in tumors compared to normal liver tissue (38), there is no apparent effect on the 
estimation of mean tissue levels of tCho using the water signal as a reference at a TE 
of 30 msec.  Also the T1 of tCho protons increases by about a factor of 2 (19) as well 
as the T1 of water (38), so there is no expected effect of T1 relaxation on the tCho 
estimations at the TR of 2000 ms either.
To evaluate the repeatability of measuring the tCho concentration in the tumor in 
the liver as a biomarker for treatment response we measured inter-session variability 
in a group of patients and in a group of volunteers. The repeatability in the volunteers 
was better than in the patients. This is understandable as the tumor is more hetero-
geneous than the liver, with respect to the tCho signal. A slight misplacement of the 
voxel may give a larger change in the tCho level. Moreover, during each breathing 
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cycle a tumor in the liver moves on average 9mm (range 2-19mm) (41,42). This 
could lead to voxel misregistration and outervoxel contamination (5). As the patient 
may breath differently in the two sessions, this could lead to a decreased repeat-
ability in those cases, while in healthy volunteers the effect is less due to the more 
homogeneous liver tissue.
An inter-session repeatability study at 1.5T of the choline/water ratio measured 
by PRESS localization in patients with different abdominal metastases (8 out 9 
were liver metastasis) showed a fractional repeatability coefficient of 0.73 using a 
standard 1H MRS method. This improved to 0.46 and 0.44 using respiratory gating 
and offline individual spectral phase and frequency correction (43). In our study, 
without respiratory gating, we found a fractional repeatability coefficient of 0.40 in 
normal appearing liver tissue in healthy volunteers and 1.31 in tumors in patients. 
The latter is 80% higher than in the indicated study. Our results imply that the tCho 
concentration would have to change 131% to be confidently detected in individual 
patient cases.
The results of the indicated study imply that the choline/water signal would have to 
change almost 50% to be confidently detected in individual cases, with respiratory 
gating and offline corrections. Large changes in the tCho signal due to treatment 
have been detected in some cases (20,43).
In the evaluation of new treatments the tCho signal measured by the MRS method in 
this work may be explored as a biomarker when sufficiently large treated and control 
groups are included. However, from the above evaluations it is clear that the use of 
the tCho signal from single voxels in the liver for treatment response monitoring 
in individual cases is of little use. Both for the evaluation of new treatments and 
of treatment response monitoring it would be desirable to perform multiple voxel 
localization with improved field homogeneity and motion correction. Recently, a 
method for liver 1H MRS was proposed to overcome blurring by motion, resulting in 
bad field inhomogeneity, by using a real-time navigator gating both for the measure-
ment preparation steps (B0 shimming, water frequency determination, receiver gain 
optimization, and water suppression) and for the PRESS data acquisition including 
intravoxel signal suppression to avoid a chemical shift artefact (44). This approach 
may provide excellent spectral quality, but does not solve the problem of voxel 
misplacement in diagnostic and treatment assessments due to tumor heterogeneity.
An option to address this heterogeneity of tumors in the liver is the measurement of 
multiple voxels, but smaller than the 8 ml volumes that have been used up till now, 
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in one examination. However, a 1H MR spectroscopic imaging (MRSI) measurement 
would be more suitable, so that voxels at the appropriate location can be selected 
after the measurement has been performed. MRSI has been extensively applied 
in the brain and in the prostate. In particular adiabatic sequences with low power 
refocusing pulses might be attractive for liver applications (45). The challenge is 
to equip these spectroscopic imaging sequences with adequate motion correction 
modules.
In conclusion, an increased tCho signal is not observed in 1H MR spectra of liver 
metastasis of colorectal cancer. This may be due to the background of a high tCho 
signal in spectra of normal liver, to the presence of necrosis in the tumor areas or to 
an intrinsic lower tCho content in metastatic tumor tissue.
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Chapter 4
Diffusion weighted Mr imaging in liver 
metastases of colorectal cancer: repeatability and 
biological validation
This chapter is based on: 
Heijmen L, ter Voert EE, Nagtegaal ID, Span P, Bussink J, Punt CJ, de Wilt JH, Sweep 
FC, Heerschap A, van Laarhoven HW. Diffusion-weighted MR imaging in liver 
metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol. 
2013;23:748-56.
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abstract
Background: Before diffusion weighted imaging can be implemented in standard 
clinical practice for response monitoring, data on repeatability are needed to assess 
which differences outside the range of normal variation can be detected in an indi-
vidual patient. In this study we assessed the repeatability of the apparent diffusion 
coefficient (ADC) values in colorectal liver metastases. To provide a biological basis 
for these values, their relation with histopathology was assessed. 
Methods: Diffusion weighted imaging was performed twice in 1 week in patients 
scheduled for metastasectomy of colorectal liver metastases. Correlation between 
ADC values and apoptosis marker p53, anti-apoptotic protein BCL-2, proliferation 
marker Ki67 and serum vascular endothelial growth factor (VEGF) concentration 
were assessed. 
Results: A good repeatability coefficient of the mean ADC (coefficient of repeatabil-
ity 0.20 *10-3 mm2/s) was observed in colorectal liver metastases (n=21). The ADC 
value was related to the proliferation index and BCL-2 expression of the metastases. 
Furthermore, in metastases recently treated with systemic therapy, the ADC was 
significantly higher (1.27 *10-3 mm2/s vs. 1.05 *10-3 mm2/s, P=0.02).
Conclusion: The good repeatability, correlation with histopathology and implied sen-
sitivity for systemic treatment-induced antitumor effects suggest that DWI might be 
an excellent tool to monitor response in metastatic colorectal cancer.
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Introduction
Colorectal cancer is the second leading cause of cancer-related death in Europe 
(1) and despite improved treatment, almost half of patients with colorectal cancer 
will develop distant metastases, primarily in the liver. Only a small percentage of 
the patients with liver metastases can be treated by metastasectomy with curative 
intent (2). Palliative systemic therapy prolongs the median overall survival, but 
only approximately 50% of patients respond to this potentially toxic and expensive 
treatment (3). Response evaluation is commonly performed after 8–9 weeks of 
treatment. A tool to monitor therapy response early is therefore desirable, as this 
would prevent unnecessary toxicity and costs.
Assessment of cancer and their metastases with functional imaging may lead to 
improved diagnosis and early knowledge of treatment efficacy. Diffusion weighted 
MR imaging (DWI) is a promising functional imaging tool for tissue characterization, 
response prediction and response evaluation in cancer (4, 5). From DW MR images 
an apparent diffusion coefficient (ADC) can be calculated, which is a measure of 
water mobility. A high apparent diffusion coefficient implies that water can move 
freely, for instance when few intact cell structures, such as membranes, are present 
(6). Cellular processes, like apoptosis and proliferation influence cell density and 
thus the ADC value. In a study of animals with a colorectal cancer graft a correlation 
between ADC and both apoptotic index and proliferation index was observed (7). 
Several clinical studies show that a higher pretreatment ADC value is associated 
with a poorer response to chemo- and/or radiotherapy (5, 8-10). High ADC values 
indicate there are necrotic areas with poor vascular supply, which might explain det-
rimental treatment outcome (8, 11, 12). Poor vascular supply with hypoxia leads to 
upregulated serum vascular endothelial growth factor (VEGF), which is associated 
with advanced disease stage and unfavorable outcome (13, 14). 
In most tumors, including liver metastases of colorectal cancer, an increase in ADC 
after the start of treatment occurs in response to treatment, reflecting treatment-
induced cell death (8, 15-19). However, timing is essential to witness this response 
to treatment: in later stages of treatment, tissue reorganization results in the forma-
tion of fibrosis, which could alter ADC values again (20).
Before diffusion weighted imaging can be implemented in standard clinical practice, 
data on repeatability are needed to assess which differences outside the range of 
normal variation can be detected in an individual patient. Previously, in malignant 
hepatic tumors, mainly hepatocellular carcinoma, it has been shown that limits of 
98
••
••
 C
ha
pt
er
 4
agreement of the mean ADC value in repeated DWI ranged between 28.5% and 
31.3% (21). However, repeatability could depend on the specific type of tumor and 
its heterogeneity. In this study we assessed the repeatability of the mean tumor ADC 
value, as well as the repeatability of the distribution of ADC values, using a histogram 
analysis. To provide a biological basis for these ADC values, we also assessed the 
relation between apoptosis marker p53, anti-apoptotic protein BCL-2, proliferation 
marker Ki67 and serum VEGF levels.
Materials and methods
patients
Between August 2009 and January 2011, patients with liver metastases of colorectal 
cancer who were scheduled for metastasectomy were approached for participa-
tion in this study. Patients with a contra-indication to MRI (claustrophobia, MRI-
incompatible implants, pacemaker) were excluded. Previous systemic treatment was 
allowed and patients received chemotherapy up until 1 month before study partici-
pation. No chemotherapy or other anti-tumor therapy was administered between 
the two DWI examinations. A total of 19 patients were included. This study had 
institutional review board approval (CMO region Arnhem-Nijmegen). All patients 
read and signed informed consent before entering the study. 
DWI
Respiratory triggered diffusion weighted imaging was performed twice within 
a week. All patients underwent surgery within 3 weeks of the last measurement. 
Measurements were performed on a 1.5-Tesla whole body MR system (Magnetom 
Avanto, Siemens Medical Solutions, Erlangen, Germany) using the body coil for 
excitation and a six-channel body matrix coil combined with a 24- channel spine 
matrix coil for signal reception. DWI was performed with an EPI (echo planar imag-
ing) sequence and diffusion weighted images were obtained in three orthogonal 
directions with b-values of 50, 300 and 600 s/mm2. 2D-PACE (prospective acquisi-
tion correction) navigator triggering was applied to reduce breathing motion by 
synchronizing the measurement with the patient’s breathing cycle. Parallel imaging 
combined with GRAPPA (generalised autocalibrating partially parallel acquisition) 
and an acceleration factor of 2 allowed increased imaging speeds, to further reduce 
motion artifacts. To suppress the fat signal, SPAIR (spectrally adiabatic inversion 
recovery) was included. Other imaging parameters were as follows: TR 2000 ms; 
TE 82 ms; 30 transversal slices of 6.0-mm thickness separated by 1.2 mm; field of 
view 400x400 mm; matrix size 192x192; bandwidth 1736 Hz/px; three averages; 
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anterior–posterior phase encoding direction. The ADC images were calculated 
automatically by the Syngo VB17 software using a noise level of 10.
On all slices with visible tumor a region of interest (ROI) was drawn around the 
tumor. The ROI was drawn on the b_50 image for optimal contrast between tumor 
and background. Given the high contrast between the liver and the tumor on the 
low b-value images, no problems occurred drawing the regions of interest. Further-
more, of all patients recent FDG PET were available, which was used to eliminate any 
uncertainty whether a lesion could be for example a cyst (with also high contrast) 
instead of a liver metastasis. ROIs on test and retest images were drawn in the same 
session by the same reader (a researcher with 2 years’ experience) using Inveon 
Research Workplace (IRW 3.0, Siemens Healthcare). This software overlays the ADC 
map on the b-50 images. By adjusting the transparency of both layers the ROI can 
now be drawn in the exact right position in both layers at the same time. The ROI 
is therefore automatically in the exact right position on the ADC map. Afterwards 
all voxel ADC values in the ROI were exported to an Microsoft excel file. No voxel 
values were excluded from the analyses. The mean ADC, 10th, 25th, 50th, 75th and 
90th percentiles of all voxel ADC values in the tumor ROI were calculated. 
Immunohistochemistry
Of 19 colorectal cancer patients who participated in the study histological material 
of 21 different liver metastases (from 17 different patients) was available for analy-
sis. Immunohistochemistry of consecutive 5-μm paraffin-embedded sections was 
performed for Ki67 (proliferation), p53 and BCL-2 (anti-apoptosis). Sections were 
mounted on a SuperFrost slide and dried overnight at 37°C. Sections were deparaf-
finised in histosafe and rehydrated in graded ethanol solutions before staining. Sec-
tions were incubated in citrate buffer (pH 6.0). Staining was performed with com-
mercially available antibodies. Ki67 was stained with a primary monoclonal mouse 
antibody MIB-1 (Dako, the Netherlands), p53 with mouse monoclonal p53 antibody 
clone DO-7 (Neomarkers, Fremont, CA, USA) and BCL-2 with monoclonal mouse 
BCL-2 antibody clone 124 (Dako, the Netherlands). For detection an anti-mouse 
polymer detection kit (PowerVision, Richmond, VA, USA) was used. Diaminobenzi-
dine (DAB) was used as chromogen and hematoxylin was used as counterstaining.
BCL-2 staining was scored as negative or focally positive by an experienced patholo-
gist. Other sections were digitalised using a light microscope (DM6000 Leica, Wet-
zlar, Germany; objective of 10× at 100× magnification) using a Macintosh computer 
running IPLab for Macintosh (Scanalytics Inc., Fairfax, VA, USA), which controlled 
this motorized system and generated 24-bit color composite images (pixel size 1.8 
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μm) as described previously by Rademakers et al. (22). An ROI was drawn around 
the tumor area, excluding evident necrosis. Necroses often gives aspecific staining 
results, and only a few data including necrotic areas were available for analyses. For 
all slices the optimal threshold for positive staining was determined. The fraction 
of positive staining in the tumor area and fraction of positive cells (labeling index) 
were determined using Image J software (22). From the p53 and Ki67 sections the 
fraction-positive haematoxylin nuclear staining was determined and averaged. The 
positive nuclear fraction was used as a surrogate marker of cell density. 
eLISa
Before imaging EDTA blood samples were taken from all 19 patients. Samples were 
kept on ice until centrifugation, 10 min 2000 rounds/min at 4°C. The plasma was 
frozen and stored at -80°C until further analysis. Plasma levels of VEGF-A and were 
determined in duplicate using an in-house available enzyme linked immunosorbent 
assay (ELISA). Mean concentrations per patient are reported in nanograms per mil-
lilitre (ng/L).
Statistics
A lesion-by-lesion analysis was performed to assess the intra-observer repeatability, 
by the use of a Bland–Altman analysis (23). Because differences between the two 
acquisitions were not proportional to the mean ADC value, we expressed standard 
deviation, coefficient of repeatability and limits of agreement as absolute numbers 
instead of a percentage. Mean, standard deviation and coefficient of repeatability 
were calculated. Coefficient of repeatability was calculated using the formula: CR= 
1.96*SD. The SD was calculated by squaring all the differences, adding them up, 
dividing them by the number of measurements and taking the square root (23). 
The coefficient of repeatability describes -within the paired ADC measurements- the 
difference that is smaller in 95% of the pairs. Therefore, the coefficient of repeat-
ability could also be viewed as a boundary: changes smaller than the coefficient 
of repeatability could come from measurement errors and normal variation, while 
larger changes can be considered real biological changes.
The limits of agreement were calculated by adding (upper limit) or subtracting 
(lower limit) the coefficient of repeatability from the mean difference. The coef-
ficient of variation was calculated by dividing the standard deviation by the average 
of the mean ADC values.
As the mean ADC values of liver metastases were normally distributed, Student’s t 
test was performed to assess whether the mean ADC values of tumors treated with 
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systemic therapy before inclusion in the study differed from untreated tumors and 
to compare ADC values between BCL-2-positive and -negative tumors. A Pearson 
correlation coefficient was calculated between the fractions of positive staining and 
mean ADC values, measured on both examinations.
results
patients
Nineteen patients were included in this study. Because of illness, one patient did not 
complete the second MR examination. In total, 23 metastases were detected on DWI 
in 19 patients. The average size of the metastases was 31.3 cm3 (range 0.7–130.4 
cm3), 18 metastases were located in the right liver lobe and 5 in the left liver lobe. 
Three patients who had completed both MRIs did not undergo the planned metas-
tasectomy; one metastasectomy was converted to radiofrequent ablation and two 
patients had unresectable metastases. Therefore, histological data were available for 
16 patients. Most patients had received systemic treatment before inclusion in the 
study. An overview of the patients’ characteristics is given in Table 1.
Gender Age Location 
primary 
tumor
DWI 1 DWI 2 Previous systemic therapy Liver 
metastases
1 M 60 Rectum complete complete Yes
(Neoadjuvant)
Resected
2 F 50 Rectum complete complete Yes
(Neoadjuvant)
Unresectable
3 M 79 Caecum complete complete Yes
(Neoadjuvant)
Resected
4 A 56 Sigmoid complete complete Yes
(>1 year before study 
participation)
Resected
5 M 62 Sigmoid complete complete Yes
(>1 year before study 
participation)
Resected
6 F 48 Rectum complete complete Yes
(>1 year before study 
participation)
Resected
7 F 71 Sigmoid complete complete Yes
(7 months before study 
participation)
Resected
8 M 64 Caecum complete complete Yes
(> 1 year before study 
participation)
Conversion to 
RFA
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repeatability of DWI
Liver metastases were commonly visible on ADC maps as hypointense lesions (Fig. 
1). Histogram analysis of the ADC values within the liver metastasis showed that the 
distribution did not follow a Gaussian distribution pattern, but has a positive skew 
(Fig. 2).
The mean ADC value in all liver metastases was 1.17 (± 0.11) *10-3 mm2/s. The 
coefficient of repeatability for the mean ADC value of the tumor, assessed by a 
lesion-by-lesion analyses of 21 metastases that were imaged twice, was 0.20 *10-3 
mm2/s. The limits of agreement were -0.22 and 0.19 *10-3 mm2/s. The coefficient 
of variation was 8.9%.
For all percentiles in the Bland–Altman analysis the distribution of differences versus 
the mean of all liver lesions showed that the difference in ADC values between the 
first and second examinations did not depend on the mean ADC value (Fig. 3).
Table 1: Characteristics of all participating patients (continued)
Gender Age Location 
primary 
tumor
DWI 1 DWI 2 Previous systemic therapy Liver 
metastases
9 M 59 Rectum complete complete Yes
(Neoadjuvant )
Resected
10 M 72 Sigmoid complete complete Yes
(2 months before study 
participation)
Resected
11 F 56 Sigmoid complete complete Yes
(>1 year before study 
participation)
Resected
12 M 69 Caecum complete -
(felt 
unwell)
No Unresectable
13 F 72 Rectum complete complete Yes
(>1 year before study 
participation)
Resected
14 M 61 Sigmoid complete complete Yes
(Neoadjuvant)
Resected
15 M 61 Sigmoid complete complete No Resected
16 M 76 Rectum complete complete No Resected
17 F 67 Caecum complete complete Yes
(Neoadjuvant) 
Resected
18 M 61 Caecum complete complete No Resected
19 M 59 Rectum complete complete No Resected
Table 1: Characteristics of all participating patients
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Figure 1: Left: a b-50 weighted image. The contrast between metastasis and surrounding liver tissue is 
very clear. Right: the ADC map of the same metastasis showing a dark cell-dense rim and a light necrotic 
centre.
Furthermore, the repeatability of the ADC mean did not depend on the volume of 
the metastases, previous treatment or the location in the right or left liver lobe. 
Compared with the repeatability of the mean ADC value, the repeatability was 
slightly worse at the other points of the distribution. Nevertheless, for all percentiles 
the coefficient of repeatability was below 0.30 *10-3 mm2/s (Table 2).
Figure 2: Histograms of the ADC values of the metastasis obtained from the first and second DWI scan 
of the patient of which the images are shown in figure 1. A Gaussian distribution is represented by the 
black curve.
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aDC and previous treatment
The mean ADC value of the lesions in patients pretreated with systemic therapy 
was higher compared with the ADC of untreated lesions. The higher ADC values 
were more prominent in the most recently treated patients: metastases in patients 
who had received their last systemic treatment within 3 months of the first DWI had 
a mean ADC of 1.27 *10-3 mm2/s compared with 1.05 *10-3 mm2/s in previously 
untreated tumors (P=0.02) (Fig. 4).
apoptosis and proliferation
The anti-apoptotic biomarker BCL-2 was expressed in 6 metastases. The mean 
ADC value of BCL-2-expressing metastases was significantly lower than the mean 
ADC of BCL-2-negative metastases (1.24 *10-3 vs. 1.03 *10-3 mm/s2, P<0.01). 
Both the BCL-2-negative and focally positive group contained recently treated and 
chemotherapy-naive metastases.
Figure 3: Bland-Altman plots of the mean ADC values of each metastasis showing the difference 
between the first and second scan on the y-axis and the mean ADC value on the x-axis. The red lines 
show the limits of agreement. The difference is not proportional to the mean ADC value.
Percentile Mean
(*10-3 mm2/s)
Coefficient of 
repeatability
(*10-3 mm2/s)
Lower limit of 
agreement
(*10-3 mm2/s)
Upper limit of 
agreement
(*10-3 mm2/s)
Mean 1.17 0.20 -0.22 0.19
P10 0.76 0.26 -0.28 0.24
P25 0.95 0.25 -0.25 0.25
P50 1.16 0.22 -0.21 0.22
P75 1.37 0.22 -0.24 0.20
P90 1.72 0.28 -0.30 0.26
Table 2: Mean, coefficient of repeatability and limits of agreement of the mean ADC, 10th, 25th, 50th, 
75th and 90th percentiles
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Protein p53 was expressed in most tumors. In 15 out of 21 tumors p53 was expressed 
in more than 1% of the nuclei. The other tumors had a very low expression of p53. 
The average labeling index of p53 was 0.20 (range 0.00–0.61). However, p53- 
expression did not correlate with the ADC value.
The average labeling index of the proliferation marker Ki67 was 0.13 (range 
0.00–0.34). Ki67 significantly correlated with ADC values. The lower the ADC value 
the higher the proliferation index (r=-0.61, P=0.006). Both ADC and Ki67 labeling 
index correlated with nuclear density, which was used as a surrogate marker for cell 
density. A strong positive correlation was observed between Ki67 expression and 
the nuclear density (r=0.74, P<0.001), while a negative correlation between ADC 
and nuclear density was observed (r=-0.56, P=0.017) (Figs. 5, 6).
As the Ki67 expression and BCL-2 expression was only determined in vital tumor 
tissue, represented by the lower ADC values, we evaluated the relation between 
the 10th, 25th and 90th percentiles and the immunohistochemical results. The 90th 
percentile did not correlate with the labeling index of Ki67 (r=-0.16, P=0.52) and 
did not differ in BCL-2-negative or focally positive tumors (1.77 *10-3 vs. 1.75 *10-3 
mm/s2, P=0.92). However, for the 10th and 25th percentile ADC values a correlation 
Figure 4: Box plot of the mean ADC-values, showing a higher mean ADC-value in the recently treated 
tumor metastases. The mean ADC in recently treated metastases was 1.27 *10-3 mm2/s versus 1.05 
*10-3 mm2/s in untreated tumors (p=0.02).
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Figure 6: Example of a tumor with a high (labeling index: 0.61) (A) and a tumor with low (labeling 
index: 0.00) (B) expression of p53 and an example of a tumor with high (labeling index: 0.34) (C) and 
low (labeling index: 0.00)  (D) KI 67 expression, and an example of a tumor with focally positive BCL-2 
staining(VD:124/mm2) (E) and a tumor with no BCL-2 staining (F).
Figure 5: A scatter plot (A) of the KI67 labeling index( x-axis) and mean ADC value (y-axis) shows a 
significant negative correlation, r=-0.61 p<0.01 . The mean ADC value is negatively correlated to the 
nuclear density, the surrogate marker for cell density, r=-0.56 y p=0.02 (plot B).
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with Ki67 was observed (r=-0.64, P=0.003 and -0.68, P=0.002, respectively). The 
10th and 25th percentile ADC values were also significantly lower in BCL-2 focally 
positive tumors (0.64 *10-3 vs. 0.85 *10-3 mm/s2, P=0.02 and 0.77 *10-3 vs. 1.02 
*10-3 mm/s2, P=0.008, respectively).
VeGF
The average VEGF-A concentration in the serum was 4.0 ng/mL. VEGF concentration 
correlated with the mean ADC value in lesion(s) (r=0.59, P=0.004). We observed a 
higher VEGF-A concentration in sera of patients pretreated with systemic therapy: 
VEGF-A was 8.2 (± 2.5) ng/mL in patients pretreated with bevacizumab-containing 
neoadjuvant chemotherapy vs. 2.0 (± 1.1) ng/mL in all other patients (P<0.001) 
(Fig. 7).
Figure 7: Left: VEGF-A expression is higher in neoadjuvant treated patients, which included bevacizumab 
(green dots). Right: VEGF-A levels correlated with the mean ADC value of the tumours.
Discussion
The mean findings of this study are a mean ADC in colorectal liver metastases of 1.17 
*10-3 mm2/s with a coefficient of repeatability of 0.20 *10-3 mm2/s. The mean ADC 
value correlated with the expression of proliferation marker Ki67 and anti-apoptotic 
marker BCL-2.
DWI in liver metastases showed excellent repeatability, both compared with other 
imaging techniques and compared with other repeatability data from the DWI 
application. For instance, a previous study assessing repeatability of kep in liver 
metastases measured with dynamic contrast enhanced MRI observed a coefficient 
of repeatability of 0.009 with a mean value of 0.033 (27%) (24). Moreover, the 
repeatability of oesophageal and breast cancer measured with FDG and FLT-PET was 
approximately 30% (25). The repeatability was also better compared with primary 
liver tumors measured with DWI (21). Good repeatability may be (partly) due to 
the use of respiratory triggering, minimizing the negative effects of breathing move-
ment. 
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However, the most important question remains whether the repeatability is suf-
ficient to use DWI for (early) response monitoring. Cui et al showed that the mean 
ADC of average liver metastases responding to chemotherapy increased by 0.22 
after 1 week of treatment, while non-responding lesions did not change significantly 
(8). Koh et al. (16) measured liver metastases before and after chemotherapy and 
found that the responding lesion (measured with b-values 150–500) increased from 
a mean of 1.15 *10-3 mm2/s before treatment to 1.41 *10-3 mm2/s at the end of 
treatment. According to the repeatability established in our study, these reported 
changes can be detected confidently by our measurement technique.
Although histopathology only represents a small vital tumor area and the ADC value 
represents the entire tumor, the mean ADC showed an excellent correlation with 
histopathological data, as did the 10th and 25th percentiles. Conversely, the high 
ADC values (90th percentile) did not correlate with histopathology, suggesting 
that the low ADC values, which represent vital tumor tissue, correlate better with 
histopathology than the high ADC values, which represent the excluded necrotic 
and non-vital areas. Mean ADC was significantly lower in BCL-2-expressing tumors, 
which could be explained by the anti-apoptotic effect of this protein. By prevention 
of apoptosis more cell membranes will remain intact, and therefore promote a low 
mean ADC value. However, the labeling index of p53 did not correlate with the mean 
ADC value. The effect of p53 expression and p53-regulated apoptosis on cell density 
and thus ADC value may not be straightforward. Accumulation of p53, as detected 
by immunohistochemistry, does not necessarily imply the presence of mutated, 
inactive p53. Furthermore, the absence of p53 accumulation does not always mean 
that functional p53 is present, for instance when p53 is deleted (26).
The ADC value was inversely correlated with the proliferation index, measured by 
Ki67 expression. This is probably due to the influence of proliferation on the cell 
density of the tissue. We used the fraction of positive haematoxylin staining in the 
tumor area as a surrogate marker of cell density and observed a correlation of both 
Ki67 with cell density as well as a correlation of ADC values with cell density. Of 
course the fraction of the tumor with positive staining for nuclei depends not only 
on cell density, but also on the size of the nuclei and number of nuclei per cell.
Finally, the ADC values correlated with the VEGF concentrations in the plasma of 
patients. Metastases treated with bevacizumab-containing regimens had a higher 
ADC value, and higher VEGF levels in their plasma. An increased (bound) VEGF level 
in the serum after bevacizumab administration has been observed in several studies 
(27). A possible explanation is that the clearance of VEGF bound to bevacizumab 
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is lower than that of free VEGF. As a result, the total VEGF level may rise while the 
free (functional) VEGF levels may decrease during bevacizumab treatment (28). 
However, VEGF is also known to increase vascular permeability (29). Therefore, 
VEGF levels could also have a direct impact on ADC values, which could also explain 
the correlation between ADC and VEGF level.
In conclusion, we observed an excellent repeatability coefficient of the mean ADC in 
colorectal liver metastases. The ADC value was related to the proliferation index and 
BCL-2 expression of the metastases. Furthermore, in recently treated metastases 
the ADC value was notably higher. The very good repeatability, the correlation with 
histopathology and the implied sensitivity for systemic treatment-induced antitu-
mor effects suggest that DWI might be an adequate tool for response monitoring in 
metastatic colorectal cancer.
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Chapter 5
repeatability and biological basis of in vivo t2
* 
magnetic resonance imaging of liver metastasis 
of colorectal cancer
This chapter is based on: 
ter Voert EG, Heijmen L, de Wilt JH, Bussink J, Punt CJ, van Laarhoven HW, Heerschap 
A. Reproducibility and biological basis of in vivo T(2)* magnetic resonance imaging 
of liver metastasis of colorectal cancer. Magn Reson Med. 2013;70:1145-52.
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abstract
In this study the repeatability of T2
* MR imaging in colorectal liver metastases was 
assessed and T2
* values were correlated with the expression of the hypoxia related 
markers GLUT-1 and CA-IX as well as the relative vascular area, and the vessel den-
sity in resected tumors. The repeatability of T2
* was analyzed in 18 patients with in 
total 22 colorectal liver metastases using the Bland & Altman method for the 16th 
, 50th, and 84th percentile values. Immunohistochemical staining was performed on 
17 resected tumors obtained from 16 patients. The median T2
* of all liver metastases 
was 25.0 ± 5.6 ms vs. 23.0 ± 4.1 ms (median ± st.dev.) in normal liver. The coeffi-
cient of repeatability was 11.2 ms and the limits of agreement were -13.2 ms and 9.1 
ms for median T2
* values. On average T2
* showed fair repeatability. No correlations 
between T2
* values, hypoxia and vascularity related markers were observed.
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Introduction
In colorectal cancer about 50% of the patients develop distant metastasis, mainly 
in the liver (1–3). Resection of colorectal metastases can only be performed in 
few patients with metastatic disease. Currently, non resectable metastatic disease 
is treated with cytotoxic drugs like 5-fluorouracil, capecitabine, oxaliplatin and/or 
irinotecan, often combined with bevacizumab, an antibody against vascular endo-
thelial growth factor. In standard clinical practice, approximately six to nine weeks 
after start of treatment, computed tomography is performed and tumor size is 
assessed to evaluate treatment. Monitoring response at an earlier stage is desirable, 
as only a subset of patients receiving chemotherapy responds to this potentially 
toxic and expensive therapy. Therefore, predictive markers are needed to determine 
treatment efficacy at an early stage.
Changes in tumor size can also be imaged with magnetic resonance (MRI), which in 
addition offers the potential to acquire functional information, for example, dynamic 
contrast enhanced MRI (DCE-MRI) to measure tumor vascularity (4). There is 
an increasing interest in MR to image T2* (or R2* =1/T2*), intrinsic susceptibility-
weighted or blood oxygenation level dependent (BOLD) MRI, as an alternative for 
DCE-MRI as this circumvents the need for contrast agent administration (5–10). 
The transverse magnetization relaxation T2
* represents both spin-spin relaxation and 
magnetic field inhomogeneities (11). A major factor affecting T2
* relaxation is deoxy-
genated hemoglobin in blood. When hemoglobin is oxygenated, it is diamagnetic, but 
when deoxygenated, it becomes paramagnetic (12,13). Paramagnetic deoxyhemo-
globin affects the local magnetic field sensed by nearby water protons in blood and 
surrounding tissues, which leads to a decrease in the T2
* time. Specific parameters 
that may influence T2
* in tissue are blood oxygen saturation, hematocrit, blood flow, 
and blood volume (14). In vessels near hypoxic tissue, it is likely that more oxygen is 
released from hemoglobin. If blood flow remains the same this will result in a higher 
deoxyhemoglobin level and therefore the T2
* relaxation time in and near the vessel 
will decrease. This is of clinical importance, since hypoxic tumors are likely to have an 
increased resistance to radiation therapy and chemotherapy (15,16).
Tumor hypoxia may result from poor vascularity in solid tumors and is associated 
with a higher uptake of glucose by glucose transporters (GLUT1) and increased H+ 
ion production. Intracellular H+ and HCO3- ions can form H2O and CO2 which can 
freely diffuse through the cell membrane. Once outside the cell, membrane-bound 
carbonic anhydrase IX (CA-IX) catalyzes the reverse process. Next, the HCO3- ions 
are transported back into the cell thereby trapping the H+ ions in the extracellular 
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space. Therefore, in hypoxic conditions, GLUT1 and CA-IX are up-regulated and can 
be used as surrogate measures of hypoxia in tumors (17).
To predict treatment outcome or monitor therapy, differences in T2
* should reflect 
true differences in tumor biology and not variations in the MR system or body physi-
ology. Knowledge of repeatability is of special relevance in early response monitor-
ing. Therefore, this study aimed to assess the repeatability of T2
* MRI in colorectal 
liver metastases next to normal appearing liver. As T2
* is expected to be governed 
by tumor hypoxia and tissue vascularity we also investigated the correlation of T2
* 
with the expression of the hypoxia related markers GLUT-1 and CA-IX as well as the 
relative vascular area (RVA), and vessel density (VD) as measures of vascularity in 
metastases.
Methods
patients
Between August 2009 and January 2011 twenty patients with liver metastases of 
histologically proven colorectal cancer, who were scheduled for metastasectomy 
were included. Prior to surgery, patients underwent two MRI examinations to assess 
repeatability. Two of these patients did not complete the MR part of the study. The 
remaining eighteen patients, eleven males and seven females, were analyzed in this 
study. Median age was 61 years (range 48 – 79). All measurements were carried 
out after approval of the local institutional medical ethics committee and written 
informed consent was obtained from each patient.
Magnetic resonance imaging
All MRI examinations were performed on a 1.5T whole body MR system (Magnetom 
Avanto, Siemens Healthcare, Erlangen, Germany) using the body coil for excitation 
and a six channel body matrix coil combined with a twenty-four channel spine matrix 
coil for signal reception. After conventional T1- and T2-weighted imaging, T2
* imag-
ing was performed using a spoiled gradient-recalled echo, FLASH 2D, sequence. 
Every image slice was obtained with a TR of 225 ms, and multiple TE values (4.76, 
9.53, 14.29, 19.06, 23.82, 28.58, 33.35, 38.11, 42.88, 47.64, 52.40 ms). Other scan 
parameters were: flip angle: 25 degrees, field of view: 400 mm, slice thickness: 6.0 
mm, matrix size: 128x128. Parallel acquisition (GRAPPA) with an acceleration factor 
of 2 was used. Patients continued normal shallow breathing during the scans, no 
breath-hold or respiratory gating was applied. T2
* imaging was followed by diffu-
sion weighted MRI (DWI) as colorectal liver metastasis are usually clearly visible on 
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these images. DWI was performed with respiratory triggered echo planar imaging 
(EPI) sequence and b-values 50-300-600 s/mm2 in three orthogonal directions. The 
measurement protocol was repeated after 2-8 days (median: 4 days).
Mr post processing
T2
* maps were generated using in-house built software based on Matlab (Math-
Works, Natick, MA, USA). The echo time data was fitted pixel by pixel to a mono-
exponential curve SI = A ρ exp( - TE / T2
*) + B where ρ is the proton density, TE is 
the echo time, and the parameter of interest T2
*, the relaxation time. An arbitrary 
scale factor A, and a baseline B, were added to incorporate scanner dependencies. 
Software allowed to overlay the DWI (b=50 s/mm2) images, the T1 and T2 weighted 
images on the calculated T2
* maps. By adjusting the transparency of the different 
layers, 3D regions of interest (ROIs) could be drawn in the exact right position in all 
layers at the same time using the information from all the different imaging tech-
niques. To compare the repeatability of the lesions with that of normal liver tissue, 
additional 3D ROIs with the same volume and in the same liver region as the lesions 
were drawn in normal appearing liver tissue excluding large blood vessels and bile 
ducts. Datasets obtained on scan day one and scan day two were processed in the 
same session to be able to draw the liver ROIs in both datasets in the same position. 
In addition, all ROIs were drawn by same reader (a researcher with 4 years’ expe-
rience). Voxel values inside the ROIs were extracted and analyzed in a histogram, 
which provided additional information on the distribution of T2
* values within the 
lesion or normal appearing liver tissue.
Immunohistochemistry
Immunohistochemical staining was performed on 17 resected tumors obtained 
from 16 patients to assess the relation between T2
*, hypoxia and tumor vascularity. 
Expressions of GLUT-1 and CA-IX were investigated as hypoxia related markers, 
and the expression of CD34 as a marker of tumor vascularity. The following pro-
tocol describes the immunohistochemical staining and scoring of the resected liver 
metastasis sections.
First, H&E-staining (hematoxylin and eosin) was performed. If viable tumor cells were 
present, immunohistochemistry of 5 μm paraffin embedded sections was performed.
For all immunohistochemical staining sections were deparaffinized in histosafe and 
rehydrated in graded ethanol solutions and kept for 30 minutes in Target Retrieval 
Solution. The peroxidases in the sections were blocked by keeping them in 3% H2O2 
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in methanol for 15 minutes. The sections were preincubated with 5% normal donkey 
serum in primary antibody diluent (PAD, Abcam, Cambridge, UK) for 30 minutes at 
room temperature.
For GLUT-1 staining rabbit-anti-GLUT-1 (RB-9052 P1) 1:400 in PAD was used for 45 
minutes in 37 °C, followed by donkey anti-rabbit biotine 1:500 in a phosphate buffer 
solution (PBS) for 60 minutes at room temperature. For CA-IX staining mouse-anti-
CA-IX (1:25 in PAD) was applied on the tumor sections and kept overnight at 4 °C. 
Sections were incubated with a second antibody, F(ab’)2-Donkey-anti-mouse IgG 
BIOTINE (1:200 in PBS) for 60 min. at room temperature. For CD34 staining mouse-
antiCD34 (1:10 in PAD) was applied to all tumor sections and kept overnight at 4 °C 
. The sections were incubated with a second antibody, F(ab’)2-Donkey-anti-mouse 
IgG (1:200 in PBS) for 60 min. at room temperature.
All sections were stained with diaminobenzidine (DAB) for 10 minutes. Hematoxylin 
was used for counterstaining. Sections were dehydrated and mounted with KP 
mounting medium. Between all steps, the sections were rinsed with PBS. 
All slices were digitized using a bright field light microscope equipped with a 10× mag-
nification objective lens (Leica, Wetzlar, Germany) and Image Processing Lab software 
(Scanalytics Inc., Fairfax, VA, USA). A region of interest was drawn around the tumor 
area, excluding evident necrosis. For all slices the optimal threshold for positive staining 
was determined. The fraction of positive staining in the tumor area and the fraction of 
positive cells were calculated (18). With CD34 the relative vascular area in the tumor 
area was calculated and the number of vessels per square mm were scored.
Statistics
Statistical analysis were done using the PASW Statistics 18.0.2 (IBM Corporation, 
Armonk, New York, USA) and Prism 4.0 (GraphPad Software Inc., La Jolla, San 
Diego, CA, USA) software packages. For each lesion and volume matched normal 
liver region the 16th, 50th, and 84th percentiles of the T2
* values were calculated. 
The 50th percentile is also known as the median and equals the mean in a normal 
distribution. To provide more insight in the distribution of the T2
* values, the 16th 
and 84th percentile values were added, since they are one standard deviation from 
the mean in a normal distribution.
The Wilcoxon signed rank test was applied to indicate significant differences between 
the 16th, 50th, and 84th percentile values of tumor on day one and two, liver on day 
one and two, tumor and liver on day one, and tumor and liver on day two. 
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Spearman’s rank correlation coefficient was applied to test for significant correla-
tions between the 16th, 50th, and 84th percentile values and lesion size. And the same 
test was repeated for the normal appearing liver regions.
The repeatability was assessed using Bland Altman analyses (19,20). In the Bland-
Altman plot the difference in median T2
* values measured on the first and second 
scan day is plotted against the mean of the two median T2
* values. The coefficient 
of repeatability describes, within the paired T2
* measurements, the difference that 
is smaller in 95% of the pairs. The coefficient of repeatability can also be seen as a 
boundary: changes smaller than the coefficient of repeatability could come from 
measurement errors and normal biological variation, while larger changes can be 
considered real biological changes e.g. after applying therapy. The coefficient of 
repeatability can be calculated by multiplying the standard deviation of the dif-
ference with 1.96. The 1.96 stems from the normal distribution where 95% of the 
measurements are within 1.96 times the standard deviation. The standard deviation 
of the difference was calculated by squaring all the differences, taking the sum and 
dividing it by the number of measurements and finally taking the square root. The 
limits of agreement were calculated by adding (upper limit) or subtracting (lower 
limit) the coefficient of repeatability from the mean difference. This was repeated 
for the normal appearing liver regions and for the 16th and 84th percentile values of 
the T2
* values to provide more insight in the repeatability of the distribution of the 
T2
* values.
Spearman’s rank correlation coefficients were calculated between the average T2
*, 
by averaging the two median T2
* values of both the first and the second scan, and 
the expression of the hypoxia related markers GLUT-1 and CA-IX as well as the rela-
tive vascular area, and the vessel density. This was again repeated for the 16th and 
84th percentile values of the T2
* values.
results
A total of 22 colorectal liver metastases were analyzed in 18 patients. Median tumor 
size was 8.03 cm3 (range 0.87-138 cm3). Regions of interest (ROIs) were drawn 
on a calculated T2
* map, also using a diffusion weighted b=50 s/mm2 image and 
conventional T1 and T2 weighted images (see figure 1). Subsequently, the histogram 
distribution of T2
* values in tumor ROIs and in matched normal appearing liver ROIs 
were analyzed (see figure 2 for an example). 
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Figure 1: Example of a T2
* map (A), a diffusion weighted b=50 s/mm2 image (B), a T1 (C) and a T2 
weighted image (D), at the same location, in the same patient. Images on the left are obtained on scan 
day one, images on the right on scan day two. The red line indicates the tumor region of interest.
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Figure 2: Example of the histogram distribution of T2
* values in a tumor ROI (left) and in a size matched 
normal appearing liver ROI (right). The bars indicate the counts on scan day one (red) and two (blue), 
the Gaussian shaped curves in the background are fitted normal distributions for scan day one (red) 
and two (blue). The vertical lines above the bars indicate the 16th, 50th and 84th percentile values in the 
measured data for scan day one (red) and two (blue). 
There was no significant difference (Wilcoxon signed-rank test) between the 16th, 
50th, and 84th percentile values of T2
* measured on scan day one and two for tumor 
tissue nor for the normal appearing liver tissue (see table 1). There was also no differ-
ence (Wilcoxon signed-rank test) between the 16th and 50th percentile values of tumor 
and normal appearing liver tissue. There was however a significant difference between 
the 84th percentile values of tumor and normal appearing liver for both the day one 
and two measurements (Wilcoxon signed-rank test (tumor – liver); day one: z=-2.99, 
p<0.01; day two: z=-2.88, p<0.01; both based on a positive rank). This indicates that 
the tumor tissue has more higher T2
* values then the normal liver tissue.
Median T2
* Median T2
*
Limits of agreement Coefficient of repeatability
Day 1 Day 2 Day 1 & 2
[ms] [ms] [ms] [ms] [ms] [ms] [% of median]
Tumor P16 19.0 16.8 17.8 ± 4.9 -8.2 7.7 7.9 44.7
P50 24.5 24.0 25.0 ± 5.6 -13.2 9.1 11.2 44.6
P84 31.5 32.0 30.2 ± 10.2 -18.7 14.1 16.4 54.4
Liver P16 17.0 17.4 17.1 ± 4.7 -9.1 6.4 7.8 45.3
P50 22.0 24.1 23.0 ± 4.1 -9.9 6.5 8.2 35.6
P84 26.8 28.7 27.6 ± 4.8 -8.7 6.8 7.7 28.0
Table 1: The median T2
* values on day one, median T2
* values on day two, the median T2
* values on day 
one and two (by first averaging per ROI the day one and two values) ± standard deviation, the limits of 
agreement, and the coefficient of repeatability of the Bland Altman analysis for the 16th, 50th and 84th 
percentiles.
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The 16th and 50th percentile values of the tumors and the size matched liver regions 
were not significantly correlated (Spearman’s rank correlation coefficient) to their 
volume, calculated as the volume of the 3D ROIs. The 84th percentile values on 
the other hand, were significantly correlated (tumor: r=0.48, p=0.02; liver: r=0.52, 
p=0.01) to their volume. The standard deviation of the T2
* values of the tumors 
and the size matched liver regions was also significantly correlated (tumor: r=0.71, 
p<0.01; liver: r=0.73, p<0.01) to their volume. This indicates that larger ROIs have a 
larger spread and higher T2
* values.
The coefficient of repeatability for the median T2
* values was 11.2 ms for liver metas-
tases and 8.2 ms for the normal appearing liver regions (table 1, figure 3). The limits 
of agreement for median T2
* values were -13.2 ms and 9.1 ms for liver metastases and 
-9.9 ms and 6.5 ms for the normal appearing liver regions. Small differences in the dis-
tribution are seen between measurement day one and two. Besides the median or 50th 
percentile value, the Bland Altman analyses was also performed on the 16th and 84th 
percentile values, to provide more insight in the actual distribution of T2
* values in each 
lesion. The coefficient of repeatability and the range indicated by the limits of agree-
ment, increase with increasing percentile values in tumor tissue but remains constant 
in normal liver tissue (table 1, figure 3). The Bland Altman plots in figure 3 show that 
Figure 3: Bland Altman analysis of the 16th, 50th and the 84th percentile of the T2* values in normal 
appearing liver tissue (left) and tumor (right). The black dot-dashed lines indicate the mean difference 
and the red dashed lines indicate the limits of agreement.
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the differences do not vary in any obvious systematic way over the range of measure-
ment. In case the differences would be proportional to the mean for example, a cone 
shaped cloud of data points would be visible, and a log transform of the data would be 
recommended (20,21). Kendall’s tau rank correlation coefficient test confirmed that 
there was no correlation between the difference in T2
* and the mean T2
*. The only 
exception was the 50th percentile of the liver which had a negative correlation of -0.38 
and a p-value of 0.02. The data was however not transformed since the correlation 
was only minor and transformed data is often more difficult to interpret. 
t2
* and the correlation with markers of hypoxia and vascularity
Histologic material was obtained from 17 resected tumors in 16 patients. An 
example of the immunohistochemical stained sections is shown in figure 4. After 
Figure 4: Example of a tumor with low (fraction: 0.01) (A) and high (fraction: 0.42) (B) CA IX 
expression, an example of a tumor with low (fraction: 0.00) (C) and a tumor with high (fraction: 0.33) 
(D) expression of GLUT1, and an example of a tumor with a low vascular density (VD: 30/mm2) (E) and 
a tumor with a high vascular density (VD:124/mm2) (F).
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carefully analyzing the stained sections and performing Spearman’s rank correlation 
coefficient between the median T2
* and the expression of GLUT-1, CA-IX, the rela-
tive vascular area, and vessel density, no significant correlations were found (table 
2). In addition, the 16th and 84th percentile values of T2
* also showed no significant 
correlation. 
Spearman’s rank correlation coefficient
Glut-1 CA-IX RVA VD
r p-value r p-value r p-value r p-value
Tumor
T2
*
P16 -0.03 0.90 0.15 0.55 0.30 0.24 0.12 0.65
P50 -0.11 0.67 -0.13 0.61 0.22 0.40 0.14 0.58
P84 0.17 0.52 -0.06 0.82 0.28 0.28 0.17 0.51
Table 2: The Spearman’s rank correlation coefficients and p-values between the 16th, 50th and 84th 
percentile values of T2
* and GLUT-1, CA-IX, the relative vascular area (RVA), and the vessel density 
(VD).
Discussion
MR imaging of T2
* relaxation provides a functional biomarker of potential value 
in the diagnosis of liver lesions. In this study, the repeatability of T2
* MR imaging 
in colorectal liver metastases was investigated and showed fair repeatability. The 
distribution of the lower T2
* values, the 16th and 50th percentile values, in colorectal 
liver metastases did not significantly differ from surrounding normal appearing liver 
tissue. The colorectal liver metastases however appeared to have more higher T2
* 
values, i.e. the 84th percentile values, than surrounding normal appearing liver tissue. 
From Bland Altman analyses it can be concluded that a change due to treatment 
should induce at least a 45% difference in the median T2
* value to make a distinction 
between a true change in tumor biology and variations in the MR system or body 
physiology. Alonzi et al (22) investigated the R2
* (=1/T2
*) repeatability of malignant 
prostate tissue and found a repeatability of 64.6%. It will depend on the extent of the 
anticipated treatment induced changes if the current repeatability of median T2
* is 
sufficient to predict treatment outcome at an early stage.
The variation in T2
* values in consecutive measurements in the present study can 
be explained by several factors. First of all, temporary occlusions in the poor tumor 
vasculature can cause transient, fluctuating hypoxia in some tumor regions (23). 
As erythrocytes, which contain (de)oxyhemoglobin, cannot pass these temporary 
occlusions temporary occlusions will influence the measured T2
* signal. Compared 
to other organs, T2
* imaging of the liver is challenging because of potential field 
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inhomogeneities and artifacts caused by respiratory movement, and cardiac and 
aortic pulsations (24–26). Although respiratory and cardiac gating can be applied, 
this may increase scan time and thus patient discomfort and costs. Breath-hold 
acquisitions may reduce artifacts, but multiple breath-hold scans would be required 
to image the entire liver which is hard to perform for patients with advanced cancer. 
In our study we instructed patients to breath shallowly. This avoided long scanning 
times and difficult breath-holds, thereby promoting patients’ comfort. Shallow 
breathing combined with liver tumor registration and motion correction could 
further improve repeatability. Finally, since T2
* is related to small fluctuations in 
local magnetic field, it is crucial for its proper application that good magnetic field 
homogeneity is obtained over the region of interest; especially considering the many 
different tissue types and air containing compartments near the liver. 
Contrary to our expectations, no correlations between T2
* values, hypoxia and 
vascularity  were observed. A study on primary rectal adenocarcinoma by Atkin et 
al. (27), however, also showed a lack of correlation between R2
*, CA IX and vessel 
density (CD31).
The Warburg effect – anaerobic glycolysis despite the presence of oxygen -  could 
explain the lack of correlation between measured T2
* values and the expression of 
GLUT-1 and CA-IX (28,29). Malignant rapidly-growing tumor cells often produce 
energy by a high rate of glycolysis even in the presence of oxygen (30). This implies 
that these cells could have a high expression of GLUT-1 and CA-IX in the presence 
of oxygen in order to allow for the high influx of glucose and efflux of the H+ ions. 
In these oxygenated areas the deoxyhemoglobin concentration will be low as less 
oxygen is released by hemoglobin. Therefore, these regions appear as non-hypoxic 
on the T2
* images, while the same region appears ‘hypoxic’ based on the increased 
expression of GLUT-1 and CA-IX. 
The absence of a correlation between measured T2
* values and the RVA and VD can 
partially be explained by the fact that the CD34 marker attaches to both perfused 
and non perfused vascular endothelial cells. In contrast, T2
* only reflects oxygenation 
in vessels, and adjacent tissue. This difference could specifically be relevant for T2
* 
measurements in tumors, as the tumor microvasculature is usually less stable, more 
leaky and suffers more from temporary occlusions than mature microvasculature 
(31).
Next to the above mentioned causes, T2
* values may also be influenced by other 
factors. Increased blood flow may result in a lower blood desaturation if the oxygen 
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consumption of nearby tissue remains constant. The amount of deoxyhemoglobin 
decreases and the measured T2
* value will therefore increase. An increased blood 
volume, on the other hand, could result in increased amounts of deoxyhemoglobin, 
if the blood desaturation remains constant. The effect of vasodilatation or vaso-
constriction on T2
* is therefore difficult to predict as it will have an effect on both 
blood flow and volume. Hematocrit, the volume percentage of red blood cells in 
blood, determines the amount of hemoglobin present in the blood and it is known 
to decrease in smaller vessels (32,33). Since the hematocrit can vary in patients 
due to various reasons, the amount of deoxyhemoglobin could also change and thus 
influence the measured T2
* value. The blood oxygenation level is another factor that 
could vary. Due to the oxygen consumption of tissues adjacent to the tumor the 
oxygenation level of blood arriving at the tumor may already be lower, thus having 
a higher amount of deoxyhemoglobin. A decrease in blood pH could also result in 
an increased oxygen release by hemoglobin, resulting in more deoxyhemoglobin. 
Besides the previous mentioned blood related parameters other effects like iron 
accumulation can also influence the magnetic field. Since iron is ferromagnetic, it 
can decrease measured T2
* values.
In conclusion, the average T2
* values in colorectal liver metastases showed fair 
repeatability. No correlations between T2
* values, endogenous hypoxia related pro-
teins and vascularity related markers RVA and VD were observed.
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Chapter 6
reduced respiratory motion artifacts using 
structural similarity in fast 2D dynamic contrast 
enhanced MrI of liver lesions with an automated 
arterial input function determination
This chapter is based on: 
ter Voert EE, Heijmen L, Punt CJ, de Wilt JH, van Laarhoven HW, Heerschap A. 
Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic 
contrast enhanced MRI of liver lesions. NMR Biomed. 2016;29:1526-35.
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abstract
Purpose: To improve dynamic contrast enhanced MRI (DCE-MRI) of liver lesions by 
removing motion corrupted images as identified by a structural similarity (SSIM) 
algorithm. To assess the effect of this correction on the pharmacokinetic parameter 
Ktrans using automatically determined arterial input functions (AIFs).
Materials and Methods: Fifteen patients with colorectal liver metastases were mea-
sured twice with a T1 weighted FLASH sequence for DCE-MRI (time resolution 1.2 
s). AIFs were automatically derived from contrast inflow in the aorta of each patient. 
Thereafter SSIM identified motion corrupted images of the liver were removed from 
the DCE dataset. From this corrected data set Ktrans and its repeatability were deter-
mined employing the individual AIFs.
Results: Using the SSIM algorithm a median fraction of 46% (range 37-50%) of the 
liver images in DCE time series was labeled as motion distorted. Rejection of these 
images resulted in a significantly lower median Ktrans (p<0.05) and lower coefficient 
of repeatability of Ktrans in liver metastases compared to an analysis without correc-
tion.
Conclusions: SSIM correction improves the repeatability of the DCE-MRI parameter 
Ktrans in liver metastasis and reduces contamination of Ktrans values of lesions with 
that of surrounding normal liver tissue.
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Introduction
Colorectal cancer is one of the most common cancers in the Western world. Approxi-
mately 50% of the patients develop metastases, mostly in the liver (1), which is 
often dealt with by partial liver resection (2). Non-resectable metastatic disease is 
currently treated with cytostatics such as 5-fluorouracil, which may be combined 
with an anti-angiogenic drug like bevacizumab (3). The therapy response in patients 
with colorectal liver metastases can be evaluated by dynamic contrast-enhanced MR 
imaging (DCE-MRI) which provides a quantitative assessment of tumor vascularity, 
such as vessel permeability (4,5). However, the robust application of DCE-MRI to 
liver tumors is hampered by respiratory motion. 
At rest, a healthy person breathes 12 to 15 times per minute. During each breath 
cycle a tumor in the liver moves on average 9 mm (range 2 to 19 mm) in cranio-
caudal direction (6–8). Common respiratory and cardiac gating cannot be applied in 
high-temporal-resolution DCE-MRI, as sampling of the initial contrast bolus passage, 
to determine an arterial input function (AIF), requires a temporal resolution below 
2 seconds. During typical multi-slice 2D DCE-MR imaging with a slice thickness of 
6 mm and 50% inter-slice distance a whole tumor volume in the liver can easily 
move from one slice to another and back again during a breath cycle. Because of 
the unpredictable liver movement it is difficult to substitute for the missing data in 
the inter-slice gap and thus to reconstruct the position and displacement of a tumor, 
which makes the application of motion correction algorithms problematic.
One option to overcome this motion problem is by imaging in the sagittal or coronal 
instead of transverse plane. However, in sagittal imaging the phase-encoding direc-
tion is cranio-caudal or anterior-posterior, the directions with the largest motion, 
leading to more artifacts like ghosting. In coronal and transverse imaging, a left-right 
phase encoding direction avoids these artifacts. As we wish to have the aorta as a 
reference vessel in the same plane as the tumor, which may be more difficult in the 
coronal plane, we perform high-temporal-resolution multi-slice DCE-MRI of the liver 
in the transverse direction.
If the repeated image acquisition in time series to monitor contrast uptake is per-
formed rapidly (less than 2 seconds per image) it is possible to delete images that 
are affected by motion, so that still sufficient images remain for a pharmacokinetic 
analysis of tissue contrast uptake (commonly performed at a time resolution of more 
than 2 seconds). This requires an algorithm that can detect if images are similar, i.e. 
recorded at moments when the liver is in the same position. The only changes in 
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these images will be due to the uptake of contrast agent. With a structural similarity 
(SSIM) algorithm the similarity between images can be assessed (9).
In a pharmacokinetic analysis of DCE-MRI data often a population-averaged AIF is 
used for practical reasons. To account for patient dependent variations in arterial 
flow, individual AIFs can be determined from the first contrast bolus passage sampled 
by high-temporal-resolution MRI. Because the manual selection of the arterial voxels 
that show a proper transient effect of the contrast agent on the MR signal, is cum-
bersome and error-prone we developed an algorithm that automatically searches 
for voxels with these effects in supplying blood vessels to determine an AIF (10). For 
liver lesions the aorta is a potentially useful artery for this purpose, as it is detectable 
in transverse body MR images that also include the liver and is representative for 
arterial blood flow to tumors in the liver (11,12).
In this study we aimed to improve DCE-MRI of liver lesions by removing motion 
distorted or displaced images that are identified by a structural similarity (SSIM) 
algorithm. The effect of this correction on the pharmacokinetic parameter Ktrans was 
assessed in data processed with automatically determined individual AIFs.
Materials and Methods
patients
Twenty patients with liver metastases of histologically proven colorectal cancer 
were included in this study for two DCE-MRI examinations. Two of these patients did 
not complete both MRIs and in three patients one of the MR datasets was incorrectly 
recorded. Of the remaining fifteen patients, eight males and seven females, one 
colorectal liver metastases for each patient was analyzed. Median age was 61 years 
(range 48 – 79 years). Patients with a contra-indication to MRI or to the contrast 
agent were excluded. Patients who had previous systemic treatment or chemo-
therapy until 1 month before the first examination were allowed to participate. To 
assess the repeatability of the MR measurement the patients were examined twice 
with a median time between the two examinations of 4 days (range 2-8 days). No 
anti-tumor therapy was administered between the two scans. All measurements 
were carried out after approval of the local institutional medical ethics committee 
and written informed consent was obtained from each patient. 
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Magnetic resonance imaging
MRI was performed on a 1.5T whole body MR system (Magnetom Avanto, Siemens 
Healthcare, Erlangen, Germany) using the body coil for excitation and a six channel 
body matrix coil combined with a twenty-four channel spine matrix coil for signal 
reception. 
After conventional T1- and T2-weighted imaging, diffusion weighted MRI (DWI) was 
performed to visualize colorectal liver metastasis, with respiratory triggered echo 
planar imaging (EPI) and b-values 50-300-600 s/mm2 in three orthogonal direc-
tions. Other parameters were: repetition time (TR) 2000 ms, echo time (TE) 82 ms, 
3 averages, transverse slices of 6 mm thick each, 1.2 mm distance between slices, 
matrix size 192x192, field of view 400x400 mm, bandwidth 1735 Hz/pixel, spectral 
attenuated inversion recovery (SPAIR) fat suppression, parallel imaging with gen-
eralized autocalibrating partially parallel acquisition (GRAPPA) and an acceleration 
factor of 2.
Gadoteric acid (Gd-DOTA, Dotarem(®), Guerbet, Roissy CdG, France) was adminis-
tered by intravenous bolus injection (15 ml, 0.5 M, 2.5 ml/s) and flushed with saline 
(20 ml, 2.5 ml/s) employing an MR compatible injector (OptiStar LE, Covidien/
Tyco Healthcare/Mallinckrodt, Dublin, Ireland). Using a T1 weighted fast low-angle 
shot (FLASH 2D) spoiled gradient-recalled echo sequence with a time resolution of 
1.2 seconds, the Gd-DOTA uptake in the tumor and the bolus passage in the aorta 
was monitored for 3 minutes. Sequence parameters: TR 21 ms, TE 1.57 ms, 45o flip 
angle, 6 transverse slices, each 6 mm thick and 3 mm inter-slice distance, matrix size 
256x125, field of view 400x325 mm, number of signal averages (NSA) 1, bandwidth 
1030 Hz/pixel. GRAPPA parallel acquisition was applied with an acceleration factor 
of 2. During the scans patients continued normal shallow breathing without breath-
hold or respiratory gating. Before Gd-DOTA injection, proton density weighted 
images were recorded with the same sequence parameters and slice locations as the 
DCE-MRI except for a 10o flip angle and a TR of 250 ms. 
post processing DCe-MrI
First, the proton density weighted MR data were combined with the DCE-MRI data 
to calculate Gd-DOTA concentration time curves for every tissue voxel in every slice, 
assuming that the contrast agent concentration C(t) (mM) is proportional to the 
change in the longitudinal or spin-lattice relaxation rate R1(=1/T1) (13). 
1 10 11 ( ) 1 ( )T t T rC t   (1)
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where T1 (s) is the longitudinal relaxation time and T10 (s) this time at t=0 before 
the contrast injection, r1 (s
-1 mM-1) is the longitudinal relaxivity of the contrast 
agent. Vascular properties are then estimated from the concentration time curves 
with a pharmacokinetic model.
regions of interest
For each patient, an average intensity map and an average contrast concentration 
map was calculated by adding voxel wise all intensities respectively concentrations, 
in time, from the DCE-MRI dataset and dividing it by the number of time points. 
On these maps, and with the aid of conventional T1 and T2 weighted MR and DW 
images (b=50 s/mm2), ROIs were manually drawn around the metastatic lesions in 
the liver and around the aorta on all slices with a visible metastatic lesion or aorta by 
a researcher with 4 years experience. In addition, ROIs with a diameter of approxi-
mately 15-20 mm were drawn in normal appearing liver tissue, avoiding large vessels 
and ducts. The C(t) curves of voxels inside the different ROIs were extracted for 
pharmacokinetic modeling.
pharmacokinetic modeling
To derive vascular parameter values we applied the extended version of the pharma-
cokinetic model described by Kety and for MR by Tofts et al. (14,15).
( )
0
( ) ( ) ( )
trans
e
K tt
vtrans
t p p pC t v C t K e C d
τ
τ τ
− −
  ∫  (2)
where Ct (mM) is the (tumor) tissue contrast agent concentration, Cp (mM) con-
trast agent concentration in the blood plasma, vp the plasma volume fraction, ve the 
fraction of extravascular extracellular space (EES). Ktrans (s-1) is the volume transfer 
constant between blood plasma and the EES; it represents multiple physiological 
properties (15). 
The parameter Ktrans was estimated for every voxel inside the metastatic lesion ROI 
by fitting the model Ct(t) to the measured Ct(t) by an in house developed software 
program using Matlab 2013a (MathWorks, Natick, Massachusetts, USA). A least-
squares nonlinear curve-fitting algorithm with unit weights was applied except for 
the ten time points before and after the top of the first bolus passage peak. These 
time points had an additional weighting factor of five. Tumor tissue areas with low 
average contrast agent concentration (< 0.2x10-3 mM) were assumed to be badly 
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perfused and necrotic and therefore excluded from analysis, since in these areas the 
Tofts model does not apply (16).
automatic aIF extraction
The time dependent variation of the arterial whole blood concentration of the 
contrast agent Cb(t), also known as arterial input function (AIF), was determined 
from voxels in the aorta for each individual patient. The aorta was chosen as it is 
visible in all transverse MRI slices depicting the liver. As the Cb(t) curves in these 
voxels may suffer from severe flow and pulsation artifacts we applied an algorithm, 
that only selects those Cb(t) curves from the aorta in which these artifacts are 
absent or minimally present. A first selection of voxels was made using the method 
described by Rijpkema et al. (10), after which we submitted the Cb(t) curves of the 
remaining voxels to further selection criteria. For this purpose the average height of 
the remaining first-pass peaks is determined as well as the time this peak occurred. 
Only Cb(t) curves that have a first-pass peak height in the range of this average 
height plus/minus one standard deviation, and a peak time point in the range of the 
average peak time point plus/minus 5 time points were selected. Next, an average 
Cb(t) curve was calculated after aligning the remaining Cb(t) curves by time shifting 
to the average first-pass peak time point. The final Cb(t) curve or AIF was obtained 
by fitting the average Cb(t) curve to the functional form of the AIF as described by 
Parker et al. (17).The parameters describing this functional AIF form were initially 
set to the reported population average values and then allowed to vary within a 
certain range in the fitting process.
The time dependent plasma concentration of the contrast agent, Cp(t), was obtained 
from Cp(t) = Cb(t)/(1-Hct), in which we assumed a haematocrit (Hct) value of 0.42. 
Since the AIF was obtained from the aorta and not from vessels directly supplying 
the (tumor) tissue there is a small time delay between the onset of the Cp(t) and the 
onset of the Ct(t) curve. Therefore the onset of the Cp(t) curve for every (tumor) 
tissue voxel was shifted in time for the fit of the Ct(t) curve.
SSIM algorithm
To be able to select only those time points where the (tumor) tissue is in the same 
position, images from the dynamic DCE-MRI series were compared with correspond-
ing proton density reference images. Among the algorithms available for image 
comparison we choose the SSIM algorithm as this method compares two images, 
based on luminance, image contrast, and structure. These three comparisons are 
combined into a so-called structural similarity index (SSIM) (9):
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 (3)
with x and y the two non-negative image signals, µx the mean of x, µy the mean of y, 
σx
2 the variance of x, σy
2 the variance of y, σxy the covariance of x and y, c1=(k1L)
2 
and c2=(k2L)
2 two variables to stabilize the division with weak denominator, L the 
dynamic range of the voxel values, k1=0.01 and k2=0.03 by default. The index value 
achieves the maximum value of one only if the two image signals x and y are equal. 
The integral (or sum in the discrete case) applied in the calculations of the mean, 
the variance and the covariance was implemented as a convolution with a Gaussian 
probability density function (standard deviation:1.5, kernel size: 11 voxels). The 
SSIM index of an entire image was calculated by taking the arithmetic mean of all 
values in the calculated SSIM map.
Since the SSIM index is also slowly changing with time due to the uptake of contrast 
agent, the dynamic datasets cannot be filtered with a fixed threshold. Therefore 
we applied a low pass filter (Gaussian, standard deviation:3.5, kernel size: 27 time 
points) to the SSIM index time curve and discarded all the DCE-MRI images with a 
SSIM index under this smoothed line. The (tumor) tissue contrast agent concentra-
tion Ct(t) is now obtained only from the remaining data points in the dynamic series, 
arising from slices with an almost identical position in the liver.
repeatability studies
The SSIM algorithm was applied to select only DCE-MRI data of the liver that were 
minimally affected by motion. We hypothesized that this will improve the repeat-
ability of parameters derived from the pharmacokinetic modeling. This was tested 
in repeatability studies A and B, in which the same proton density and dynamic 
DCE-MRI datasets, and the same ROIs were used. In study A we included all dynamic 
DCE-MRI images for the (tumor) tissue Ct(t) and in study B we excluded dynamic 
DCE-MRI images that were shifted or distorted due to motion, as identified by the 
SSIM algorithm. In both studies the AIFs were obtained from the individual patient 
data sets. 
Statistics
Statistical analysis were done using PASW Statistics 18.0.2 (IBM Corporation, 
Armonk, New York, USA), Prism 4.0 (GraphPad Software Inc., La Jolla, San Diego, 
CA, USA) and Excel (Excel 2007, Microsoft Corporation, Redmond, Washington, 
USA). The signals of all tumor and normal appearing liver tissue ROIs were voxel 
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by voxel analyzed with the pharmacokinetic model. Next, median Ktrans values were 
calculated from all voxels inside the ROIs. Then, the repeatability was assessed using 
Bland-Altman analyses (18). In this analysis the difference in median Ktrans values of 
the first and second measurement were plotted against the average median Ktrans 
value of day one and two. The mean difference and the limits of agreement, average 
difference ± 1.96 standard deviation of the difference and the coefficient of repeat-
ability were calculated. In addition, the difference in median Ktrans obtained from the 
tumor and normal appearing liver tissue was compared as was the difference in time 
delay between the onset of the AIF or Cp(t) in the aorta and the onset of the Ct(t) 
in the tissue. Comparisons were performed with the Wilcoxon signed rank test and 
differences with p<0.05 were deemed statistically significant.
results
tissue contrast agent concentration time curves and SSIM
A comparison of the time dependent contrast uptake in tumor voxels (Ct(t)) 
and in the aorta (Cb(t) or Cp(t)) reveals that the onset time of the Ct(t) curve is 
delayed compared that of the aorta curve (Fig 1, blue lines). Contrast agent first 
flows through the aorta, where Cb(t) is measured, then to smaller arteries and finally 
enters the capillaries and the tumor tissue, where Ct(t) is measured. After rejection 
of data points by the SSIM correction (vide infra), the sampling frequency of the 
measured Ct(t) curve becomes lower than that of the measured Cb(t) curve (blue 
lines in Figs. 1B and 1A respectively). 
The automatic AIF extraction algorithm selects aortic voxels with a contrast agent 
concentration time curve Cb(t), approaching the ideal AIF shape, to be combined 
for the final individual AIF curve. Only a limited number of voxels not far from the 
luminal wall of the aorta fulfill the criteria for this selection (Fig. 2). Moreover, from 
all the voxels selected by the AIF extraction algorithm on average 0% was from the 
top slice, where aortic blood enters the MRI volume of interest covered by 6 slices, 
and 3%, 19%, 14%, 28% and 36% were from the remaining five subsequently lower 
positioned slices. After haematocrit correction the Cp(t) model curve (Fig 1A, red 
line) was used as input for the extended Tofts model. By fitting equation 2 of this 
model to the measured Ct(t) data (with and without SSIM correction) a Ct(t) model 
curve was obtained (Fig. 1B, red line). 
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In the SSIM algorithm each image of a slice recorded at the successive time points 
in the dynamic series is compared with the reference proton density image of the 
corresponding slice. The resulting SSIM index is plotted against the time that the 
dynamic DCE-MRI dataset was recorded (Fig. 3). A high SSIM index value means 
that the compared images are almost similar, and thus that the dynamic DCE-MRI 
image was recorded in approximately the same location as the reference proton 
density image. The median fraction of deleted images was 0.46 (range 0.37-0.50). 
Note that there were about 13 cycles per minute, indicated by the black line, cor-
responding to a normal human breathing cycle at rest.
Figure 1: Fitting of contrast induced changes in T1-weighted signal intensity for pharmacokinetic 
modeling. (A)  Measured arterial blood contrast agent concentration vs. time curve (blue), Cb(t), is 
the curve also known as arterial input function (AIF). After hematocrit correction it becomes the Cp(t) 
curve. The fit of the measured data with a population- based AIF model function is shown in red. (B) 
The corresponding measured tumor tissue contrast agent concentration vs. time curve (blue), Ct(t). 
The fit with the extended Tofts model (eq. 2) is shown in red, the rejected time points, identified by the 
SSIM algorithm, are indicated by black dots. The Cp(t) model curve in A was shifted in time to have the 
same onset time as the Ct(t) curve. 
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Figure 2: Mean T1 weighted intensity image with a green ROI indicating the aortic region, where the 
automatic AIF extraction algorithm searched for voxels with a contrast agent concentration time curve 
approaching an ideal AIF shape. The locations of the selected voxels are indicated by red dots. From the 
time curves in these voxels the final AIF was determined.
Figure 3: An example of SSIM index values obtained for successive images of one slice, recorded during 
an DCE-MRI measurement. The first image slice of the proton density dataset is compared with the 
first image slice of each dynamic DCE-MRI dataset recorded at the different time points using the SSIM 
algorithm. The resulting SSIM index values (circles) are plotted against the time that the dynamic DCE-
MRI dataset was recorded. The black line connects all the index values and the red line indicates the 
smoothed curve after applying a low-pass filter.
effect of SSIM correction on Ktrans values and repeatability
To evaluate the effect of SSIM on T1 weighted images and K
trans we reconstructed 
average T1 weighted intensity images of transverse body sections and calculated 
Ktrans maps of the liver (Fig. 4). As can be seen by a comparison of figure 4A and 
4B and in the difference image (Fig. 4C) contrast enhancement in the liver is much 
less blurred after SSIM. This is also apparent in the Ktrans maps of the liver (compare 
Fig. 4D and E). For example, higher Ktrans values are observed near the tumor edge 
in Ktrans maps without SSIM correction (Fig. 4D) as compared to maps with SSIM 
(Fig 4E), which is likely due to motion, as surrounding tissue may move into the 
140
••
••
••
 C
ha
pt
er
 6
registered tumor ROI and then causes an artificial increase in Ktrans due to a partial 
volume effect (Fig. 4F). 
Figure 4: Mean T1 weighted intensity images (top row, A and B) and K
trans parameter maps (bottom 
row, D and E). The Ktrans parameter maps are from a selected region in the liver as indicated by the 
green boxes in A and B. The first column shows the mean T1 weighted intensity image (A) and K
trans 
parameter map (D) without SSIM correction applied. The second column shows the same mean T1 
weighted intensity image and Ktrans parameter map, but this time with the SSIM correction applied (B 
and E respectively). The third column shows difference maps of the second minus first column (C and 
F). The white and black ROIs indicate the same tumor area and the necrotic tumor parts. Contrast in 
the mean T1 weighted intensity image and K
trans parameter map without SSIM correction appears more 
blurred then the corrected ones. 
In the studies of data processed with individual AIFs, the median Ktrans values in liver 
metastases were significantly lower (Wilcoxon signed rank test, p<0.05) when cor-
rected with SSIM (3.53x10-3 ± 1.89x10-3 s-1, median ± st.dev.) as compared to those 
without correction (4.12x10-3 ± 2.04x10-3 s-1); see Table 1. The repeated Ktrans 
determinations were subjected to Bland-Altman analyses (Fig. 5 and Table 1). The 
coefficient of repeatability for Ktrans was 1.44x10-3 s-1 (40.7% of median) for liver 
metastases with SSIM correction and 2.39x10-3 s-1 (57.9% of median) without cor-
rection. The limits of agreement for median Ktrans were -1.14x10-3 s-1 and 1.73x10-3 
s-1 for liver metastases corrected with SSIM and -2.15x10-3 s-1 and 2.62x10-3 s-1 
without correction. Small differences in the distribution were seen between mea-
surements at day one and two, but the difference in Ktrans was not correlated to the 
mean Ktrans (Fig. 5).
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Figure 5: Bland Altman analysis of the Ktrans values for the datasets determined with individual AIFs, 
without SSIM motion correction (A) and with this correction (B). The blue dashed lines indicate the 
mean difference and the red dashed lines indicate the limits of agreement.
Without SSIM With SSIM
(x10-3 s-1) (x10-3 s-1)
Ktrans in normal tissuea 9.42 ± 3.64 10.66 ± 3.20
Ktrans in tumor tissuea 4.12 ± 2.04 3.53 ± 1.89
(x10-3 s-1) (x10-3 s-1)
Coefficient of repeatabilityb 2.39 1.44
Mean differenceb 0.234 0.294
Limits of agreementb -2.15 / 2.62 -1.14 / 1.73
(s) (s)
Difference in onset timea,c 8.6 ± 2.8 8.0 ± 2.2
Table 1: Pharmacokinetic and repeatability parameter values
a Median ± std. dev., b in tumor tissue, c Normal – tumor tissue, ‘Normal tissue’ is normal appearing liver 
tissue. For both normal and tumor tissue we used a single input model, although a dual input model may 
be more appropriate to derive the ‘true’ Ktrans for normal liver tissue
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The median Ktrans in tumor tissue is two to three times lower than the median Ktrans 
in normal appearing liver tissue as calculated by the same pharmacokinetic model 
(Table 1). In normal appearing liver tissue the contrast agent arrived later then in 
tumor tissue as reflected by an approximately 8 seconds difference in onset time 
between the Ct(t) in normal appearing liver tissue and the Ct(t) in tumor tissue, 
which was significant in all four studies (Wilcoxon signed rank test, P<0.01) (Table 
1).
Discussion
In this paper we report the successful implementation of a procedure that removes 
motion displaced or distorted images as identified by a structural similarity method 
to reduce the effect of motion in fast multi-slice 2D DCE-MRI of the liver. A consider-
ably improved repeatability was achieved for the pharmacokinetic parameter Ktrans 
in human liver tumors, which was determined with an automatically selected AIF 
from contrast passage through the aorta in individual patients.
To minimize the influence of motion on MR image quality both prospective and 
retrospective approaches have been developed. For DCE-MRI our retrospective 
method has several advantages. For example, a commonly used prospective method 
to overcome motion artifacts is breath-hold scanning but this has its limitations as 
patients cannot hold their breath for more than 20 seconds (19). Longer exami-
nations require difficult breathing instructions and acquisition breaks to allow the 
patient to breath, which results in missing data and liver displacements. Another 
popular prospective method is the navigator technique, in which the position of 
the diaphragm is monitored to record the respiratory phase (20). Alternatively, an 
external pneumatic belt can be used (21). As these methods depend on the patients 
breathing frequency, only one dataset can be obtained every 3 to 4 seconds, which 
is too slow for a reliable AIF. Prospectively it may also help to use k-space trajectories 
that are less sensitive to motion like radial or spiral sampling (22,23).
Retrospective methods can be distinguished in two classes of motion correction. 
One class tries to remove ghosts and blur caused by motion during MRI acquisitions. 
Several ways to correct for these artifacts have been proposed (24). However, 
since our fast 2D FLASH sequence is less prone to ghosting and blurring, the class 
of methods focusing on correction of motion artifacts acquired between scans in 
dynamic imaging is more relevant. This includes image registration by rigid and 
affine, B-spline based non-rigid methods, but these intensity based algorithms are 
prone to fail due to contrast inflow effects (25,26). It was also proposed to separate 
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contrast and motion components by combining registration with statistical methods 
(27), or to combine registration and motion correction in a pharmacokinetic model 
(28). All methods that assume rigid body motion are cumbersome as respiratory 
motion causes liver deformations. The more complex non-rigid body approaches 
require reference data and/or relatively long computational times. In addition, most 
approaches have been designed for 3D rather than for fast 2D MR datasets with gaps 
between the slices. Therefore we turned to the simpler method with the rejection of 
motion corrupted images as identified by SSIM. 
As tissue water magnetization in multi-slice fast 2D MRI is at near-equilibrium 
after several excitations, a change in magnetization is assumed to be only due to 
a contrast agent effect. But because of motion, tissue near the edge of a slice may 
not be regularly excited and therefore magnetization in these regions may not be 
constant. The SSIM algorithm in the DCE-MRI analysis filters the effect of tissue 
motion and non-constant magnetization. Moreover, because of the many RF pulses, 
spatial imperfection of the pulses and the relative thick slices any remaining effect 
on the measured signal is expected to be minimal. In 3D MRI the RF pulses select 
an entire volume so that non-constant magnetization only occurs in tissue located 
at the edges of the volume. However, without compromising SNR or spatial resolu-
tion, 3D MRI currently is too slow to capture a proper AIF. Recently, parallel transmit 
techniques have been developed to zoom in on smaller FOVs, that allow for higher 
temporal resolution than in conventional 3D MRI (29,30), but these techniques are 
not readily available yet and may be of little benefit for whole liver MRI, in particular 
if the aorta has to be included for AIF determinations.
A proper arterial input function is essential in pharmacokinetic modeling of DCE-MRI 
data (31–34). To derive the pharmacokinetic parameter Ktrans for liver tumors we 
used AIFs determined from voxels in the aorta, which requires some explanation 
as most blood in the liver is delivered by two vessels, the hepatic artery and the 
portal vein. Blood in the hepatic artery comes from the aorta and in the portal vein 
from the gastrointestinal tract, spleen, and pancreas. This means that the contrast 
agent first arrives in liver tissue via the hepatic artery and then by the portal vein 
(12). The portal vein contributes about 75% and the hepatic artery 25% of the total 
blood flow to the normal liver (35). However, in patients with liver metastases the 
hepatic artery fraction increases as blood flow to metastases is predominantly arte-
rial (11,12,36). Moreover, in normal appearing liver tissue, the perfusion fraction by 
the hepatic artery is also increased if metastases occur elsewhere in the liver (37). 
As the aorta supplies the hepatic artery and is visible in most DCE-MR images we 
selected this vessel to obtain an AIF for liver tumors. Because pulsation and other 
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flow artifacts in the aorta may disturb the quality of the extracted AIF, we used strict 
criteria and an automated procedure in the selection of voxels with proper contrast 
uptake curves. As a result only a relatively small fraction of the voxels located in the 
aorta contributed to the individual AIFs. Our automatic procedure also rejects voxels 
suffering from inflow artifacts as the majority of the voxels selected for the AIF were 
from the two most caudal-oriented MRI slices, which are expected to suffer least 
from these artifacts (32).
Our observation that the contrast agent arrives about 8 seconds later in normal 
appearing liver than in tumor tissue agrees with the dual input from the hepatic 
artery and the portal vein to normal appearing liver (38). Variable arrival times 
for this tissue due to differences in the contribution of both input functions, may 
have contributed to the higher variation observed for median Ktrans values in normal 
appearing liver tissue.
Tissue contrast uptake in DCE-MRI of human liver tumors can also be referenced to 
an individual vascular normalization function obtained from the spleen (5), but this 
organ is not always visible in abdominal DCE-MRI’s and vessels of the spleen may 
be susceptible to agents targeting tumor vascularity. The Ktrans values determined 
with an AIF from aorta voxels reproduced better in the present study compared to 
a study using the same method (7), possibly because of a better registration of the 
contrast bolus passage by a higher temporal resolution (1.2 vs. 2 s) and prolonged 
scan time (180 vs. 90 s). The use of more specific prior knowledge in the selection 
and fitting of Cp(t) curves is also expected to improve the accuracy of AIFs (10,17) 
and thus repeatability. 
In the calculation of the pharmaco-kinetic parameters from contrast uptake a linear 
relationship between contrast agent concentration and change in R1 is assumed. 
However, at the higher concentrations typically occurring during the first bolus 
peak in the aorta this relationship may not be linear anymore due to various factors 
such as T2* saturation effects of the contrast agent enhanced signal (39–43). We 
minimized the influence of these effects by automatic selecting for Cb(t) curves with 
proper characteristics and by fitting a Cb(t) model function instead of directly using 
the numerical data points. More dedicated fitting methods have been proposed that 
correct AIFs for signal saturation at high contrast levels.(44). As we have used the 
same AIFs in the comparison between the SSIM corrected and uncorrected datasets 
no effect on the outcome of the correction results is anticipated. 
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We demonstrate that removing images by an SSIM procedure improves the repeat-
ability of Ktrans assessments in liver metastases. Normal appearing liver tissue sur-
rounding the tumor has a higher contrast agent concentration than tumor tissue 
and also a higher apparent Ktrans (Fig. 4, Table 1 and (19)). Motion that causes 
normal appearing liver tissue to move into the ROI registered for tumor tissue will 
artificially increase Ktrans due to a partial volume effect. This explains why a lower 
Ktrans is observed in the tumor ROI after SSIM correction. Our values for Ktrans in liver 
tumors are in the range of values reported by others (5,19,45). 
In conclusion, we describe the successful implementation of a DCI-MRI method to 
assess vascularity in liver lesions using a SSIM method to delete motion affected MR 
images. We showed that this correction decreased the contamination of transfer 
constant Ktrans for liver tumors with that of normal appearing liver tissue and it 
significantly improved the repeatability of Ktrans as derived from DCE-MRI data with 
the application of individual AIFs. This SSIM post- processing method is simple and 
fast and can be readily implemented in the analysis of sequential MR series such as 
in DCE-MRI. It can also be applied to other abdominal regions and may be of use in 
other functional MR acquisition protocols.
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Chapter 7
Comparison of liver SUV using unenhanced Ct 
versus contrast enhanced Ct for attenuation 
correction in 18F-FDG pet/Ct
This chapter is based on:
ter Voert EE, van Laarhoven HW, Kok PJ, Oyen WJ, Visser EP, de Geus-Oei LF. 
Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for 
attenuation correction in (18)F-FDG PET/CT. Nucl Med Commun. 2014;35:472-7.
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abstract
Purpose: Comparison of standardized uptake values (SUVs) in liver tissue using 
whole-body unenhanced low-dose CT and contrast enhanced high-dose CT for PET 
attenuation correction in PET/CT scanning.
Methods: Ten patients scheduled for 18F-FDG PET and contrast enhanced CT of 
the abdomen were included. PET data were corrected for attenuation using both 
unenhanced low dose CT images and contrast enhanced high dose CT images. Dif-
ferences in SUVmean and SUVmax were compared in 3 liver regions.
Results: The average SUVmean and SUVmax of all regions was 2.43 and 2.91 g/cm
3 in 
the unenhanced dataset and 2.53 and 3.17 g/cm3 in the enhanced dataset. 
Conclusion: SUVmean and SUVmax values were significantly elevated in liver tissue 
when using PET images corrected for attenuation with contrast enhanced high dose 
CT compared to unenhanced low dose CT. Although the differences may not be rel-
evant in daily clinical practice, unenhanced and contrast enhanced CT should not be 
used randomly for attenuation correction if exact quantitative results are required.
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Introduction
In oncology, computed tomography (CT) and positron emission tomography (PET) 
are modalities that are frequently used in the clinical work up of cancer patients and 
the monitoring of treatment efficacy. CT imaging has a high spatial and temporal 
resolution allowing for noninvasive detection of lesions and accurate determination 
of their size and position. PET has a relatively low spatial resolution compared to CT, 
but it can provide valuable functional information of suspect lesions.
The introduction of modern integrated PET/CT scanners not only resulted in easier 
coregistration of the PET and CT images (1,2), but the anatomical CT images can 
also be used for accurate localization of lesions detected with PET. Furthermore, the 
CT data can be used for PET attenuation correction, thereby replacing the trans-
mission scan with the external radionuclide (e.g. 68Ge) sources. This has improved 
attenuation correction since CT has much lower noise and is more patient friendly, 
since it has shorter scan time (2,3).
Because of the lower energy of the CT x-rays (usually 40-140 keV) compared to the 
high energy PET emission photons (511keV) the CT attenuation maps should be 
converted to PET attenuation maps. A common way to do this is by segmenting the 
CT attenuation maps into different tissue regions (e.g. air, soft tissue and bone) and 
scale the CT attenuation coefficient to reflect the attenuation of the PET emission 
photons.
CT examinations of soft tissues and organs in the abdomen require the application 
of a contrast agent as without contrast these tissues have similar Hounsfield units. 
Since CT contrast agents are designed to be opaque for the x-rays used in CT, body 
regions with high concentrations of contrast agent appear as dense tissue regions 
on CT. Since the contrast agent is less opaque to the PET photons and the segmen-
tation algorithms were not designed to take CT contrast agents into account, use 
of contrast enhanced CT data for attenuation maps in PET may result in artifacts 
and overestimation of radionuclide activity in these regions. Therefore, patients 
scheduled for both PET/CT and abdominal contrast enhanced CT often receive 
two CT scans: one fast low-dose CT for PET attenuation correction and registration 
and one diagnostic abdominal contrast enhanced high dose CT. In case the contrast 
enhanced CT provides similar results as the unenhanced CT for PET attenuation cor-
rection, one could consider omitting the latter from the protocol to further reduce 
patient discomfort, radiation exposure.
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In this study we compared the quantitative differences in liver uptake between 
PET images corrected for attenuation with unenhanced low-dose CT data and PET 
images corrected with contrast enhanced high-dose CT data. The liver was chosen 
as the organ of interest as it is one of the most common sites of cancer metastases. 
Also, PERCIST 1.0 requires calculation of background SUV in the liver (4).
Methods
patients
Ten patients, four males and six females with a median age of 60 years (range 21-80), 
scheduled for 18F-FDG PET and abdominal contrast enhanced CT, were included in 
this study. All patients had liver lesions suspect for metastatic disease. Patient char-
acteristics, history, diabetic status, renal function, and treatment are listed in table 
1. For this retrospective single-institution study no approval of the local institutional 
medical ethics committee and no written informed consent was necessary since the 
PET/CT scans are part of the standard patient care and no foreseeable harm was 
expected to result from additional PET image reconstructions used in the study.
pet/Ct imaging
All patients fasted for six hours prior to injection of 18F-FDG (activity in MBq = 13.8 
x bodyweight / (min/bed)), (5). Sixty minutes post-injection, whole-body PET was 
performed on an integrated PET/CT scanner (Biograph Duo, Siemens Healthcare, 
Gender Age Diabetic MDRD History Treatment before PET
normal>60 (ml/
min/1,73m2)
1 M 79 No >90 Esophageal cancer No
2 M 40 No 67
Nonseminoma 
testicular cancer and 
gliosarcoma
No
3 F 80 No 57 GIST No
4 F 21 No >90 CDH 1 mutation No
5 F 56 No 88 GIST Imatinib, 2 weeks
6 M 64 No 80 GIST Sunitinib
7 F 50 No 64 GIST Imatinib, 2 weeks
8 M 75 No 73 No
9 F 68 No 72 GIST Imatinib, >1 year
10 F 30 No 90 Cervical cancer Cisplatin/Paclitaxel, 1 course
Table 1: Characteristics of all participating patients
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Erlangen, Germany). For PET, a 3-dimensional whole body emission scan was 
acquired during free breathing. The acquisition time per bed position was 4 minutes.
Before acquisition of the PET scan a whole-body unenhanced low-dose CT was 
acquired in the caudocranial direction. Scanning parameters for CT were: care dose 
reference at 50 mAs, 130 kV, 5 mm slice collimation, 0.8 s rotation time, and a pitch of 
1.5. After the acquisition of the PET scan 100ml Optiray 300 (Covidien, Hazelwood, 
MO, USA) was administered intravenously. After a delay of 60 seconds, a diagnostic 
CT of the abdomen was recorded. Scanning parameters were: care dose reference at 
110 mAs, 130 kV, 2.5 mm slice collimation, 0.8 s rotation time, and a pitch of 1.25. 
During CT scanning patients were instructed to hold their breath almost at the end 
of expiration to obtain a comparable liver position as with free breathing during PET 
(6).
CT images were reconstructed using standard manufacturer-supplied software. 
Matrix size: 512x512, FOV: 700x700 mm2, pixel size: 1.37x1.37 mm2. Whole body 
scans had 296 slices with a thickness of 6 mm and the abdominal scans consisted of 
77 slices with 3 mm thickness. PET images where reconstructed with the same stan-
dard manufacturer-supplied software using an iterative reconstruction method (2 
iterations, 8 subsets) and a Gaussian convolution kernel with FWHM of 5.0. Matrix 
size: 128x128, FOV: 680x680 mm2, pixel size: 5.3x5.3 mm2, slice thickness: 3 mm, 
95 slices.
Per patient two PET attenuation corrected datasets were created, one corrected 
with the unenhanced CT and one corrected with the contrast enhanced CT. For each 
patient, in both attenuation corrected PET datasets, three spherical ROIs (median 
diameter 25 mm, range 21-27 mm, depending on available anatomical space) were 
drawn in healthy liver (ROI 1, 2, 3 in liver segments V/VI, II/III, VII/VIII respectively) 
by the same reader to also assess within-liver variation.
The voxel values of every ROI were extracted. Values are representing the activity 
[Bq/cm3] and were corrected for decay between time of 18F-FDG injection and the 
start of PET scanning using the 18F half-life of 109.77 min. Next, the standard uptake 
values (SUVmean and SUVmax), normalized to body weight, were calculated for each 
ROI. 
Statistical analysis
Statistical analyses were performed using Prism 4.0 (GraphPad Software Inc., La 
Jolla, San Diego, CA, USA) software package. The differences between median 
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SUVmean values obtained from the unenhanced dataset and the enhanced dataset 
were calculated and compared per ROI location using the Wilcoxon signed rank test 
(a paired difference test). In addition, for each patient the average SUVmean was cal-
culated by averaging the three SUVmean values of the three ROIs in the same dataset 
type. Next, the two medians of the average SUVmean values of the two dataset types 
were calculated and their differences compared using the Wilcoxon signed rank test. 
Finally this procedure was repeated for the SUVmax values.
results
An example of an unenhanced and contrast enhanced liver CT image and the corre-
sponding attenuation corrected PET-images are shown in figure 1. The unenhanced 
images show homogeneous liver tissue. After injection of contrast agent, the vas-
culature is opaque due to the high intravascular concentration of contrast agent. 
Since the liver is generally well perfused, the contrast agent will quickly spread to 
all areas of healthy liver tissue, generally increasing the opacity. Consequently, the 
PET image which is attenuation corrected with the contrast enhanced CT dataset 
appears slightly brighter (using the same grayscale) than the unenhanced CT cor-
rected PET image. In this case, the attenuation correction algorithm overestimated 
the activity due to the CT contrast agent that is opaque for x-rays. The per patient 
SUVmean and SUVmax values are plotted in figure 2A and B respectively. Figure 2A 
shows that most SUVmean values of the unenhanced datasets are scattered in the 1.8 
- 2.8 g/cm3 region as are the SUVmean values of the enhanced datasets. The median 
SUVmean values are, however, slightly higher for the enhanced datasets compared to 
the unenhanced datasets in all ROIs and in the average group. Most SUVmax values 
(figure 2B) of the enhanced datasets are scattered in a slightly higher 2.2 - 3.7 g/
cm3 region as are again the SUVmax values of the unenhanced datasets. The differ-
ence between the median SUVmax values of the unenhanced and enhanced datasets 
is however larger compared to the difference between the median SUVmean values of 
the unenhanced and enhanced datasets (table 2). Another interesting finding is that 
the SUVmean and SUVmax values appear to be higher in liver segments II/III (ROI-2) 
compared to the values in liver segments V/VI (ROI-1) and VII/VIII (ROI-3). Of note, 
the high outlier found in all sub plots originates from the same patient. The reason 
for this high outlier is unknown.
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Table 2 lists the median SUVmean and SUVmax values of the three ROI locations, for 
both the unenhanced and enhanced datasets, together with their differences and 
p-values of the Wilcoxon signed rank test. Overall, the median SUVmean and SUVmax 
values of all three ROI regions in the enhanced dataset were significantly higher 
than the median SUVmean and SUVmax values in the same regions in the unenhanced 
dataset. The average difference in SUVmean value was 0.09 g/cm
3 (3.7%, p<0.01) 
and the average difference in SUVmax value was 0.26 g/cm
3 (8.3%, p<0.01).
Figure 1: An example of: an unenhanced CT image (A), a contrast enhanced CT image (B), a PET 
image attenuation corrected with the unenhanced CT (C), a PET image attenuation corrected with 
the contrast enhanced CT (D), a PET/CT overlay image (E) combining (A) and (C), a PET/CT overlay 
image (F) combining (B) and (D). All images are from the same patient in the same liver location. The 
ROI in liver segment II/III is indicated by the semi transparent blue area.
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Figure 2: Scatterplot showing the SUVmean 
(A) and SUVmax (B) for the three regions 
of interest (ROI-1, 2, 3 in liver regions V/
VI, II/III and VII/VIII resp.) and the average 
(Av.) of the three ROIs in 10 patients. 
All for the dataset corrected with the 
unenhanced (UE) CT and the contrast 
enhanced (CE) CT. The red lines indicate 
the median.
Unenhanced CT 
corrected
Contrast enhanced 
CT corrected
Difference P values
ROI
SUVmean 
[g/cm3]
SUVmax
[g/cm3]
SUVmean 
[g/cm3]
SUVmax 
[g/cm3]
SUVmean 
[g/cm3] / (%)
SUVmax 
[g/cm3] / (%)
SUVmean SUVmax
1 2.34±0.45 2.78±0.52 2.49±0.39 3.05±0.54 0.15 / (6.0) 0.27 / (8.9)   0.04 <0.01
2 2.48±0.46 3.07±0.46 2.58±0.51 3.38±0.53 0.11 / (4.1) 0.31 / (9.1) <0.01 <0.01
3 2.45±0.54 2.92±0.51 2.53±0.57 3.08±0.54 0.08 / (3.1) 0.16 / (5.1) <0.01 <0.01
Av. 2.43±0.47 2.91±0.45 2.53±0.48 3.17±0.47 0.09 / (3.7) 0.26 / (8.3) <0.01 <0.01
Table 2: Comparison of the median SUV±SD values between the datasets corrected with the 
unenhanced CT and the contrast enhanced CT for the three regions of interest (ROI-1, 2, 3 in liver 
regions V/VI, II/III and VII/VIII resp.) and the average (Av.) of the three ROIs in 10 patients. The 
differences in the SUV values are also indicated, as well as the p-values of the Wilcoxon signed rank test 
showing the differences are statistically significant.
Discussion 
This study investigated the differences in SUVs in normal appearing liver tissue 
using whole-body unenhanced low-dose CT and contrast enhanced high-dose CT 
for attenuation correction in combined PET/CT scanning. We found that the mea-
sured SUVmean and SUVmax were statistically significant elevated (3.7% and 8.3%, 
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respectively) in liver tissue corrected for attenuation with contrast enhanced high-
dose CT compared to unenhanced low-dose CT.
In line with our results, a previous study investigating the effect of IV contrast media 
on integrated PET/CT (7), observed a SUVmax increase of 6.3% for normal liver tis-
sue. Another study investigating whether an intravenous iodinated contrast agent 
produced significant attenuation correction artifacts in SUV levels in PET/CT (8), 
observed a mean SUVmax increase of 5.8% in normal liver tissue (segment VI). Addi-
tionally we observed that the differences in measured SUVmean and SUVmax varies 
between different liver segments V/VI (ROI-1), II/III (ROI-2) and VII/VIII (ROI-3). 
Especially liver segment II/III (ROI-2) appears to have elevated SUVmean and SUVmax 
values. The exact reason for these elevated values are not known. Since we expect 
similar liver tissue composition in all liver segments we did not expect a difference 
in metabolic activity. Since liver segment II/III is a relatively small, elongated part 
that lies just beneath the lungs and the heart, we suspect that the elevated values 
found in this segment can be due to breathing and cardiac motion. During the free 
breathing PET scan other surrounding tissues are likely pushed back and forth in the 
same position as liver segment II/III is expected to be according to the breath hold 
CT scan.
Even though the differences we found in our study were significant in all three liver 
regions, the differences were small and it may be questioned whether they are clini-
cally relevant. A recent study investigating 18F-FDG PET/CT of liver metastases in 
colorectal cancer (9), observed a coefficient of repeatability of about 31% and 39% 
for respectively SUVmean and SUVmax. An earlier study investigating the repeatability 
of 18F-FDG PET in a multicenter study of patients with advanced gastrointestinal 
malignancies (10) found comparable lower and upper limits of agreement (-28.4%, 
39.6%) for SUVmax. This implies that changes in SUVmean and SUVmax should exceed 
this threshold before they can be considered real biological changes. The differences 
found in our study are relatively small compared to these numbers. Therefore, using 
the contrast enhanced CT data for attenuation correction instead of unenhanced CT 
data will not be a problem in routine clinical care where exact quantification is not 
needed. However, some factors should be taken into account.
According to the PERCIST 1.0 criteria, background 18F-FDG activity could be deter-
mined in healthy liver tissue of the right hepatic lobe (4). Based on the results of this 
and other studies, the use of contrast enhanced attenuation corrected PET images 
for measuring the background level, will lead to slightly increased background 
SUV values. Of note, for baseline and follow-up studies the PERCIST 1.0 criteria 
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recommend that both studies are performed on the same scanner using a compa-
rable protocol (4). If both studies use contrast enhanced attenuation corrected PET 
images, the background level will in both studies be increased. In addition, this study 
demonstrates that careful selection of liver segments for background measurements 
is required. Due to the measured differences in SUV in different liver regions the 
same liver region should be used in follow-up scans.
Also, if exact quantitative 18F-FDG PET results are required for research or clinical 
practice, contrast enhanced high-dose CT cannot be equated with unenhanced low-
dose CT for attenuation correction.
In our study we focused on normal healthy liver tissue. Other studies have investi-
gated tumour tissue and noted larger differences in SUV in regions with higher con-
centrations of contrast agent (7). It is also important to note that we used standard 
manufacturer-supplied software. Other manufacturers may provide software with 
different attenuation correction algorithms, which may lead to different results.
In case a patient is scheduled for multiple PET/CT scans (in a relative short time) 
and there is no need of exact quantification one could consider omitting the unen-
hanced CT and use the contrast enhanced CT for attenuation correction, thereby 
reducing patients radiation exposure and discomfort. Especially in pediatric patients 
it is desirable to minimize the cumulative radiation exposure. Recently, hybrid PET/
MRI systems have been developed, which could even further reduce the radiation 
exposure, however, at present PERCIST criteria have not been validated for PET/
MRI. Moreover, these systems are not widely available yet.
It can be concluded that a small, yet statistically significant quantitative difference in 
normal liver tissue is detected between PET images corrected with unenhanced low-
dose and contrast enhanced high-dose CT based data. For qualitative interpretation 
in routine clinical practice either CT can be used. However, if quantitative results are 
required it is recommended to use the unenhanced low-dose CT.
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Chapter 8
Multimodality imaging to predict response to 
systemic treatment in patients with advanced 
colorectal cancer
This chapter is based on: 
Heijmen L, ter Voert EE, Oyen WJ, Punt CJ, van Spronsen DJ, Heerschap A, de Geus-
Oei LF, van Laarhoven HW. Multimodality imaging to predict response to systemic 
treatment in patients with advanced colorectal cancer. PLoS One. 2015;10:e0120823.
162
••
••
••
••
 C
ha
pt
er
 8
abstract
Background: Aim of this study was to investigate the potential of 18F-FDG PET, dif-
fusion weighted imaging (DWI) and susceptibility-weighted (T2
*) MRI to predict 
response to systemic treatment in patients with colorectal liver metastases. The 
predictive values of pretreatment measurements and of early changes one week 
after start of therapy, were evaluated.
Patients and methods: Imaging was performed prior to and one week after start of 
first line chemotherapy in 39 patients with colorectal liver metastases. 18F-FDG PET 
scans were performed on a PET/CT scanner and DWI and T2
* were performed on a 
1.5T MR scanner. The maximum standardized uptake values (SUV), total lesion gly-
colysis (TLG), apparent diffusion coefficient (ADC) and T2
* value were assessed in 
the same lesions. Up to 5 liver metastases per patient were analyzed. Outcome mea-
sures were progression free survival (PFS), overall survival (OS) and size response.
Results: At pretreatment, high SUVmax, high TLG, low ADC and high T2
* were associ-
ated with a shorter OS. Low pretreatment ADC value was associated with shorter 
PFS. After 1 week a significant drop in SUVmax and rise in ADC were observed. The 
drop in SUV was correlated with the rise in ADC (r=-0.58, p=0.002). Neither change 
in ADC nor in SUV was predictive of PFS or OS. T2
* did not significantly change after 
start of treatment. 
Conclusion: Pretreatment SUVmax, TLG, ADC, and T2
* values in colorectal liver metas-
tases are predictive of patient outcome. Despite sensitivity of DWI and 18F-FDG PET 
for early treatment effects, change in these parameters was not predictive of long 
term outcome.
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Introduction
The liver is the most frequently affected organ in disseminated colorectal cancer 
and most patients with metastatic disease rely on palliative systemic treatment (1). 
Depending on the schedule, response is commonly evaluated 8-9 weeks after start 
of treatment. Currently, response to treatment is monitored by size response evalu-
ation according to the RECIST criteria (2). A reliable tool that predicts response early 
after start of therapy is desirable, as this would prevent unnecessary toxicity and 
costs.
Size response evaluation may be a suboptimal method to assess efficacy of targeted 
therapies, since necrosis or fibrosis without reduction in tumor size may occur (3, 
4). The outcome of palliative systemic therapy has improved in recent years by the 
addition of targeted agents to cytotoxic treatment. The addition of bevacizumab, 
a monoclonal antibody which targets the vascular endothelial growth factor has 
resulted in significant benefits in progression free survival and overall survival (5). 
Several functional imaging techniques have shown potential for prediction of 
response as well as early response monitoring. In a systematic review, the role of 
18F-FDG PET in treatment response prediction and monitoring in advanced stage 
colorectal cancer was evaluated. Four out of five studies showed changes in stan-
dardized uptake values (SUV) of 18F-FDG PET after start of systemic treatment (6) 
and two of these four studies showed a correlation with long term outcome (7, 8). 
In the palliative setting, metabolic response after one cycle of chemotherapy was a 
stronger predictor for survival than RECIST evaluation after 3 cycles of chemother-
apy (9). However, combined with other functional imaging techniques 18F-FDG-PET 
might be an earlier and stronger predictor of response to therapy.
Diffusion weighted imaging (DWI) is another promising functional imaging tool for 
tissue characterization, pretreatment response prediction and response evaluation 
in cancer (10, 11). From the diffusion weighted MR images an apparent diffusion 
coefficient (ADC) can be calculated, which is a measure for the mobility of water. 
The ADC is inversely correlated to the cell density, since cellular membranes inhibit 
water movement (12). Changes in ADC may precede changes in tumor size, since 
early after start of treatment changes in cellularity and necrosis may already occur. 
It has been demonstrated that ADC increased within days after chemotherapy in 
colorectal cancer metastases (13, 14). These studies investigated the correlation 
between ADC change and response in metastases. However, to be implemented in 
clinic, changes in ADC should predict response or (progression free) survival in the 
patient.
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Vascular changes induced by bevacizumab and chemotherapeutic treatment may 
also be indicative of response. Furthermore, vascular status by itself may predict 
response, since hypoxia and vascular supply of the chemotherapy influence treat-
ment efficacy. T2
* MRI, also called intrinsic susceptibility-weighted MRI or BOLD, is 
investigated as an alternative to (dynamic) contrast enhanced imaging (15, 16). The 
transverse relaxation time, T2
*, is dependent on magnetic field inhomogeneity and is 
therefore significantly affected by the presence of paramagnetic deoxyhemoglobin. 
The higher the deoxyhemoglobin concentration, the lower the T2
* value (17). To 
our knowledge, thus far no studies using T2
* for response prediction of metastatic 
colorectal cancer have been published.
The aim of this prospective study was to assess the predictive value of 18F-FDG PET, 
DWI and T2
* MRI for response to first line chemotherapy and outcome in advanced 
stage colorectal cancer patients. 
Material and methods
patients
Between August 2009 and September 2012 patients of 18 years and older with 
histologically confirmed colorectal cancer and non-resectable colorectal liver metas-
tases starting first line palliative or neoadjuvant chemotherapy were approached for 
participation in this study. Exclusion criteria were: Karnofsky performance status 
<70, (adjuvant) chemotherapy <6 months before study participation, renal function 
impairment (MDRD <60 ml/min/1.73 m2) or pregnancy. Specific contra-indications 
for 18F-FDG PET (including diabetes mellitus) or MRI only excluded patients for 
either the PET or MRI part of the study protocol. In total, 39 patients were enrolled, 
28 males and 11 females (mean age 62 years, range 29-77 years). The study was 
approved by the institutional review board (CMO region Arnhem-Nijmegen). All 
patients provided written informed consent before entering the study. 
Imaging methods
Before start of chemotherapy 18F-FDG PET, contrast CT and MRI were performed. 
These scans were performed median 5 days before start of treatment. One week 
after start of chemotherapy (range 6-8 days), 18F-FDG PET and MRI were repeated. 
After 3 cycles of chemotherapy an 18F-FDG PET and contrast CT were performed to 
assess treatment response. 
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PET CT-scans were performed on a PET/CT scanner: a Biograph Duo (Siemens 
Medical Solutions USA, Inc., Knoxville, TN, USA) for the first 26 patients and a Bio-
graph mCT PET/CT scanner for the 13 most recently enrolled patients. Both PET/
CT-scanners were accredited by the EANM-EARL QA/QC program for quantitative 
PET (18). Images of the Biograph Duo scanner were reconstructed using the 4 itera-
tions/16 subsets (4i/16s) OSEM-2D reconstruction algorithm, smoothed with a 5 
mm FWHM Gaussian filter. Images of the Biograph mCT scanner were reconstructed 
using TrueX, time of flight and the 3i/21s reconstruction algorithm, smoothed with 
an 8-mm FWHM Gaussian filter. All PET scans were corrected with a low dose CT for 
attenuation correction (19). 
Contrast enhanced CT using ioversol (125ml Optiray 350) was performed. Scanning 
parameters for contrast-enhanced CT imaging were care dose referenced at 80 mAs 
for the thorax and 130mAs for the abdomen, 110 kV, rotation time 0.8s, slice 3 
mm, slice collimation 2.5mm, feed/rotation 10mm for thorax and 6.3mm for the 
abdomen on the Biograph duo. A delay of 40s after injection of ioversol was applied 
for thorax imaging and a delay of 10s was set to automatically shift to the abdominal 
imaging. The scanning parameters for CT on the Biograph mCT were set as follows: 
200 mAs, 120 kV, pitch 1.2, slice 1 mm, delay of 40s after contrast injection and 
bolus tracking. 
DWI and gradient echo measurements to obtain ADC and T2
* values were performed 
on a 1.5T MR system (Magnetom Avanto, Siemens Medical Solutions, Erlangen, Ger-
many) using a body coil for excitation and a body matrix coil combined with spine 
matrix coil for signal reception. DWI was performed with an EPI sequence and diffu-
sion weighted images were obtained in three orthogonal directions with b-values of 
50, 300, and 600 s/mm2. A 2D- Prospective Acquisition CorrEction navigator trig-
gering was used to avoid respiratory motion artifacts. Parallel imaging was combined 
with Generalized Autocalibrating Partially Parallel Acquisition and an acceleration 
factor of 2. Spectrally Adiabatic Inversion Recovery was included to suppress the fat 
signal. Other scan parameters were as follows: TR 2000 ms; TE 82 ms; 30 transversal 
slices of 6.0 mm thickness separated by 1.2 mm; field of view 400x400 mm; matrix 
size 192x192; bandwidth 1736 Hz/px; 3 averages; anterior-posterior phase encod-
ing direction. 
To obtain T2
* images a spoiled gradient-recalled echo, FLASH 2D, sequence was 
employed. Each slice was obtained with multiple TE values (4.76, 9.53, 14.29, 
19.06, 23.82, 28.58, 33.35, 38.11, 42.88, 47.64, 52.40 ms) and a TR of 225 ms. 
Other parameters were as follows: flip angle 25 degrees; field of view 400x400mm2; 
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slice thickness 6.0 mm; matrix size 128x128. Parallel acquisition (GRAPPA) with an 
acceleration factor of 2 was used. Patients continued normal breathing during the 
T2
* scans.
Image analysis
The maximum and mean SUV (SUVmax and SUVmean) of the liver lesions with a 
maximum of 5 liver lesions per patient were assessed by applying a variable threshold 
delineation method based on the signal-to-background ratio (20). The liver lesions 
were selected based on good visible separation from other metastases and the right 
kidney on the PET images. The SUV was corrected for total body weight. The adap-
tive threshold was calculated with the formula: threshold=SUVbackground+0.41*(SUV
max-SUVbackground) (21).
All tumors were delineated using Inveon Research Workplace (IRW 3.0, Siemens 
Medical Solutions, USA). A volume weighted average of the SUVmax over the 
assessed liver lesions was calculated. A total lesion glycolysis (TLG) was calculated 
by multiplying the metabolic volume with the SUVmean. The sum of the total lesion 
glycolysis of the assessed tumors was calculated.
The ADC images were calculated automatically by the Syngo VB17 scanner soft-
ware using a noise level of 10. ROI’s were manually drawn on the diffusion weighted 
b=50s/mm2 images for optimal tumor-background contrast and were drawn around 
the entire metastasis (on all slices). ROI’s were drawn around the same lesions as 
delineated on the PET scans. Inveon Research Workplace  overlays the ADC map on 
diffusion weighted b=50s/mm2 image. The mean ADC value in each metastasis was 
calculated. 
T2
* maps were generated using in-house built software based on Matlab (MathWorks, 
Natick, MA, USA). The echo time data was fitted pixel by pixel to a mono-exponential 
curve. ROIs drawn on diffusion weighted b=50s/mm2 image were copied on the T2
* 
map, to calculate the mean T2
* values. Baseline images and the images one week 
after start of treatment were analyzed by  before the outcome after 3 cycles was 
evaluated. To evaluate CT response, the maximum lesion diameters after 3 and 6 
cycles were compared to lesion size before start of treatment.
Statistics
The following outcomes are indicative of the prognostic performance that can be 
demonstrated with a power of approximately 80% and an overall alpha of 0.05 for 
different assumptions regarding the hazard ratio (HR) and standard deviation (SD) 
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of the imaging parameter. In case of a high prognostic performance (HR=0.8) of the 
imaging parameter, the standard deviation needs to be at least 2, for 30 patients per 
group to be sufficient. For a HR of 0.90, 30 patients per group are sufficient if SD is 
at least 4.25, whereas 40 patients are required to demonstrate this association with 
an SD of 3.75. If the prognostic performance is even poorer (HR 0.95), 40 patients 
are sufficient if the SD is at least 7.5 and 60 if SD is 6. In total, 39 patients were 
enrolled in our study. Therefore, this study can demonstrate the prognostic value of 
an imaging parameter, if the imaging parameter has high prognostic performance.
All data acquired were imported in SPSS 20.0 (IBM SPSS Statistic, SPSS Inc., IBM, 
Chicago, IL). To assess the predictive value of the pretreatment SUVmax, TLG, ADC 
and T2
* measurement to progression free and overall survival a Cox proportional 
regression analysis was used. A multivariate Cox proportional regression analysis was 
used to assess predictive value of combined parameters. Given the limited number 
of patients in this study, no multivariate analysis to correct for (other) prognostic 
parameters was performed. Progression free survival was defined as the time from 
start of therapy to disease progression on CT (defined according to RECIST criteria) 
or death by any cause. Overall survival was defined as time from start of treatment 
to death by any cause.
A paired sample T-test was performed to assess whether the measured SUV, T2
* and 
ADC one week after start of therapy significantly differed from the values before 
start of therapy. Cox regression analysis was performed to assess the predictive 
value for PFS and OS, if the parameters showed a statistically significant change after 
a week. 
Furthermore, we assessed the correlation between the pretreatment values and early 
changes on PET and MRI with the changes on CT after 3 cycles of chemotherapy in a 
lesion-by-lesion and patient-by-patient analysis. 
results
patients
Thirty-nine patients participated in the study. In total, 154 liver metastases were 
assessed. Patient characteristics are summarized in Table 1. Two patients underwent 
MRI only. In two patients only an 18F-FDG PET/CT was performed. The first follow-
up scan (one week after start of treatment) was not completed by eight patients. 
Side effects of chemotherapy was the main reason for protocol deviations. The final 
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follow-up scans (after 3 treatment cycles) were not completed by 7 patients (Table 
2 and 3). Median follow-up was 65.5 weeks (range 2 - 221 weeks). After three 
cycles 43.6% (N=17) of the patients showed partial response, 41.0% (N=18) of 
the patients had stable disease and 12.8% (N=5) of the patients died or had severe 
progression clinically. 
predictive value of pretreatment 18F-FDG pet and MrI parameters
An example of a pretreatment 18F-FDG PET, DWI, ADC map and T2
* image of a 
patient with multiple liver metastases is shown in Figure 1. In general, high uptake of 
FDG was visible in the liver metastases on the PET-images. On the ADC-map, there 
was a dark signal (low ADC) in the rim of all tumors and high signal in the centre of 
most tumors, indicating central necrosis. There was little contrast between liver and 
tumor on the T2
*-map.
Sex 71.8% male (N=28)
28.2% female (N=11)
Mean age 62 years (range 29-77)
Localization primary tumor 41.0% Right hemicolon  (N=16)
28.2% Left hemicolon, including sigmoid (N=11)
23.1% Rectal cancer (N=9)
7.7% Unknown location in colon (N=3)
Treatment CAPOX+ bevacizumab (N=32)
Capecitabine+ bevacizumab (N=4)
CAPOX (N=1)
UFT (N=1)
FOLFOX with hyperthermia (N=1)
Intention of treatment Neoadjuvant (N=5)
Palliative (N=35)
Table 1: Characteristics of participating patients. CAPOX= capecitabine and oxaliplatin; UFT= tegafur-
uracil ; FOLFOX= fluorouracil and oxaliplatin
FDG PET
     SUVmax (g/cm
3)
     TLG (g)
N=37
11.4 (4.7)
1084 (1244)
N=30
8.8 (3.7)
726 (1145)
N=29
5.0 (3.3)
144 (212)
MRI
    DWI (ADC)
     T2
* (ms)
N=36
1.21 (0.17)
30.2 (7.0)
N=29
1.27 (0.20)
26.7 (8.1)
CT (RECIST)
     Sum of diameters (mm)
N=39
153 (90)
N=31
104 (74)
Table 2: Average 18F-FDG PET, MRI and CT parameters at pretreatment, one week after start of therapy 
and after 3 cycles of therapy. 
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Figure 1: Typical images acquired with FDG PET, DWI and T2
* of a patient with multiple liver metastases. 
One  liver metastasis is delineated with a blue line on  A) 18F-FDG-PET/CT  B) a diffusion weighted 
image (b-value 50 s/mm2), C) ADC-map and D) T2
*-map.
The mean SUVmax in the liver lesions was 11.3 g/cm3 (range 5.8-20.5 g/cm3) 
and the mean sum of the TLG in the assessed liver lesions was 1084g (range 12.8-
4845g). The SUVmax value was not a significant predictor of PFS, but was predictive 
of OS. Each 1.0 increase in SUVmax was associated with a 1.125 higher risk of death 
(95% CI 1.020-1.241, p=0.02). Although TLG was not predictive of PFS, it did show 
predictive value for OS: each 100g increase in pretreatment TLG value was associ-
ated with a 1.047 increased hazard of dying (95% BI 1.010-1.085, p=0.01).
The average pretreatment ADC value was 1.21 *10-3 mm2/s and the average pre-
treatment T2
* value was 30.2 ms. The pretreatment ADC value was a significant 
predictor of both PFS and OS: a 0.1 *10-3 mm2/s higher pretreatment ADC value 
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provided a hazard ratio of 0.749 for progression (95% CI 0.561-1.000, p=0.05) and 
a decreased risk of dying (HR 0.667, 95% CI 0.466-0.955, p=0.03). Kaplan Meier 
survival plots for the patients with higher and lower than median ADC are shown in 
figure 2. 
Figure 2: Kaplan Meier Survival curve for a higher or lower than mean ADC value (1.21 mm2/s) at 
pretreatment, showing a significant difference in overall survival (p=0.022) and progression free survival 
(p=0.001).
Pretreatment T2
* value was a significant predictor for OS, but not for PFS. A 1 ms 
higher average T2
* time was associated with an increased risk of dying (HR 1.118, 
95% CI 1.023-1.222, p=0.01).
Combining the pretreatment ADC values and SUVmax in a multivariate model showed 
a higher predictive value for survival, p<0.01. Adding T2
* or TLG parameters did not 
increase the predictive value of the model.
Pretreatment SUVmax, ADC and T2
* were not correlated to the size change on CT 
after three cycles of chemotherapy, neither in the patient-by-patient analysis nor in 
the lesion-by-lesion analysis.
predictive value of early changes in 18F-FDG pet and MrI parameters
SUVmax significantly decreased one week after start of treatment (SUVmax: 11.3 
to 6.3, p<0.01). SUVmax decreased on average with 18.0% ±19.1% (range 66.1% 
decrease-14.8% increase).TLG decreased on average 19% ±35.0% after one week of 
treatment (1084 to 726, p=0.07). The ADC values significantly increased after one 
week of treatment from 1.20 to 1.27 *10-3 mm2/s (p=0.01). The average increase 
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was 0.07*10-3 mm2/s ± 0.13*10-3 mm2/s. The T2
* values were on average 30.2ms 
before treatment and 26.7ms one week after start of treatment. This was not a 
significant decrease (p=0.17). 
The change in ADC value was inversely correlated to the change in SUVmax, r=-0.58, 
p<0.01 (figure 3). No correlation with changes in T2
* was observed. The degree 
of change in SUVmax, TLG and ADC were not predictive of either PFS or OS. Also 
combined changes in SUVmax, TLG and ADC did not predict PFS or OS. 
Figure 3: Regression analysis of the changes in SUVmax on differences in ADC one week after start of 
treatment ( r=-0.58, p=0.002). The fit line (red) and 95% confidence interval (black) are shown. 
Furthermore, the change in SUVmax, TLG and ADC after one week did not correlate 
to size change on CT after 3 cycles in a lesion by lesion analyses or patient-by-patient 
analysis. As shown in figure 4, there is no difference between CT responders and 
non-responders in change in SUVmax or ADC. Of note, in only 23 metastases an 
increase in SUV after one week of treatment was observed, of which 16 metastases 
had a reduced diameter after 3 cycles.
In previous studies the reproducibility of FDG PET and DWI in liver metastases was 
assessed (22). When patients with an increase in ADC over 0.20 *10-3 mm2/s (twice 
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the standard deviation of normal variation) and decrease in SUVmax over 40% were 
classified as responder, there was still no significant difference in CT response, PFS 
or OS. 
Figure 4: Boxplots showing the change in SUVmax and ADC in patients with partial response, minor 
response, stable disease and in patient unable to perform the scan after 3 cycles due to clinical 
progression or death. There was no relation between response and changes in SUVmax or ADC.  
Discussion
pretreatment 18F-FDG pet and MrI parameters
Combining the pretreatment ADC values and SUVmax in a multivariate model showed 
a higher predictive value for survival. Also, a correlation between SUVmax and survival 
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was observed. This is in line with previous studies, performed in patients with both 
primary resectable and irresectable colorectal liver metastases, in which significantly 
higher pretreatment SUV was associated with poorer outcome (7, 23). 
In this study, lower pretreatment ADC values predicted poorer outcome, which may 
be related to the association between ADC values and histological grade. In breast 
and prostate cancer lower ADC values were correlated with higher histological grade 
and higher Gleason score (24-26). In colorectal cancer, a higher histological grade is 
correlated with an adverse outcome (27, 28).
A low T2
* value, indicating higher concentration of deoxyhemoglobin, was favorable 
for longer OS, but did not correlate with PFS. However, the deoxyhemoglobin is not 
only dependent on hypoxia. In very poor vascular supply and necrotic areas, there 
may be also very little deoxyhemoglobin present.
early changes in 18F-FDG pet and MrI parameters
Both 18F-FDG PET and DWI showed therapy induced changes one week after start 
of treatment. The changes in 18F-FDG PET and DWI were correlated, suggesting 
an association between treatment effects leading to decreased cellular density and 
metabolic response.
Unfortunately, the measured treatment effects were not predictive of survival or CT-
response. The lack of relation between changes in 18F-FDG PET and MRI parameters 
and treatment outcome can be attributed to several factors. In contrast to compa-
rable previous studies, bevacizumab was part of the standard treatment regimen in 
the present study. Antiangiogenic treatments, such as bevacizumab, may alter the 
distribution of intravenously injected tracers or contrast agents in the tumor (29). 
Decrease in SUV might therefore, in part, reflect alterations in tumor blood supply, 
rather than metabolic changes. This might obscure the association between meta-
bolic response and treatment outcome. The use of a variable threshold to delineate 
the tumor on 18F-FDG-PET may have resulted in an underestimation of the effect of 
treatment on TLG, since SUVmax decreased as an effect to treatment and therefore 
the threshold was lower for the second scan. However, the use of a fixed threshold is 
also problematic due to high background activity in liver tissue. 
DWI and T2
* are not dependent on administration of intravenous contrast agents. 
However, the observed increase in ADC and reduction in T2
* may be a reflection of 
therapy induced necrosis, related to a favorable outcome, as well as to bevacizumab 
induced reduction in vascularization and hypoxia, related to therapy resistance and 
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a dismal outcome. Thus, the relation between outcome and changes in DWI and T2
* 
are obscured by differential effects on the tumor. T2
* did not significantly alter after 
start of treatment. Therefore, this parameter may be less suitable as a predictor of 
response to therapy. 
Finally, the interval between start of treatment and the first evaluation may be of 
crucial importance for response monitoring with 18F-FDG PET and ADC. An interval 
of one week after start of targeted therapy containing treatment might be too short 
for 18F-FDG PET. 1-2 weeks after start of treatment a flare-up phenomenon has 
been described, defined by an initial rise in metabolic activity in lesions that would 
respond later on (30). This phenomenon might also interfere with the measured 
parameters.
Conversely, changes in ADC cannot only precede changes in tumor size, but may 
even disappear after a certain time due to activated repair mechanisms (31). In 
a previous study an increase in ADC in colorectal and gastric liver metastases (of 
23 patients) was described after 3 and 7 days of treatment. However, only a weak 
correlation between change in ADC on day 3 and final change in size could be estab-
lished, whereas no significant correlation between changes at day 7 and final lesion 
size was observed (13). Therefore, it might be more effective to measure ADC at a 
shorter time interval after start of treatment. Finally, we can only speculate on the 
optimal interval for early response prediction using T2
* in the present study. In a 
breast cancer study after 2 cycles of chemotherapy, however, a significant increase 
in T2
* was observed (32), suggesting that longer time intervals may benefit.
Study limitations
Although the number of included patients and evaluated metastases is limited, it is 
reasonably compared to other imaging studies. Given the burden of imaging proce-
dures and associated costs, acceptable sample size is in the range of 30-70 patients. 
For a hazard ratio of 0.85 (power 80% and α 0.05) 40 patients would be sufficient to 
demonstrate this association with a standard deviation of 2.5. Therefore, with this 
number of patients hazard ratio’s can be calculated, but not with high prognostic 
performance.
The patients with the poorest treatment outcome could not complete all scans 
which limits correlation with changes in size after 3 cycles. The use of two different 
PET-CT scanners should not have influenced the predictive value of the pretreat-
ment SUV and TLG measurements as both scanners were EANM-EARL accredited 
for quantitative PET. 
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Conclusion
Pretreatment SUVmax, TLG values, ADC and T2
* in colorectal liver metastases are 
predictive of patient survival. In the future, this could provide the opportunity to 
select patients who could benefit from chemotherapy prior to start of treatment. 
Early effects after one week of treatment with chemo- and targeted therapy can be 
measured with 18F-FDG PET and DWI, however, these effects were not predictive of 
long term outcome in this study.
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Summary
Colorectal cancer is one of the most common cancers in the Western world and 
many patients develop distant metastases, most frequently in the liver. When pos-
sible, curative treatment of liver metastases is performed, often by a partial resection 
of the liver. However, for most patients with metastatic disease palliative systemic 
treatment is the only therapeutic option. This palliative systemic therapy prolongs 
the median overall survival of the patient population as a whole, but, in fact, only a 
subset of patients responds to this potentially toxic and expensive treatment.
Approximately 8-9 weeks after start of treatment, the response is monitored by 
a tumor size evaluation according to the RECIST criteria (1,2). However, this size 
response evaluation may be suboptimal (3). A reliable imaging method that pre-
dicts response to therapy before or early after start of treatment would be highly 
desirable as this may prevent unnecessary toxicity and costs. Therefore, predic-
tive imaging markers are needed, that preferably provide insight into the biology 
of colorectal cancer. Imaging techniques to detect some potential biomarkers are 
briefly explained in chapter 1.
Chapter 2 discusses in vivo MR spectroscopy and provides a number of adequate 
research tools to study metabolism in liver tumors and metastasis. Since knowledge 
of some technical background is indispensable, a general introduction into the basics 
of MRS, which partially also applies to MRI, is provided. In addition, some technical 
issues of MRS as applied to tumors and metastases in the liver are discussed.
Since proton (1H) MRS can be performed with standard MR hardware and 1H has 
the highest MR sensitivity, it is the most applied MRS method. The major drawback 
of 1H MRS is the relatively small chemical shift range for the many resonances of in 
vivo detectable compounds, resulting in limited spectral resolution. In liver tumor 
studies the lactate resonance, which relates to tumor energy metabolism (Warburg 
effect), overlaps with large lipid resonances. Fortunately, with so-called spectral 
editing techniques it is possible to separate the lactate signal from the lipid signals. 
The total choline (tCho) peak has been employed as biomarker to identify malig-
nant tumors. An increase of this peak is associated with cell membrane synthesis in 
rapidly growing tumors. However, the tCho peak is composed of several unresolved 
resonances of different choline containing compounds, which makes signal changes 
difficult to interpret. 
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Another way to study important metabolites involved in membrane metabolism is 
by using 31P MRS. In 31P MR spectra of tumors resolved signals for phosphorylated 
choline and ethanolamine containing compounds can be detected. From several 
studies it is known that an increase of these phosphomonoesters (PMEs) is asso-
ciated with tumor progression and that successful treatment is associated with a 
decrease in PME levels. Therefore 31P MRS could very well be used for treatment 
response monitoring. Besides the signals from phospholipid metabolism, 31P MR 
spectra of liver also show signals of ATP and Pi which can be used to investigate 
tumor energy metabolism and the chemical shift of the latter can also be used to 
deduce intracellular pH. Unfortunately, the spatial resolution of 31P MR spectra 
is an order of magnitude lower compared to 1H MRS, due to lower sensitivity of 
phosphorus.
MRS of substrates labeled with 13C are a unique way to measure the dynamics of 
metabolic conversions in vivo, but it has been little used to examine human liver 
metabolism due to its technical complexity and relative low sensitivity. The recent 
development of signal intensity enhancement by hyperpolarization may open new 
ways to examine livers by dynamic imaging of stable isotope labeled metabolites.
Before conclusions can be drawn from imaging parameters, data on repeatability 
are needed to assess which differences outside the range of normal variation can 
be detected. If changes within a tumor are larger than can be attributed to normal 
variation (e.g. variations in the MR system or body physiology), it can be assumed 
that this is due to treatment effect.
Chapter 3 describes the repeatability of the tCho signal obtained by single voxel 
1H MRS in normal liver tissue and liver metastases of colorectal cancer. In addition, 
for interpretation purposes, a few ex vivo normal and tumor tissue specimens are 
subjected to high-resolution magic angle spinning (HRMAS) NMR spectroscopy. 
This is the second study with estimates of absolute tCho content in the liver and 
demonstrates that this content in apparently normal liver does not change when 
a colorectal metastasis is present. The increased tCho signal, a hallmark of malig-
nancy in many other body tumors, was not observed for these liver metastasis. This 
appears to be in contrast to studies on primary liver tumors showing a higher tCho 
content. Our finding of a similar or even decreased tCho may be caused by intrinsic 
differences between primary and metastatic tumors but also may be due to a high 
background tCho signal in the liver or to variable partial volume effects of tumor 
necrosis diluting the tCho signal. The rather poor repeatability of tCho assessment 
183
Sum
m
ary, discussion and future perspectives
was probably caused by respiratory motion of the heterogeneous tumor tissue, and 
the difficulty of proper voxel replacement in heterogeneous tumor tissue.
Chapter 4 describes the repeatability and biological validation of diffusion weighted 
imaging (DWI). Patients scheduled for metastasectomy of colorectal liver metas-
tases were scanned twice within one week. DWI was performed and the apparent 
diffusion coefficients (ADCs) were assessed in 21 colorectal liver metastasis. To 
provide a biological basis for these ADC values, its relation with apoptosis marker 
p53, anti-apoptotic protein BCL-2, proliferation marker Ki67 and serum VEGF levels 
was also assessed. Using the Bland & Altman method, a repeatability coefficient of 
0.20 x 10-3 mm2/s for mean ADC was observed in these metastases and the mean 
ADC was 1.17 ± 0.11 x 10-3 mm2/s. Metastases in recently treated patients had a 
mean ADC of 1.27 x 10-3 mm2/s compared with 1.05 x 10-3 mm2/s in previously 
untreated tumors (P=0.02). The ADC value was related to the proliferation index 
and BCL-2 expression of the metastases. The good repeatability, correlation with 
histopathology and implied sensitivity for systemic treatment-induced antitumor 
effects suggest that DWI might be an excellent tool to monitor response in meta-
static colorectal cancer.
Chapter 5 describes the repeatability and biological validation of using T2
* MRI 
to characterize liver tumors. Eighteen patients scheduled for metastasectomy 
of colorectal liver metastases were scanned twice within one week. T2
* MRI was 
performed and assessed in normal liver tissue and in 22 colorectal liver metastasis. 
To provide a biological basis for these T2
* values, its relation with the expression 
of the hypoxia-related markers GLUT-1 and CA-IX as well as the relative vascular 
area, and the vessel density in resected tumors was also assessed. Immunohisto-
chemical staining was therefore performed on 17 resected tumors obtained from 16 
patients. Using the Bland & Altman method, a repeatability coefficient of 11.2 ms 
for mean T2
* was observed in these metastases. The mean T2
* was 25.0 ± 5.6 ms in 
liver metastasis and 23.0 ± 4.1 ms in normal liver tissue. On average T2
* showed fair 
repeatability. No correlations between T2
* values, hypoxia and vascularity related 
markers were observed.
Chapter 6 presents the successful implementation of a procedure to remove motion 
displaced or distorted images as identified by a structural similarity method to reduce 
the effect of motion in fast multi-slice DCE-MRI of the liver. In fifteen patients with 
colorectal liver metastases DCE-MRI was performed twice within one week. Datas-
ets with contrast agent concentrations were calculated and AIFs were automatically 
derived from contrast inflow in voxels located in the aorta of each patient. Thereafter 
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SSIM identified motion corrupted images of the liver were removed from the dataset. 
From this corrected data set Ktrans and its repeatability were determined. Rejection 
of these images resulted in a significantly (p<0.05) lower median Ktrans (3.53 ± 1.89 
x 10-3 s-1) and lower coefficient of repeatability of Ktrans (1.44 x 10-3 s-1) in liver 
metastases compared to an analysis without correction (4.12 ± 2.04 x 10-3 s-1 and 
2.39 x 10-3 s-1, respectively). Thus, the SSIM correction improved the repeatability of 
the DCE-MRI parameter Ktrans in liver metastasis and reduced contamination of Ktrans 
values of lesions with that of surrounding normal liver tissue.
Chapter 7 describes the use of a contrast enhanced CT for PET attenuation cor-
rection. Ten patients scheduled for 18F-FDG PET and contrast enhanced CT of 
the abdomen were included. PET data were corrected for attenuation using both 
unenhanced low dose CT images and contrast enhanced high dose CT images. The 
differences in SUVmean and SUVmax were compared in 3 liver regions. The average 
SUVmean and SUVmax of all regions was 2.43 and 2.91 g/cm
3 in the unenhanced 
dataset and 2.53 and 3.17 g/cm3 in the enhanced dataset. Both SUVmean and SUVmax 
values were significantly elevated in liver tissue when using PET images corrected 
for attenuation with contrast enhanced high dose CT compared to unenhanced low 
dose CT. Although the different quantitative measures may not affect daily clinical 
practice, unenhanced and contrast enhanced CT should not be used randomly for 
attenuation correction if exact quantitative results are required.
The potential of 18F-FDG PET, DWI, and T2
* MRI to predict response to systemic 
treatment in patients with colorectal liver metastases is described in chapter 8. 
Pretreatment measurements and early changes one week after start of therapy were 
evaluated on their predictive value.
In 39 patients with colorectal liver metastases, imaging was performed prior to and 
one week after start of first line chemotherapy. The 18F-FDG PET scans were per-
formed on a hybrid PET/CT scanner and were almost immediately followed by DWI 
and T2
* MRI scans, which were performed on a 1.5T MR system. The maximum stan-
dardized uptake values (SUVmax), total lesion glycolysis (TLG), apparent diffusion 
coefficients (ADCs) and T2
* values were assessed in the same lesions. A maximum 
of 5 liver metastases per patient were analyzed. The progression free survival (PFS) 
was the primary outcome measure. The predictive value for overall survival (OS) 
was the secondary outcome measure. 
A low pretreatment ADC was associated with a poorer PFS and OS. A high pre-
treatment SUVmax, TLG and T2
* were associated with poorer OS. After one week, 
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a significant drop in SUVmax and rise in ADC were observed. The drop in SUVmax 
correlated with a rise in ADC, however, neither the change in ADC nor in SUVmax 
was predictive of PFS or OS. T2
* did not significantly change after start of treatment. 
Pretreatment SUVmax, TLG, ADC, and T2
* values in colorectal liver metastases are 
prognostic of patient outcome. Despite sensitivity of DWI and 18F-FDG PET for early 
treatment effects, changes in this parameter did not predict long term outcome.
Discussion and future perspectives
adoption of novel molecular and functional imaging modalities
Conventional response evaluation based on tumor size may be a suboptimal method 
for early assessment of response to systemic treatment, as tumors may not show a 
significant change in size, despite efficacy at the molecular level (3). Therefore new 
methods predicting and/or allowing monitoring of efficacy of treatment are highly 
desirable as this would prevent unnecessary toxicity and costs. In this thesis a number 
of novel and adequate molecular and functional imaging techniques were provided 
for prediction of response and/or early response monitoring. The combination of 
some of these molecular and functional imaging techniques provides information 
for a more complete and reliable diagnosis. Despite the high potential of several 
techniques, they are not yet applied often in a clinical setting for diagnosis and 
treatment monitoring of liver tumors and metastasis. While conventional response 
evaluation based on tumor size is well defined (e.g. RECIST) and relative easy to 
perform, the new molecular and functional imaging techniques are technically more 
challenging and suffering from the lack of a general consensus on a specific set of 
response criteria and well defined guidelines. So far, only for 18F-FDG PET a widely 
accepted guideline is available: the PERCIST criteria (4,5), although a first attempt 
was made to harmonize DWI as well (6).
The optimal time point for response evaluation after initiating treatment, for 
example, has to be clearly determined for every molecular and functional imaging 
technique and possibly tumor type. This interval between start of treatment and 
the first scan may be of crucial importance in monitoring with 18F-FDG PET, ADC 
and T2
*. Previous studies showed moderate results on the repeatability of 18F-FDG 
PET (7), and T2
* (8), indicating that a somewhat larger treatment effect is needed 
to discriminate treatment effects from normal variability. Therefore scanning at the 
exact right moment, when the change in treatment effect is maximal, is important 
(9). ADC values may already start to decrease 24 hours after start of treatment and 
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increase again after a certain time due to activated repair mechanisms (10,11). The 
optimal time interval for early response monitoring using T2
* is not clear as it did 
not significantly change after start of treatment in our study (8,12). A significant 
increase in T2
* was however observed after 2 cycles of chemotherapy in a breast 
cancer study (13), suggesting that longer time intervals may be beneficial.
Another example that makes the adaption of new imaging techniques difficult is 
the lack of consensus on imaging parameter values and analysis models. The DWI 
technique applied in our study, for example, is not complex and it showed good 
repeatability in liver metastases. However, without consensus on the procedures, 
the ADC values cannot easily be compared with DWI examinations performed in 
other centers. A different underlying model, for instance a mono-exponential versus 
a bi-exponential model, or a different number or distribution of b-values could eas-
ily result in different ADC values (14). Moreover, even with the same model and 
b-values, different ADC values could result from the same tissue due to the fact 
that the diffusion time is a hidden parameter in the b-value and could vary with 
different echo times and due to different implementations of the pulse sequence 
on various MRI systems. For T2
* imaging there is also no consensus on the optimal 
echo times that should be applied for each tissue type. Likewise, with DCE-MRI and 
pharmacokinetic modeling there is no agreement on the minimal required temporal 
resolution required to sample the first bolus passage or the location where it should 
preferably be measured. This is important, as the sampled AIF has a large effect 
on the outcome of the pharmacological parameters. Moreover, the extended Tofts 
model is one of the most applied models in DCE-MRI (15), however, it is perhaps 
not the optimal model for all tissues. The liver for example, has a dual input from the 
hepatic artery and the portal vein, although the blood flow to metastases is assumed 
predominantly arterial (16). 
New imaging techniques need to have a reliable performance and their results 
should preferably have been validated with other methods such as histopathology. 
Moreover, as new methods may themselves add significantly to the cost and time 
of patient management, it has to be proven that they are beneficial for diagnosis, 
treatment outcome and/or patient care. Together this makes adoption of these new 
imaging techniques challenging (17).
Liver motion and Mr
A common problem for all liver imaging modalities is respiratory motion and, to 
some smaller extent, cardiac and bowel motion. At rest, a healthy person breathes 
12 to 15 times per minute and during each breath cycle a tumor in the liver moves on 
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average 9 mm (range 2 to 19 mm) in cranio-caudal direction (18-20). To minimize 
the influence of motion on MR many prospective and retrospective approaches have 
been developed, as described in chapter 5. The conventional prospective methods 
like breath-hold scanning, navigator techniques and techniques using an external 
pneumatic belt are often applied (21-23). Although some scan time is lost waiting 
for the right liver position to re-occur in the breathing cycle, these methods are 
considered relatively easy to apply and fairly reliable. As reported in chapter 3 for 
example, respiratory triggering with a navigator resulted in a good repeatability for 
DWI. Currently, sequences that use k-space trajectories that are less sensitive to 
motion, like radial or spiral sampling, are also becoming more commonly applied 
(24,25). The large advantage of all the prospective methods is that the image qual-
ity can be checked while the patient is still in the scanner, allowing reacquiring of a 
failed acquisition. Sometimes the ‘waiting for the right liver position to re-occur’ is 
unwanted, as e.g. with DCE-MRI, or even unnecessary as new imaging techniques 
together with post processing could relocate image data to the right position, remove 
artifacts like ghosting, and thus result in higher quality images. Many of these post 
processing techniques still require a significant amount of computing time, meaning 
that the radiologists have to wait with reporting until the post processed images are 
available. In future, when computing power increases these methods may be applied 
to further optimize image quality.
In MR spectroscopy motion can lead to voxel misregistration and outer voxel con-
tamination. Also, the (automatic) shim process, to create a homogeneous magnetic 
field, is more difficult to perform due to motion, and thus more time consuming. 
Apart from motion, iron could have been accumulated in the liver, making the pro-
cess even more difficult. Moreover, even after a successful shim process and creating 
a fairly homogeneous magnetic field, different breathing patterns (e.g. deep vs 
shallow breathing) could again lead to a reduced homogeneous magnetic field. An 
inhomogeneous magnetic field results in broadening of the spectral resonances, 
and thus a reduced SNR and the risk of more signal overlap in the spectra. Also, 
a larger suppression bandwidth could be required to (partially) suppress the large 
water peak. This could however also result in the suppression of metabolites with a 
resonance frequency close to the water peak.
Repeated breath-hold acquisitions may be applied but there is no guarantee that the 
liver (tumor) is every time in the exact same position, and as no imaging is performed 
it is also not easy to verify. Respiratory and cardiac gating could be applied, but will 
lead to a significant increase the total scan time as MRS usually involves many signal 
averages to increase the SNR. An elegant way to solve the signal broadening effect 
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due to motion is by acquiring individual spectra and perform a frequency alignment 
before averaging to increase the SNR.
Mr spectroscopy in the liver
Besides 18F-FDG PET, DWI, T2
* and DCE-MRI, MR spectroscopy could be valuable 
in future studies. It can provide specific information on tumor pathophysiology and 
metabolism. This may include data on the type, grade, and stage of the tumor, which 
thus can assist in further management of the disease. As was described in chapter 2, 
most metabolites in the body contain 1H, and many can thus potentially be measured 
with 1H MRS. Moreover, obtaining 1H MRS spectra should be relatively easy com-
pared to MRS with other nuclei as the same scanner hardware can be applied. The 
total choline signal (tCho) is one of the most interesting signals as it is reported to 
be related to cell membrane turnover and tumor aggressiveness (26,27). In addition, 
decreased choline levels have been observed after successful treatment (28-30). In 
the liver the situation is, however, somewhat different. As we demonstrate, healthy 
liver tissue has an already relatively high tCho levels. Due to respiratory motion, 
healthy liver tissue could move inside the MRS voxel, thereby contaminating the 
tumor tCho signal. A solution could be the in chapter 3 discussed application of real-
time navigator gating both for the measurement preparation steps (B0 shimming, 
water frequency determination, receiver gain optimization, and water suppression) 
and for the PRESS data acquisition including intravoxel signal suppression to avoid a 
chemical shift artefact (31). This approach may provide excellent spectral quality, 
but does not solve the problem of voxel misplacement in diagnostic and treatment 
assessments due to tumor heterogeneity. Especially larger colorectal metastases 
can have central necrosis, which could decrease the tCho signal in the tumor voxel.
Analyzing the 1H liver spectra is also not straight forward as remaining motion 
artifacts and a large macromolecular baseline could have an effect on the fitting 
algorithm thereby decreasing the fit quality. Furthermore, absolute quantification 
of metabolites, and especially in a metabolic active organ as the liver, is difficult due 
to the absence of a stable reference signal. Additional 1H MRS measurements could 
be performed to obtain the unsuppressed water signal that could be used as a refer-
ence. Although the liver water content may change due to pathology or treatment 
effects, its variation is expected to be low compared to other references like e.g. the 
(total) lipid content or the application of an external reference (32).
As an alternative 31P MRS could be applied instead of 1H MRS. Although the sensitiv-
ity of 31P is far less than 1H, there is no need for water suppression, the macromo-
lecular baseline is absent, the resonances in the 31P spectra are better resolved and 
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the phosphomonoester and phosphodiester resonances provide more information 
than the composite tCho peak, as was discussed in chapter 2.
Patients with colorectal cancer received tablets with capecitabine as part of their 
systemic treatment. Capecitabine is a prodrug that is enzymatically converted to 
5-fluorouracil (5-FU). This drug contains a fluoride atom and 19F MRS could provide 
a unique possibility to determine the concentration of drugs in liver and tumor 
tissue, and to monitor the conversion of the prodrug to active metabolites and/or 
inactive catabolites. Previously a close association between the ability of a tumor to 
accumulate fluorouracil and the cytotoxic efficacy of the drug was reported (33).
Because of the absence of endogenous 19F metabolites in the human body (apart 
from nearly undetectable amounts in e.g. bone and teeth), all measured 19F reso-
nances originate from the fluorine containing drug or its metabolites. In addition, 
the chemical shift range of 19F MRS is relative wide and the resonances are clearly 
resolved (33-35).
In contrast to 1H MRS, performing 19F (or 31P or 13C) MRS requires additional scanner 
hardware (e.g. transmit and receive coils and amplifiers) as these nuclei have differ-
ent gyromagnetic ratios and thus Larmor frequencies compared to 1H. This means 
that next to a 1H RF coil, for imaging the anatomical area, a 19F (or 31P or 13C) RF coil 
needs to be developed, or a RF coil that is tunable to both 1H and 19F frequencies as 
the gyromagnetic ratios and thus the frequencies are not very far apart, at least in 
scanners up to 3T. A 1H/19F transmit/receive array that would cover the whole liver 
area would be optimal as was recently shown in a 7T study (36).
In contrast to 31P and 13C, which have sensitivities of 6.63% and 0.017% respec-
tively, 19F has almost the same sensitivity (83%) as 1H (100%) (37). Nevertheless, 
since there is only one 19F atom per molecule (5-FU) and the concentration of these 
molecules in liver and tumor tissue is low, the in vivo sensitivity of 19F is much lower 
compared to 1H. Again, like in 1H MRS, the measurement volume and/or the number 
of signal averages could be increased to increase the SNR.
As the expected 19F (or 31P or 13C) MRS signal is low, these coils usually need to be 
adjusted for every individual patient, e.g. tuned to the right frequency (19F, 31P or 
13C) and matched to the right impedance, to optimize signal transfer. In some coils 
this process is performed automatically, others require manual adjustments, which 
could involve several minutes. Furthermore, like 1H MRS, absolute quantification of 
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metabolites is difficult due to the absence of a stable reference signal, and respira-
tory motion complicates MRS in the liver. 
Although in vivo MRS is a particular interesting technique, allowing the concentra-
tions of various metabolites in (tumor) tissue to be investigated, all these processes 
together make that MRS is perceived as a more complicated technique requiring 
relative long total scan times and additionally a certain level of training and exper-
tise. Also the absence of well-defined guidelines and the somewhat limited support 
from scanner manufacturers, together makes that spectroscopy is currently more a 
research tool than it is applied in a daily clinical setting.
New developments such as MRS on ultra-high field scanners or hyperpolarization 
for 13C MRS could significantly increase the signal and may open new ways of liver 
assessment and imaging as already shown in some studies (38). The involved polar-
izers are, however, complex and also require a certain level of training and expertise, 
although a fully automated and commercially available polarizer for clinical use exists 
(38).
Ultra-high magnetic field Mr
Another way to increase the spin polarization is by applying higher static magnetic 
(B0) fields. As the spin polarization and the magnetic field are about linearly related, 
doubling the magnetic field doubles the spin polarization and thus, in theory, the 
SNR. This increase in SNR could be used to e.g. improve spatial or temporal resolu-
tion. Therefore high field 3T imaging is increasingly used in clinical practice, although 
conventional 1.5T systems are also still widely available. Ultra-high field systems that 
operate at 7T and even 9.4T, 10.5T, 11.7T systems are currently being explored. 
Since more technical challenges arise at (ultra-) high field strengths, these systems 
are not yet applied in daily clinical practice and are only available in (clinical) research 
projects (37). While ultra-high magnetic field MR has already shown several very 
promising results in smaller body parts like e.g. the head, heart, prostate, and breast, 
imaging large areas like the liver remains challenging at e.g. 7T. Two major challenges 
with (ultra-) high field imaging are the increased transmit (B1) field inhomogeneity 
and elevated RF power deposition in tissue. 
Specific absorption rate
The energy deposition approximately increases with the square of the magnetic 
field and therefore, scans are reaching the specific absorption rate (SAR) limits more 
quickly (39,40). This could lead to uncomfortable sensation of heating or nerve 
stimulation in the extremities of the patient. 
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transmit field inhomogeneity
Higher field strengths result in higher Larmor frequencies and shorter wavelengths 
meaning that e.g. frequency dependent dielectric properties of the diverse tissue 
types become more important and must be taken into account (37). Wavelengths 
become similar or smaller than the size of the objects imaged and this could, 
especially in larger field of views like the liver, lead to B1 inhomogeneities (41). B1 
inhomogeneities again lead to nonuniform excitation and affects, for instance, the 
flip angle, image contrast and penetration depth.
Imperfect flip angles can to some extent be avoided by applying adiabatic or com-
posite pulses, having nearly B1 independent flip angles (42). As these pulses increase 
power deposition, they could be prolonged to lower the SAR (43). New techniques 
like slice multiplexing could also be applied to reduce SAR (44).
To minimize the B1 field inhomogeneities, several approaches have been proposed. 
Static B1 shimming is the most straightforward approach where for each element 
in a transmit array an RF pulse with a certain amplitude and phase is applied while 
the pulse profile for each element remains the same (37,39,45). Another, more 
complicated, approach to optimize the B1 field is applying parallel transmit, where 
spatially tailored RF pulses are used (46-50). Each element in a transmit array is now 
assigned an individual RF pulse with a certain waveform. This means that expensive 
and complicated hardware is required for every channel (37).
Liver spectroscopy and imaging at ultra-high magnetic field
MRS would benefit from the increased SNR at high magnetic field strengths. Spectra 
can be acquired with improved spectral resolution and sensitivity, compared with low 
magnetic field strengths (51-55). The challenges with the higher Larmor frequency 
and short wavelengths for proton at 7T are only limited applicable for e.g. 31P and 
13C MRS as the gyromagnetic ratio of these nuclei, and thus the Larmor and RF 
frequencies, are much lower than for proton. This means that the B1 inhomogeneity 
effects are less severe for these nuclei than for 1H or 19F.
The multi-channel transmit/receive arrays, often applied with ultra-high field imag-
ing, enables parallel imaging. For DCE-MRI, the higher SNR allows higher acceleration 
factors to be applied, allowing higher spatial resolution images to be obtained while 
keeping the same high temporal resolution (56-60). On the other side, imaging at 
higher fields could result in more susceptibility artifacts near tissue borders, due to 
differences in magnetic susceptibility of body tissues (40). Therefore, lesions on 
top of the liver, near the lung could suffer from artifacts caused by the tissue-air 
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interface. Also, respiratory and cardiac motion could cause artifacts that could prove 
to be larger in 7T compared to 3T or 1.5T systems. Finally, the higher field and thus 
Larmor frequency also results in longer T1 relaxation times (40). The T2 relaxation is 
far less affected by the magnitude of the magnetic field compared to T1 (61), how-
ever, an increased magnetic field could cause T2
* to shorten significantly (62). The 
T2
* or susceptibility weighted imaging in our study could profit from the increased 
sensitivity for small differences in B0 susceptibility due to the higher magnetic fields 
(63-68). The system would however, also be more sensitive to other causes of field 
inhomogeneities like motion, magnetic field imperfections, tissue boundaries, or 
ferromagnetic objects, like implants (69).To avoid motion artifacts, DWI is usually 
performed using single-shot EPI. High spatial resolution DWI requires long EPI trains 
and therefore small susceptibility differences could easily add up and cause spatial 
distortions. With multi-channel transmit/receive arrays and parallel imaging, the 
higher SNR that comes with the higher field allows higher acceleration factors to be 
applied which could be used to reduce the EPI trains. This again leads to a reduced 
accumulation of susceptibility artifacts and thus reduced image distortions (56). 
The diffusion weighting part of the sequence however requires a homogeneous B1 
field for the diffusion and spin echo pulses, which may not yet be available for whole 
liver imaging. However, new techniques like readout-segmented EPI (70), combined 
with twice-refocused adiabatic spin-echo (TRASE) DWI (71,72) or single-refocused 
DWI using matched-phase adiabatic spin echo (MASE) (73) could further improve 
results.
Conclusion
In conclusion, ultra-high magnetic field MR has already shown several very promising 
results in smaller body parts. Still, imaging large areas like the liver remains chal-
lenging at 7T. This may change in the near future as several promising solutions and 
results have already been reported.
pet/Mr
The diagnostic application of combinations of independent imaging modalities have 
already been applied for many years. One recent development was the success-
ful combination of state-of-the-art PET and state-of-the-art MRI to a new hybrid 
imaging modality: PET/MR (74,75). These systems combine the molecular imaging 
technology of PET, having a high sensitivity, with the extremely versatile anatomical 
and functional imaging capabilities of MR. Examples of sequential systems are the 
Philips’ Ingenuity TF system which combines a TOF PET and a 3T MR (76), and 
General Electric’s trimodality setup combining a TOF PET/CT and a 3T MR (77). 
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Examples of fully integrated simultaneous systems are Siemen’s Biograph mMR (78) 
and General Electric’s Signa TOF PET/MR (79).
During the research described in this thesis, patients were still scanned sequentially 
by PET/CT and afterwards by MR. The PET/MR systems could speed up this process 
as MR scans could already be performed during the PET tracer uptake time. An 
advantage of the trimodality setup is that the PET/CT and MR scanners can be used 
separately. This means that either a long PET/CT or a long MR session doesn’t block 
the other modality from being used, which could save operating costs, if planned 
well. With the simultaneous systems, on the other hand, the patient doesn’t have to 
be transferred from one modality to the other and the whole procedure is reduced 
to a truly one-stop-shop technique, thereby possibly saving even more time (80). 
In addition, simultaneous PET/MR not only allows the molecular PET images to be 
well aligned with the anatomical and functional MR images, it also enables simul-
taneous acquisition of PET and MR images, which could be important for imaging 
dynamic processes or for the correction of motion effects.
With a whole body PET, usually requiring about 20 minutes, the MR part is likely to be 
the time limiting factor. As scan time is expensive, especially on simultaneous PET/
MR systems, only those MR investigations should be added that contribute most to 
a better diagnosis, keeping the total scan time as short as possible and costs low.
Early clinical studies suggest that PET/MR imaging is not only useful for oncologi-
cal liver and gastrointestinal imaging, but also for imaging lesion in brain, head and 
neck, lung, breast, prostate and bone (81-84). The well-known superior soft tissue 
contrast of MR and its option to provide additional functional information, also 
triggered an increasing interest in PET/MR imaging for neurology (85), cardiology 
(86-89), pediatrics, and for diagnosing infection and inflammation processes, and 
musculoskeletal disorders (83,84). Another, relatively new field of interest could be 
molecular theranostics where e.g. new probes are designed to visualize drug deliv-
ery, release and therapy monitoring (90). When, for example, a drug is designed to 
target a specific receptor on a tumor, a radiolabeled antibody could be administered 
to select only those patients having tumors expressing the receptor. Next, after 
administration of such a radiolabeled drug, the biodistribution and accumulation of 
the drug at the target site could be assessed (91). An example of the use of mono-
clonal antibodies for PET, also called immune-PET is 89Zr-bevacizumab. 89Zr has a 
decay half-life of 78.4 h, so PET scanning could be performed at the optimum time 
point of 4 days after injection (92-94). A simultaneous PET/MR system would be 
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ideal to perform these studies as MR provides good soft tissue contrast next to the 
possibility to include functional imaging and it provides optimal spatial alignment of 
the PET and MR images. In addition paramagnetic gadolinium or iron oxide could be 
used as a label in MRI for e.g. liposomes (95,96), although iron oxide may interfere 
with normal receptor function (97).
PET/MRI also provides some potential competitive advantages over PET/CT. PET/
CT, for instance has a low sensitivity for the detection of subcentimeter liver tumors 
due to physiological 18F-FDG activity in the liver parenchyma, limited anatomical 
information for tissues like the pelvis or the thoracic wall because of the low soft 
tissue contrast of CT, and the relatively high radiation dose for diagnostic CT images, 
which could be an issue in pediatric patients (98). Most of these limitations can 
potentially be overcome by PET/MR. On the contrary, current PET/MRI technology 
is also hampered by several shortcomings, like PET attenuation correction and the 
low sensitivity of MRI for small-scale pulmonary pathologies (98). However, new MR 
techniques like ultrashort-echo-time (UTE) and zero-echo-time (ZTE) sequences 
have been proposed for pulmonary MRI (98-101). The UTE and especially the ZTE 
techniques can also be applied for imaging bone and could thus be used for more 
accurate PET attenuation correction in PET/MR, which could be particularly impor-
tant for PET imaging of the head (102-105). 
Due to advances in PET detector technology, the latest generation of simultaneous 
PET/MR scanners also offers time-of-flight (TOF) capabilities. TOF technology is 
by no means new and the advantages in PET/CT imaging are well- known for years 
(106). It improves SNR, yielding a better tradeoff between acquisition time, image 
noise and structure contrast. It also improves imaging performance for heavier 
patients, resulting in more uniform quality over all patient sizes. As TOF provides 
more information, the reconstruction is more robust despite the presence of inac-
curacies in the measured data and/or system model (79,107-113). This is of special 
relevance in PET/MR imaging as the MR-based attenuation correction may be less 
accurate than CT-based attenuation correction, due to e.g. air cavities, field-of-view 
truncation, fat/water swaps, respiratory state mismatch(114), or metal artifacts 
in the MR images (115-119). New developments in model based techniques could 
result in more reliable attenuation maps that e.g. include bone (120). Another prom-
ising technique to improve the attenuation map and the PET image is maximum 
likelihood reconstruction of activity and attenuation (MLAA) (121-127). It tries 
to simultaneously reconstruct emission and attenuation images from PET emission 
data only. Others apply an annulus-shaped PET transmission source(128,129), or 
use the LSO crystal background radiation as a transmission source (130).
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In conclusion, PET/MR is a new and promising imaging modality, combining two 
of the most versatile technologies currently available. It shows enormous potential 
for research purposes and an increasing number of sites already implemented PET/
MR in their clinical routine. Some technical aspects still need to be improved, but 
potential solutions are currently under investigation (98,131).
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Colorectaal carcinoom is een van de meest voorkomende vormen van kanker in 
de westerse wereld en veel patiënten ontwikkelen metastasen, meest in de lever. 
Indien mogelijk wordt bij patiënten met levermetastasen een curatieve behandeling 
uitgevoerd, vaak door een partiële leverresectie. De meeste patiënten met lever-
metastasen worden echter met palliatieve systemische chemotherapie behandeld. 
Deze palliatieve behandeling verlengt de gemiddelde overleving van de patiënten, 
maar in feite reageert maar een deel van de patiënten op deze potentieel toxische 
en dure behandeling.
Ongeveer 8-9 weken na het begin van de behandeling wordt het resultaat geëva-
lueerd waarbij onder andere naar de verandering in tumorgrootte wordt gekeken. 
Een veel eerdere voorspelling van respons zou deze patienten mogelijk een onsuc-
cesvolle behandeling en dus onnodige toxiciteit en kosten kunnen besparen. Een 
methode die gebaseerd is op het meten van de tumorgrootte is dan suboptimaal 
omdat in een vroeg stadium van de behandeling bijna of helemaal geen verandering 
in tumor volume waarneembaar is. Andere behandelmethodes zoals bijvoorbeeld 
‘targeted therapies’ leiden vaak laat of soms helemaal niet tot afname van tumor-
grootte. Andere betrouwbare imaging methoden die de respons op therapie vóór 
of vlak na het begin van de behandeling voorspellen zouden daarom zeer wenselijk 
zijn. Derhalve zijn er voorspellende beeldvorming markers nodig die, bij voorkeur, 
inzicht geven in de biologie van colorectaal carcinoom en metastasen. Beeldvor-
mende technieken die een aantal potentiële biomarkers detecteren worden kort 
toegelicht in hoofdstuk 1. Aangezien enige kennis van de technische achtergrond 
van de besproken beeldvormende technieken (‘magnetic resonance imaging’ (MRI) 
en ‘positron emission tomography’ (PET)) noodzakelijk is wordt er ook een korte 
inleiding in MRI en PET gegeven. 
De MR techniek is veelzijdig en kan bijvoorbeeld gebruikt worden om verschillende 
(tumor) weefsel eigenschappen af te beelden. Met diffusie gewogen MRI (DWI) 
wordt de beweegbaarheid (apparent diffusion coefficient, ADC) van water molecu-
len afgebeeld. De beweging van water moleculen kan bijvoorbeeld beperkt zijn door 
de aanwezigheid van cel structuren zoals cell membranen. Gebieden met een hoge 
celdichtheid (bijvoorbeeld in een tumor) resulteren in een lagere beweegbaarheid 
van de watermoleculen, dus een lage ADC waarde. Bij MRI wordt de magnetisatie van 
een hoeveelheid water moleculen uit evenwicht gebracht. Na verloop van tijd keert 
de magnetisatie weer terug in de evenwichtsstand. De twee karakterestieke tijden 
hierbij zijn de T1 en de T2 (of T2*) relaxatie tijden. De T2* relaxatie is medeafhankelijk 
van de homogeniteit van het magneetveld. De homogeniteit van het magneetveld 
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in weefsel is afhankelijk van vele factoren. Een van de factoren is de aanwezigheid 
van deoxyhemoglobine. Deoxyhemoglobine is, in tegenstelling tot oxyhemoglobine, 
paramagnetisch en verstoord dus het homogene magneetveld. Het meten van T2* 
kan dus informatie geven over de (tumor) weefsel vasculatuur en mogelijke zuurstof 
arme gebieden. Bij dynamisch contrast MRI (DCE-MRI) wordt een contrastmiddel, 
dat vooral een effect heeft op de T1 relaxatie, intravenous ingespoten. Het contrast 
middel komt via het hart en de arterien in de micro circulatie terecht. Het treed uit 
de capilairen en in de ruimte tussen de cellen, waarna het weer terug opgenomen 
wordt in circulatie. Door in de tijd te scannen, kan de verandering in T1 en dus de 
concentratie van het contrastmiddel in de tijd worden gevolgd. Door het toepassen 
van een model kan vervolgens de pefusie en permeabiliteit van (tumor) weefsel 
worden bepaald. Nog een andere techniek is MR-spectroscopie (MRS). Hierbij wor-
den vaak geen afbeeldingen gemaakt maar worden de hoeveelheden van bepaalde 
moleculen in een gegeven (tumor) weefsel volume bepaald. Dit kan bijvoorbeeld 
gebruikt worden voor het meten van veranderingen in het (tumor) cel metabolisme.
Voor PET wordt gebruik gemaakt van beeldvorming met behulp van radioactieve 
isotopen. Deze radionucliden worden gekoppeld aan een molecuul en toegediend 
aan een patient. Deze moleculen worden bijvoorbeeld opgenomen door specifieke 
cellen of kunnen binden met specifieke eiwitten in het lichaam van de patient. Een 
PET scanner kan dan buiten het lichaam de photonen detecteren die in het lichaam 
zijn ontstaan door het radioactief verval van het gekoppelde isotoop. Hiermee zijn 
beelden te reconstrueren die aangeven waar in het lichaam zich de betreffende mole-
culen bevonden. De meest gebruikte PET tracer is 2-deoxy-2-[18F]fluoro-D-glucose 
(18F-FDG), een glucose analoog waarbij het zuurstof atoom op the C-2 positie is 
vervangen door 18F. Doordat tumor cellen vaak afhankelijk zijn van de glycolyse voor 
hun energie voorziening, nemen ze veel glucose en ook 18F-FDG op. De 18F-FDG kan 
niet door de cel verbruikt worden en hoopt zich op. Locaties met een verhoogde 
activiteit kunnen dus duiden op de aanwezigheid van tumoren.
Hoofdstuk 2 gaat over in vivo MR-spectroscopie en bespreekt een aantal adequate 
onderzoeks methoden om de stofwisseling in lever tumoren en metastasen ervan 
te bestuderen. Bovendien worden enkele technische problemen van MRS, zoals 
toegepast op levertumoren en levermetastasen, besproken.
Aangezien proton (1H) MRS kan worden uitgevoerd met standaard MR hardware en 
1H de hoogste MR gevoeligheid heeft, is het de meest toegepaste vorm van MRS. 
Het grote nadeel van 1H MRS is het relatief kleine frequentie bereik waarin zich de 
vele resonanties van in vivo detecteerbare verbindingen bevinden, waardoor de 
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spectrale resolutie beperkt is. In levertumor studies overlapt de lactaat resonantie, 
die betrekking heeft op tumor energiemetabolisme (Warburg effect), met grote 
lipide resonanties. Met zogenaamde spectrale bewerkingstechnieken is het toch 
mogelijk om het lactaat signaal te scheiden van de lipide signalen.
De totale choline (tCho) piek zou kunnen worden gebruikt als biomarker om 
kwaadaardige tumoren te identificeren. Een toename van deze piek hangt samen 
met celmembraan synthese in snelgroeiende tumoren. Echter, zoals de naam al 
aangeeft, bestaat de tCho piek uit meerdere niet te onderscheiden resonanties van 
verschillende choline bevattende verbindingen. Dit maakt het interpreteren van 
veranderingen in het gemeten signaal moeilijk. 
Een ander manier om belangrijke metabolieten die betrokken zijn bij membraam 
metabolisme te onderzoeken is 31P MRS. In 31P MRS spectra van tumoren is het 
mogelijk om de individuele signalen van gefosforyleerde choline en ethanolamine 
bevattende verbindingen te onderscheiden. Uit verschillende studies is bekend dat 
een toename van deze phosphomonoesters (PME) is geassocieerd met tumorpro-
gressie en dat succesvolle behandeling gepaard gaat met een vermindering van 
het PME niveau. Daarom kan 31P MRS heel goed worden gebruikt voor de respons 
monitoring van een behandeling. Naast de signalen van fosfolipidemetabolisme 
bevatten 31P MR spectra van de lever ook signalen van ATP (soort energie transport 
molecuul) en Pi (inorganic phosphate) die kunnen worden gebruikt om het energie-
metabolisme van tumoren af te leiden. De chemische verschuiving van de resonantie 
frequentie kan ook worden gebruikt om de intracellulaire pH afteleiden. Door de 
lagere gevoeligheid van fosfor is de spatitiele resolutie in 31P MR spectra een orde 
van grootte lager dan in 1H MRS.
Hoewel MRS in combinatie met het gebruik van 13C gelabelde substraten een unieke 
manier vormt om het cel metabolisme in vivo te meten, wordt het tot nu toe weinig 
gebruikt voor onderzoek in de menselijke lever. Dit vanwege de technische com-
plexiteit en de relatief lage gevoeligheid. Door de toepassing van de hyperpolarisatie 
techniek wordt de signaal intensiteit verhoogd wat nieuwe mogelijkheden biedt 
voor de dynamische beeldvorming van stabiele gelabelde metabolieten.
Voordat conclusies kunnen worden getrokken uit beeldvormende parameters 
moeten er gegevens worden verzameld over de herhaalbaarheid van de gemeten 
gegevens om te kunnen beoordelen welke verschillen buiten de normale variatie 
kunnen worden gedetecteerd. Pas wanneer gemeten veranderingen in een tumor 
groter zijn dan kan worden toegeschreven aan normale variatie (bijvoorbeeld 
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variaties in het MR systeem of door lichaamsfysiologie), kan worden aangenomen 
dat deze veroorzaakt zijn door de behandeling.
Hoofdstuk 3 beschrijft de herhaalbaarheid van het tCho signaal verkregen door 
single voxel 1H MRS in normaal leverweefsel en levermetastasen van colorectale 
kanker. Voor interpretatie doeleinden zijn er ook enkele ex-vivo monsters van 
normaal en tumorweefsel onderworpen aan high-resolution magic angle spinning 
(HRMAS) NMR-spectroscopie.
Dit onderzoek met schattingen voor absolute tCho waarden in de lever toont 
aan dat deze waarde in normaal uitziend lever weefsel niet verandert wanneer er 
een colorectale metastase aanwezig is. Een toename van het tCho signaal, een 
kenmerk van maligniteit in vele andere lichaam tumoren, werd niet waargenomen 
voor deze levermetastasen. Dit lijkt in tegenspraak met onderzoek naar primaire 
levertumoren waar verhoogde tCho waarden werden gevonden. Onze bevinding 
van vrijwel gelijke of zelfs afgenomen tCho waarden kan worden veroorzaakt door 
intrinsieke verschillen tussen primaire tumoren en metastasen, maar kan ook zijn 
ontstaan door een hoog achtergrond tCho signaal in de lever of door partial volume 
effecten waarbij het tCho signaal verdunt is door necrose in de tumor. De enigszins 
slechte herhaalbaarheid van het tCho signaal werd waarschijnlijk veroorzaakt door 
de beweging van het heterogene tumorweefsel als gevolg van de ademhaling en de 
moeilijkheid om het voxel in de exact zelfde positie te herplaatsen in het heterogene 
tumorweefsel. 
Hoofdstuk 4 beschrijft de herhaalbaarheid en de biologische validatie van diffusie 
gewogen MRI (DWI). DWI is tweemaal binnen een week uitgevoerd in patiënten 
die gepland stonden voor een metastasectomie. Hierbij werd de ADC in 21 colo-
rectale levermetastasen gemeten en gecorreleerd met apoptose marker p53, 
anti-apoptotisch eiwit BCL-2, en proliferatie marker Ki67. De gemiddelde ADC in 
de onderzochte metastasen was 1,17 ± 0,11 x 10-3 mm2/s en de herhaalbaarheid 
coëfficiënt, berekend met de Bland & Altman methode, was 0,20 x 10-3 mm2/s. 
De metastasen in recent systemisch behandelde patiënten hadden een significant 
hogere gemiddelde ADC dan onbehandelde metastasen (1,27 x 10-3 mm2/s vs. 
1,05 x 10-3 mm2/s, P=0.02). De ADC was gecorreleerd met de proliferatie-index en 
de BCL-2 expressie in de metastasen. De goede herhaalbaarheid, de correlatie met 
histopathologie en de gevoeligheid voor de systemische behandeling suggereren 
dat DWI een uitstekende techniek is om de respons in gemetastaseerd colorectaal 
carcinoom te meten.
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Hoofdstuk 5 beschrijft de herhaalbaarheid van T2
* MRI om levermetastasen te 
karakteriseren. Achttien patiënten gepland voor metastasectomie van levermeta-
stasen werden tweemaal binnen één week gescand met T2
* MRI. T2
* waarden wer-
den gemeten in normaal uitziend leverweefsel en in 22 colorectale levermetastasen. 
Voor een biologische basis werden deze T2
* waarden gecorreleerd aan de expressie 
van de hypoxie-gerelateerde markers GLUT-1 en CA-IX en met de vaatdichtheid in 
de gereseceerde tumoren. Immunohistochemische kleuringen werden uitgevoerd 
op 17 gereseceerde tumoren verkregen uit 16 patiënten. Met behulp van de Bland & 
Altman methode werd een herhaalbaarheid coëfficiënt van 11,2 ms gevonden voor 
de gemiddelde T2
* bij deze metastasen. De gemiddelde T2
* was 25,9 ± 7,1 ms in 
de levermetastasen en 22,4 ± 4,5 ms in normaal leverweefsel. Gemiddeld was de 
T2
* herhaalbaarheid redelijk. Er werd geen correlatie tussen T2
* waarden, hypoxie 
markers en vaatdichtheid waargenomen.
Hoofdstuk 6 beschrijft de succesvolle implementatie van een procedure om bewe-
gings gerelateerde artefacten te verminderen tijdens de analyse van snelle 2D DCE-
MRI. Bij vijftien patiënten met levermetastasen werd DCE-MRI tweemaal uitgevoerd 
binnen één week. Datasets met contrastmiddel concentraties werden berekend 
en arteriele input functies (AIF’s) werden automatisch afgeleid van de contrast 
instroom in voxels in de aorta van elke patiënt. Beelden met een incorrecte posi-
tie, ontstaan door ademhalingbewegingen, werden met behulp van een structural 
similarity (SSIM) algorithme geïdentificeerd en verwijderd uit de dataset. Met deze 
gecorrigeerde dataset werd Ktrans en de herhaalbaarheid ervan bepaald. Het ver-
werpen van deze incorrecte beelden resulteerde in een significant (P <0,05) lagere 
mediane Ktrans (3,53 ± 1,89 x 10-3 s-1) en een lagere coëfficiënt van herhaalbaarheid 
voor Ktrans (1,44 x 10-3 s-1) in levermetastasen vergeleken met niet gecorrigeerde 
datasets (4,12 ± 2,04 x 10-3 s-1 en 2,39 x 10-3 s-1 respectievelijk). De SSIM correctie 
verbeterde de herhaalbaarheid van de DCE-MRI parameter Ktrans in levermetastasen 
en verminderde de invloed van het omringende normale leverweefsel op Ktrans waar-
den van metastasen.
Hoofdstuk 7 beschrijft het gebruik van CT scans met contrastmiddel voor ver-
zwakkingscorrectie van de PET beelden. Bij 10 patiënten werd naast een 18F-FDG 
PET een extra CT scan van de lever met contrastmiddel gemaakt. PET datasets 
werden gecorrigeerd voor attenuatie met behulp van zowel de standaard lage dosis 
CT-beelden zonder contrastmiddel als de hoge dosis CT-beelden met contrastmid-
del. De verschillen werden gemeten in zogenaamde ‘Standardized Uptake Values’ 
(SUVs); de gemeten activiteitsconcentratie gecorrigeerd voor de geinjecteerde 
dosis en lichaamsgewicht. De verschillen in gemiddelde SUV (SUVgemiddeld) en 
210
••
••
••
••
••
 A
ck
no
w
le
dg
em
en
ts
 /
 D
an
kw
oo
rd
de verschillen in maximale SUV (SUVmax) werden vergeleken in 3 lever gebieden. 
Zowel de SUVgemiddeld en de SUVmax waarden waren significant hoger (2,53 en 3,17 
g/cm3 vs. 2,43 en 2,91 g/cm3, beide P<0.01) in leverweefsel bij het gebruik van 
PET-beelden gecorrigeerd voor attenuatie met hoge dosis CT met contrastmiddel in 
vergelijking met de lage dosis CT zonder contrastmiddel. Hoewel de verschillen niet 
erg relevant zijn voor de toepassing van PET/CT in de dagelijkse klinische praktijk, 
kunnen CT datasets met en zonder contrastmiddel niet willekeurig worden gebruikt 
voor attenuatiecorrectie als exacte kwantitatieve resultaten gevraagd zijn.
In hoofdstuk 8 wordt de voorspellende waarde van 18F-FDG PET, DWI en T2
* MRI 
op de uitkomst van de therapie en de ziekte beschreven. In deze klinische studie 
werden bij 39 patiënten met gemetastaseerd colorectaal carcinoom in de lever, 18F-
FDG PET, DWI en T2
* MRI scans uitgevoerd voorafgaand aan en een week na de 
start van de eerste lijn behandeling met chemotherapie. De DWI en T2
* MRI scans 
werden uitgevoerd op een 1,5T MR scanner en volgden vrijwel direct na de 18F-FDG 
PET scan uitgevoerd met een hybride PET/CT scanner. Na 3 kuren chemotherapie 
werd de 18F-FDG PET/CT herhaald. De SUVmax, totale laesie glycolyse (TLG), de 
ADC en T2
*-waarden werden gemeten in dezelfde levermetastasen. Hierbij werden 
per patient een maximum van 5 levermetastasen geanalyseerd. De voorspellende 
waarde voor de progressie vrije overleving en algehele overleving werd onderzocht.
Een lage ADC voor behandeling was geassocieerd met een slechtere progressie vrije 
overleving en algehele overleving. Een hoge SUVmax, TLG en T2
* voor behandeling 
was geassocieerd met slechtere algehele overleving. Eén week na start van behande-
ling werd een significante daling van SUVmax en een stijging van ADC waargenomen. 
De daling van SUVmax was gecorreleerd met een toename van ADC. Echter, noch 
de verandering in ADC noch in SUVmax was voorspellend voor de progressie vrije 
overleving en algehele overleving. T2
* veranderde niet significant na de start van de 
behandeling.
De waarden van SUVmax, TLG, ADC en T2
* gemeten in levermetastasen voor behan-
deling zijn voorspellend voor de patiënt uitkomst. Ondanks de gevoeligheid van DWI 
en 18F-FDG PET voor vroege behandeling effecten, hebben veranderingen in deze 
parameters geen voorspellendewaarde voor de lange termijn uitkomst. 
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